CLINICAL  STUDY PROTOCOL
A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent 
Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent 
Glioblastoma Multiforme  
Drug Name:  [CONTACT_414013]-701 
Protocol Number:  STML-701-0114  
Original Protocol:  Version 1.1: 1 8 February  2014  
Protocol Version:  Version 3.0: 10 July  2015  (Amendment 2) 
IND Number:  015929  
Sponsor:  Stemline Therapeutics, Inc . 
[ADDRESS_542123]  
11th Floor  
New  York, NY  [ZIP_CODE]  
Phone:   
Fax:  
Responsible Medical 
Officer   
Phone:  
Monitored by:  [CONTACT_139915], LLC  
[ADDRESS_542124]  
Raleigh, NC [ZIP_CODE]  
Phone:   
Fax:  
Proprietary Notice:  The concepts and information contained in this document or 
generated during the study are considered proprietary and may 
not be disclosed in whole or in part without the expressed, 
written consent of Stemline Therapeutics, Inc .   NCT #: [STUDY_ID_REMOVED]

SL-70 I 
Protocol STM L-701-0114 Amendment 2 
Stem line Therapeutics, Inc. 
PROTOCOL APPROVAL SIGNATURE [CONTACT_3490] 2 
10July2015 
Fl NA L, Confidential 
Protocol Title: A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent 
Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent 
Glioblastoma Multiforme 
Protocol Number: STML-701-0114 
This study will be conducted in compliance with the clinical study protocol (and amendments), 
ICH guidelines for current Good Clinical Practice and applicable regulatory requirements. 
Compliance with Good Clinical Practice standards provides public assurance that the rights, safety, and well-being of study patients are protected, consistent with the principles that have their 
origin in the Declaration of Helsinki. 
Sponsor Signatory 
 
 
Stemline Therapeutics, Inc. 
[ADDRESS_542125] Description  ................................ ............................................................  25 
 Rationale for Immunotherapy in Glioma ........................................................... 26  
 Rationale for the Selected GAA Targets ............................................................ 27  
 Rationale for the Selected Emulsifying Agent ................................................... 27  
 Rationale for the Selected Vaccine Adjuvants ................................................... 28  
1.3 Studies of GAA Vaccines Using IL- 13Rα2, EphA2, and/or Survivin  .............................. 28 
 Pediatric Study – PRO08030085  ................................ ................................ ........  30 
 Adult Study 05-115 ............................................................................................ 33  
1.4 Summary of Benefits and Risks ........................................................................................ 34 
1.5 Rationale for Use of Poly- ICLC in Stage 2  ................................ ................................ ....... 35 
1.6 Rationale for Addition of Bevacizumab in Stage 2  ...........................................................  35 
2. STUDY OBJECTIVES .......................................................................................................... 36 
2.1 Primary Objectives ............................................................................................................ 36 
2.2 Secondary Objectives ........................................................................................................ 36 
2.3 Exploratory Objectives ...................................................................................................... 36 
3. INVESTIGATIONAL PLAN ............................................................................................... 36 
3.1 Overall Study Design and Plan ......................................................................................... 36 1. 1. 1 
1.1.2 
1.1.3 
1.2.1 
1.2.2 
1.2.3 
1.2.4 
1.2.5 
1.3.1 
1.3.2 
SL-701  Page 4 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 3.2 Safety Assessments ........................................................................................................... 46 
 Toxicity Monitoring Rules ................................ .................................................  46 
 Regimen Limiting Toxicity  ................................ ................................ ................ 46 
 Routine Safety Assessments ............................................................................... 49  
 Total Blood Sample Volume .............................................................................. 50  
3.3 Efficacy Assessments ........................................................................................................ 50 
3.4 Primary and Secondary Endpoints .................................................................................... 52 
 Safety Endpoints  ................................................................ ................................ . 52 
 Efficacy Endpoints ............................................................................................. 52  
4. STUDY TREATMENTS ....................................................................................................... 53 
4.1 Study Drug Dosage and Administration ........................................................................... 53 
4.2 Allowed Concomitant Treatment ...................................................................................... 55 
4.3 Prohibi
ted Medications and Restrictions ........................................................................... 55 
4.4 Assessment of Patient Compliance ................................................................................... 56 
4.5 Study D
rug Description ..................................................................................................... 56 
 SL-701 Emulsion (Stages 1 and 2)  ................................ ................................ ..... 56 
 GM-CSF (Stage 1) .............................................................................................. 56  
 Imiquimod Cream, 5% (Stage 1) ........................................................................ 57  
 Poly-ICLC (Stage 2) ........................................................................................... 57  
 Bevacizumab (Stage 2) ....................................................................................... 57  
4.6 Study Drug Packaging and Storage ................................................................................... 58 
4.7 Study Drug Accountability ................................................................................................ 59 
5. PATIENT ENROLLMENT .................................................................................................. 59 
5.1 Inclusion Criteria ............................................................................................................... 59 
5.2 Exclusion Criteria .............................................................................................................. 61 
5.3
 Postponement of Investigational Regimen ........................................................................ 62 
5.4 Modification of Investigational Regimen .......................................................................... 63 
 Adverse Events Not Meeting the Definition of RLT  ................................ ......... 63 
 RLT and RLT-level Adverse Events .................................................................. 63  
 Modification of Bevacizumab ............................................................................ 64  
5.5 Patient Withdrawal ............................................................................................................ 64 3.2.1 
3.2.2 
3.2.3 
3.2.4 
3.4.1 
3.4.2 
4.5.1 
4.5.2 4.5.3 
4.5.4 
4.5.5 
5.4.1 
5.4.2 
5.4.3 
SL-701  Page 5 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 
 Reasons for Withdrawal  ................................ .....................................................  64 
 Withdrawal of Bevacizumab  ................................ ................................ .............. 64 
 Handling of Withdrawals ................................................................................... 65  
 Replacements ...................................................................................................... 65  
 Termination of Study by [CONTACT_2728]....................................................................... 65  
6. STUDY VISITS ...................................................................................................................... 65 
6.1 Screening ........................................................................................................................... 66 
6.2 Day 1 ................................................................................................................................. 66 
6.3 Day
 4, Day 8 (Week 1), Day 11, and Week 3 (Stage 2 only) ........................................... 67 
6.4 Weeks 2, 4, 6, 10, 12, 14, 18, 20, and 22 .......................................................................... 68 
6.5 Weeks 8 and 16 ................................................................................................................. 69 
6.6 Week 24............................................................................................................................. 70 
6.7 Weeks 26 and 30 ............................................................................................................... 71 
6.8 Weeks 28 and 32 (Stage 2 only) ........................................................................................ [ADDRESS_542126] Dose ................................................ 76 
7. STUDY ASSESSMENTS ...................................................................................................... 76 
7.1 Tumor Response Assessment ............................................................................................ 76 
7.2 Demographic Data/Medical History ................................................................................. [ADDRESS_542127]/Research Ethics Board .......................................................... [ADDRESS_542128] ................................................................................................................... 91 
11.10  Publications ....................................................................................................................... 91 
12. INVESTIGATOR’S STATE MENT ..................................................................................... [ADDRESS_542129] Criteria (version 1.1) for Response Evaluation ................................................ [ADDRESS_542130] OF IN -TEXT TABLES  
Table 1:  Characteristics of Clinical Studies of Similar GAA Peptide Vaccines 
(June 2013) ................................................................................................................... 29 
Table 2:  Patient Demographics, Baseline Disease Characteristics, and Vaccine 
Administration:  Study PRO08030085 ........................................................................ 31 
Table 3:  Summary of Treatment Emergent Adverse Events Occurring in ≥20% of All 
Patients:  Study PRO08030085 .................................................................................... 32 
Table 4:  Study Event Schedule: Stage 1 .................................................................................... 39 
Table 5:  Study Event Schedule: Stage 2 .................................................................................... 42 
Table 6:  Study Drug Dosage and Administration: Stage 1 ........................................................ 53 
Table 7:  Study Drug Dosage and Administration: Stage [ADDRESS_542131] OF IN-TEXT FIGURES 
Figure 1:  Treatment Flow Schedule for Stage [ADDRESS_542132]:  
SL-701 
Name [CONTACT_3261]:  
MPS -380 ( IL-13Rα2 345-353:1A9V), MPS -381 ( EphA2 883-891), MPS -481 ( Survivin 95-104:3 M), and MPS -199 
(Tet A830) peptides  
Study Title:  
A Phase 1/2 Study of SL -701, a Subcutaneously Injected Multivalent Glioma -Associated Antigen 
Vaccine, in Adult Patients with Recurrent Glioblastoma  Multiforme  
Study Number:  
STML -701-0114  
Study Phase:  
1/2 
Primary Objectives:  
The primary objectives are to:  
 Characterize the safety and tolerability of SL -701 and SL -701 in combination with 
bevacizumab . 
 Estimate the percent of patients alive 12 months after the initiation of SL -701 (OS -12). 
 Estimate the objective response rate (ORR) . 
Secondary Objectives:  
The secondary objectives are to:  
 Estimate the duration of response  (DR).  
 Estimate the percent of patients  alive and progression -free survival at 6 months (PFS -6) after 
the initiation of SL -701. 
 Estimate the distributions of progression -free survival ( PFS) and overall survival ( OS). 
Exploratory Objectives:  
The exploratory objectives are to:  
 Estimate  the relationships  between measures of immunogenicity and anti -tumor efficacy . 
 Evaluate available post -vaccine tumor tissue for glioma -associated antigen (GAA) expression 
status and infiltration of GAA -specific T -cells. 
Study Population:  
Approximately 76 adult patients with recurrent glioblastoma multiforme  (GBM) , [ADDRESS_542133] 
enhanced magnetic resonance imaging ( MRI) or computed tomography (CT) scans .   
SL-701  Page 10 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Study Design:  
This is a multicenter, open label phase 1/2 study evaluating the efficacy and safety of SL -701 as a 
treatment for recurrent GBM , divided into 2 stages .  Approximately  76 patients will be treated  in the 
study,  46 in Stage 1 and 30 in Stage 2; at least [ADDRESS_542134]  measureable disease .  
During Stage 1 , patients will receive SL -701 with the vaccine adjuvants granulocyte macrophage -
colony stimulating factor (GM -CSF) injection and imiquimod topi[INVESTIGATOR_211092].  The first [ADDRESS_542135] to the toxicity m onitoring rules  (Section 3.2.1 ).  During Stage [ADDRESS_542136] tumor recurrence or 
progression on the initial treatment regimen (prior to enrollment in this study) by [CONTACT_428614], which should be performed within 14 days prior to start of SL -701 (see Inclusion 
Criteria  for details) .  Subsequent tumor respons e assessments will be performed every 8 weeks 
thereafter until the Investigator determines there is evidence of progressive disease (PD) using objective 
response criteria .  Patients who are evaluable for objective response will also be followed for duration 
of response, and all treated patients will be followed for OS and PFS until assessment of the primary 
objectives is completed.  
Study Centers:  
Up to 30 sites in North America . 
Inclusion Criteria:  
1. 18 years of age or older .   
2. Histologically confirmed GBM or World Health Organization ( WHO ) Grade  IV variants 
(gliosarcoma, glioblastoma with oligodendroglial features, or giant cell glioblastoma) . 
3. Unequivocal evidence of a first tumor recurrence or progression on the initial treatme nt 
regimen (prior to enrollment on this study), consisting of surgical intervention (biopsy and/or 
resection) , radiation, and temozolomide chemotherapy, as assessed by [CONTACT_428615] [ADDRESS_542137] apply:  
 Recovery from the effects of surgery . 
 Residual disease following resection of recurrent tumor is not mandated for eligibility  into 
the study .  To best assess the extent of residual disease post -operatively, an MRI should be 
performed:  
o No later than 96 hours (h) in the immediate post -operative period; or  
o At least [ADDRESS_542138] -craniotomy (7 days for stereotactic biopsy), within [ADDRESS_542139] 1 cm in 2 planes (axial, coronal, or 
sagittal) .   
7. No evidence of hemorrhage on the baseline MRI or CT scan other than thos e that are ≤Grade [ADDRESS_542140] 2 consecutive scans .   
8. Recovery from prior therapy toxicity, defined as resolution of all treatment -related adverse 
events (AEs) to ≤Grade  1 or pre -treatment baseline  (except alopecia and lymphopenia) .   
9. At least [ADDRESS_542141] 3 weeks prior to the start of SL -701. 
11. Human leukocyte antigen ( HLA )-A2 positive . 
12. A tumor tissue sample is provided for immunohistochemical analysis of relevant antigens, 
immune markers and potential prognostic factors.  Preferably a paraffin block or 10 -12 
unstained slides will be submitted prior to study entry.  Patients for whom tumor samples are 
unavailable or inadequate are permitted to participate in the study ; however , the absence of 
available/adequate tumor specime n must be documented . 
13. Karnofsky performance status (KPS)  score  ≥70%.  
14. Adequate organ function, including the following:  
 Absolute neutrophil count (ANC) ≥1,000/μL, platelets ≥100,000/μL .   
 Serum creatinine ≤1.5 × the upper limit of normal ( ULN ).   
 Bilirubin ≤1.5 × ULN .   
 Alanine aminotransferase (A LT) and aspartate aminotransferase  (AST)  ≤2.5 × ULN .   
15. Women of childbearing potential  must have a negative serum or urine pregnancy test within 
[ADDRESS_542142] agree to use an 
acceptable form of contraception for heterosexual activity ( ie, oral contraceptives, 
double -barrier methods, hormonal injectable, transdermal, or implanted con traceptives, tubal 
ligation, or vasectomy of their sexual partner(s)  for >[ADDRESS_542143] udy drug.  
17. Female patients without childbearing potential (spontaneous amenorrhea for >12 months or 
surgically sterilized by [CONTACT_306620], hysterectomy, or bilateral oophorectomy >6 months 
before Screening) are eligible for inclusion without contraceptive  use restriction .   
18. Able and willing to comply with protocol requirements, in the opi[INVESTIGATOR_689] . 
19. A written and voluntarily signed informed consent must be obtained from the patient or legally 
authorized representative, in accordance with loca l regulations, before the initiation of any 
SL-[ADDRESS_542144] be able to read 
and understand the informed consent form  (ICF) . 
Exclusion Criteria:  
1. Prior cancer chemotherapy, bevacizumab (or other vascular endothelial growth factor 
[VEGF ]/VEGF  receptor [VEGFR] -directed agent), or an investigational agent for 
recurrent/progressive GBM or prior bevacizumab as part of initial therapy  (prior chemotherapy 
or investigat ional agents are permitted as part of initial therapy; VEGF/VEGFR -directed agents 
are not permitted) . 
2. Contrast -enhancing tumor that is any of the following:  
 Multi -focal (defined as [ADDRESS_542145]  1cm in 
2 planes that are not contiguous on either fluid -attenuated inversion recovery [FLAIR ] or 
T2 sequences ); 
 Associated with either diffuse subependymal or leptomeningeal dissemination; or  
 4 cm in any dimension . 
3. Requirement of systemic corticosteroid therapy >4 mg/day of dexamethasone or equivalent or 
requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of 
SL-701 treatment . 
4. Surgical resection or major surgical procedure w ithin 4 weeks prior to the start of SL -701, or 
stereotactic biopsy within 7 days prior to the start of SL -701. 
5. Radiation therapy, local therapy (except for surgical re -resection), or systemic therapy 
following first recurrence/progressive disease .  Exclude d local therapi[INVESTIGATOR_428551]/progressive disease  include stereotactic radiation boost, implantation of carmustine 
biodegradable wafers (Gliadel), intratumoral or convection -enhanced delivery administered 
agents, etc.  
6. Active infection requir ing intravenous  (IV) antibiotics . 
7. History of cancer (other than GBM) within the past [ADDRESS_542146] survival and/or potentially confound 
tumor response assessments within th is study .   
8. Clinically significant cardiovascular disease (eg, uncontrolled or any [LOCATION_001] Heart 
Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial 
infarction or stroke within 6 months of study entry, uncontrolle d hypertension or clinically 
significant arrhythmias not controlled by [CONTACT_12617]) . 
9. Known immunosuppressive disease or active systemic autoimmune disease (such as systemic 
lupus erythemato sus), human immunodeficiency virus infection,  active  or chronic  Hepa titis B 
or Hepatitis C, or has taken an immunosuppressive agent within 4 weeks prior to the start of 
SL-701 treatment .  Patients with vitiligo, type 1 diabetes mellitus, hypothyroidism due to 
autoimmune condition only requiring hormone replacement therapy,  psoriasis not requiring 
systemic therapy, or conditions not expected to recur in the absence of an external trigger are 
permitted to enroll .   
10. Any condition that in the Investigator's opi[INVESTIGATOR_428552] . 
SL-701  Page 13 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 11. Requires therapeutic anticoagulation with warfarin at baseline; patients must be off warfarin or 
warfarin -derivative anti -coagulants for at least 7 days prior to starting study drug; however, 
therapeutic or prophylactic therapy with low -molecular weight heparin is allowed . 
12. Has history of known coagulopathy that increases risk of bleeding or a history of clinically 
significant hemorrhage within 12 months of start of study drug.  
13. Has evidence of intratumoral or peritumoral hemorrhage on baseline MRI scan other than tho se 
that are ≤Grade [ADDRESS_542147] 2 consecutive MRI scans  
14. Has gastrointestinal bleeding or any other hemorrhage/bleeding event National Cancer Institute 
(NCI) Common Terminology Criter ia for Adverse Events ( CTCAE ) >Grade [ADDRESS_542148], Dose, and Mode of Administration:  
SL-701 consists of HLA -A2 restricted epi[INVESTIGATOR_304964], MPS -380 ( IL-13Rα2 345-353:1A9V ), MPS -381 
(EphA2 883-891), and MPS -486 ( Survivin 95-104:3 M), derived from 3  antigens that are overexpressed by 
[CONTACT_428616] .  SL-701 also includes MPS -199, a peptide that functions as a helper 
T-cell epi[INVESTIGATOR_428553], Tet A830.  SL-701 peptides are designed to activate and 
expand t he population of cytotoxic T -cells (CD8+ T -cells) that are specific for these glioma epi[INVESTIGATOR_322], 
leading to their migration into the brain and killing of glioma cells .   
In Stage 1, a complete dose of study drug consists of the administration of a sequence o f 3 agents , SL-
701 emulsion (SL-701 in Montanide®) subcutaneous (SC) injection, GM -CSF SC injection, and 
imiquimod topi[INVESTIGATOR_68549] , within a n approximate  5-minute time frame .  Topi[INVESTIGATOR_428554] 24  hours (h) after each SL -701 emulsion injection.   
In Stage 1, p atients will be treated with  SL-701 emulsion every 14 days initially for 12 doses, followed 
by [CONTACT_428617] 28 days until PD, withdrawal of informed consent, unacceptable toxicity, or 
non-compliance .  Administration parameters for SL -701 emulsion,  GM-CSF, and i miquimod are 
summarized in the table below .   
In Stage 2 , a complete dose of investigational treatment consists of the administration of a sequence of 
2 agents , SL-701 emulsion injection, and poly -ICLC intramuscular (IM) injection , within an 
approximate 20 -minute time frame.  Patients will also receive  IV bevacizumab.   SL-701 emulsion and 
the adjuvant poly -ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during 
the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) 
through Week 22, and every 4 weeks thereafter.  Bevacizumab will be administered every 2 weeks, 
subsequent to the administration o f SL-701/poly -ICLC.  Administration parameters for SL -701, poly -
ICLC and bevacizumab are summarized in the table that follows.  
SL-701  Page 14 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Agent and Dose  Preparation and Route of Administration  Schedule  
SL-701 in 
Montanide®; 
1.0 mL injection 
taken from 0.7 mL 
of SL-701 mixed at 
a 1:1  (v/v) ratio 
with 0.[ADDRESS_542149] with a radius of 18 mm will be marked out with ink at 
the injection site prior to SC injection to serve as a guide for the 
GM-CSF injection and imiquimod application.  Stage 1 :  Day 1 ; 
Weeks 2, 4, 6, 8, 10, 
12, 14, 16, 18, 20, and 
22, then every 4 weeks 
thereafter . 
Stage 2 : Days 1, 4, 8 
(Week 1), and 11; 
Weeks 2, 3, 4, 6, 8, 10, 
12, 14, 16, 18, 20, and 
22, then every 4 weeks 
thereafter , 
Stage 1 only:  GM -
CSF 150  µg GM-CSF should be administered as a SC injection immediately 
after SL -701 emulsion administration and within 1 cm from the 
center of the SL -701 emulsion injection site, prior to application 
of topi[INVESTIGATOR_160772].   Day of each SL -701 
emulsion dose , 
Stage 1 only:  
Imiquimod Cream, 
5% supplied in 
250 mg single -use 
packets  Immediately (within 5 minutes) following the administration  of 
the SL -701 emulsion, approximately one -half packet (125 mg) of 
imiquimod cream will be applied topi[INVESTIGATOR_428555].  
Study site personnel and patients will be instructed to wash hands 
before and after imiquimod topi[INVESTIGATOR_44785].  Patients will b e provided 
with instructions for the application process for the imiquimod 
cream at 24  h at the SL -701 emulsion injection site and told not 
to wash the area for 48 h after the SL -701 emulsion injection (24 
h after the second imiquimod application).2  The i miquimod 
cream should be rubbed in until the cream is no longer visible.  Day of each SL -701 
emulsion dose and 
24 h after each SL -701 
emulsion dose . 
Stage 2 only: Poly -
ICLC 1.6mg (1,600 
µg) Within 20 minutes following the administration of the SL -701 
emuls ion, poly -ICLC should be administered as an IM injection 
in the same extremity as was administered the SL -701 (deltoid 
muscle, unless contraindicated).  Day of each SL -701 
emulsion dose . 
Stage 2 only: 
Bevacizumab 
Solution for 
injection  In Stage 2, following the administration of SL -701 and poly -
ICLC, bevacizumab will be administered IV at a dose of 
10 mg/kg.  Bevacizumab infusions may occur over 30, 60 , or 90 
minutes in accordance with institutional practices and guidelines.  Day 1 ; Weeks  2, 4, 6, 
8, 10, 12, 14, 16, 18, 
20, and 22, then every 
2 weeks thereafter . 
1A 1.0 mL dose of the emulsion contains 0.3 mg each of the MPS -380, MPS -381, and MPS -486 peptides and 
0.2 mg of the MPS -199 peptide.  
2In situations where the 24h topi[INVESTIGATOR_428556] (ie , the patient forgets to apply at 24 h), the patient may apply imiquimod during an 
additional 24 -hour period subsequent to the stipulated administration time.  Sub sequent to this 24 -hour window, 
the imiquimod dose will be considered “missed” and should not be applied.  
 
The primary assessment of response will be based on modified Radiologic Assessment in Neuro -
Oncology (RANO) criteria ( Wen 2010 ).  The presence of any of the following will define PD:  
 ≥25% increase in the bidimensional product of enhancing tumor compared to pre -SL-[ADDRESS_542150] response following initiation of SL -701 (unidimensional increases in contrast -
enhancing tumor ≤1cm will not result in discontinuation of investigational therapy, unless there 
SL-701  Page 15 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 is additional clinical/radiographic evidence of unequivocal GBM progression) ; 
 New measureable contrast -enhancing lesion(s) defined as lesion(s) that are at least [ADDRESS_542151] 2 planes; or  
 Significant clinical decline not attributable to co -morbid event or change in concurrently 
administered medication .   
As part of each tumor response assessment using modified RANO criteria, information will be 
collected on the patien t’s clinical status (eg, stable, improved, or declining since the last assessment), 
functional neurological status using the KPS score , and concomitant medications, including 
corticosteroid use .  A patient with radiographic evidence of PD after initiating SL -701 may continue 
study drug for an additional 8 weeks , provided that the patient does not experience s ignificant clinical 
deterioration and/or significant toxicity, as determined by [CONTACT_428618] .  If 
follow -up imaging  after [ADDRESS_542152] -enhancing tumor ≤1cm will not 
result in discontinuation of investigational therapy, unless there is addit ional clinical/radiographic 
evidence of unequivocal GBM progression.  Follow -up imaging may be performed <8 weeks after the 
initial detection of PD (eg, after 4 weeks) if medically appropriate .  If PD is confirmed on follow -up 
imaging at 2 consecutive time  points ≥4 weeks apart, the PD date is the date that PD criteria were 
initially met .   
Concomitant Medications:  
Allowed Medications/Therapi[INVESTIGATOR_014]:  
Concomitant systemic corticosteroids are to be avoided if medically feasible .  If used, cortico steroid 
doses sho uld be the minimum necessary for appropriate clinical management .  Any patient requiring 
initiation or significant increase in corticosteroid dosing due to progressive neurologic signs or 
symptoms should undergo a rigorous evaluation for recurrent GBM .  Efforts should be made to taper 
off corticosteroids as quickly as possible in the absence of  PD.  Topi[INVESTIGATOR_428557] .  Inhaled corticosteroids may be administered as needed .  As appropriate, 
topi[INVESTIGATOR_428558] -steroidal anti -inflammatory agents or antihistamines may be used as 
alternatives.   Patients with a history of prior Hepatitis B infection with evidence of immunity (ie , 
positive HBV surface antibody [HBsAb]) should b e treated with appropriate anti -viral therapy (ie , 
lamivudine, adefovir,  or similar anti -viral agents) for the duration of investigational therapy.  
Prohibited Medications/Therapi[INVESTIGATOR_014] : 
Therapi[INVESTIGATOR_428559] -tumor intent , such as  prior 
chemotherapy, bevacizumab (or other VEGF/VEGFR -directed agent), or an investigational agent for 
recurrent/progressive GBM or prior bevacizumab as part of initial GBM therapy . 
Toxicity Monitoring Rules:  
The toxicity monitoring rules for the following events will be applied to the first [ADDRESS_542153], there will not be any 
interruption in accrual to assess these even ts. 
Regimen Limiting Toxicity : 
A regimen -limiting toxicity ( RLT ) includes any of the following  events that occur anytime through  the 
first 12  doses  of study drug (ie, from first dose through approximately 24 weeks)  which are considered 
possibly, probably or definitely related to investigational therapy : 
SL-701  Page 16 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  ≥Grade  3 bronchospasm  or Grade 2 bronchospasm that does not resolve within 24 hours 
despi[INVESTIGATOR_231064] (ie , inhaled albuterol) ; 
 ≥Grade  3 generalized  urticaria;  
 Other ≥Grade  3 allergic reaction, such as exfoliative erythroderma, anaphylaxis, or vascular 
collapse ; 
 ≥Grade 3 non -hematologic toxicity (excluding hepatic laboratory toxicity  and excluding Grade 
3 hypertension in which blood pressure resolves to <160 [systolic] and <100 [diastolic] with 
intensified antihypertensive therapy ) related to the study drug regimen including ≥Grade  3 
injection site reaction due to SL -701 emulsion or immunoadjuvant administration , with the 
exception of transient Grade ≥ 3 events as detailed below ; 
 Intolerable ≥Grade  3 skin (injection site) reaction lasting ≥7 days (at ≥Grade 3) or that recurs 
despi[INVESTIGATOR_428560] , if applicable ; 
 ≥Grade  3 constitutional symptoms (including fatigue, fever, malaise, myalgia, edema [non -
cerebral])  that persist for >[ADDRESS_542154] for >48 h despi[INVESTIGATOR_428561] , if applicable ; 
 ≥Grade  3 nausea /vomiting or diarrhea exceeding 24 h  despi[INVESTIGATOR_428562] -emetic or 
anti-diarrheal therapy , respectively ; 
 Grade  3 or 4 neutropenia with fever ; 
 Grade 4 hematologic toxicity (cytopenia) lasting >5 days ; 
 Cerebral edema associated with severe clinical manifestations  (Grade 4) , which  in the 
Investigator’s opi[INVESTIGATOR_428563].  Cerebral edema ( Grade 4)  due to underlying 
tumor progression (based on imaging), change in concurrent medications  (such as rapid 
decrease in corticosteroids) , or a co -morbid event  (such as status epi[INVESTIGATOR_428564], severe electrolyte 
imbalance) as well as <Grade [ADDRESS_542155] following each RLT .  Additionally, if a RLT  occurs in ≥[ADDRESS_542156] 3 
patients, ≥[ADDRESS_542157] 6 patients, ≥[ADDRESS_542158] 9 patients, ≥[ADDRESS_542159] 12 patients, ≥[ADDRESS_542160] 15 
patients, ≥[ADDRESS_542161] 18 patients, or ≥[ADDRESS_542162] 12 doses of study drug (ie, more 
than approximately 24 weeks following the start of investi gational therapy) will be considered RLT -
level events.  Evaluation of safety data for RLT -level events will occur according to similar 
guidelines/parameters as defined above (for RLTs).  
Sudden or Unexpected Deaths Related to SL -701: 
A safety review will t ake place following each sudden or unexpected death that is not considered by [CONTACT_428619] -related and is considered to be  related to SL -701.  Additionally, if such an 
event occurs in ≥[ADDRESS_542163] 3 patients, ≥[ADDRESS_542164] 6 patients , ≥[ADDRESS_542165] 9 patients, ≥[ADDRESS_542166] 12 patients, ≥[ADDRESS_542167] 15 patients, ≥[ADDRESS_542168] 18 patients, or ≥[ADDRESS_542169] 24 patients, 
accrual will be suspended and the Investigator , Medical Monitor and Sponsor will make decisions 
SL-701  Page 17 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 regarding the continuation of study accrual ; (Note: these are general guidelines, and lower rates of 
treatment -related deaths would likely result in study discontinuation) . 
In addition to the toxicity monitoring described above, an Independent Data Monitoring Commit tee 
(IDMC) will be established prior to the inclusion of the first patient in the study.  The IDMC will 
evaluate all available safety data when [ADDRESS_542170] 2 doses of SL -701, died, or 
withdrawn from the study .  The IDMC will also mon itor for RLTs throughout the study (ie, beyond the 
first 24 treated patients) to confirm the risk of RLTs is <33%, and the Committee may recommend 
interruption of accrual at any time during the study if excessive toxicity is observed .  Details regarding 
the content and timing of these safety reviews will be provided in the IDMC Charter.  
During Stage 2, the IDMC will also evaluate available safety data when [ADDRESS_542171] 3 doses of SL -701 (and adjvuant) and bevacizumab, died , or are withdrawn from the study.  
Assessments:  
Efficacy Assessments:  
Efficacy assessments include ORR, duration of response, OS -12, PFS -6, OS, and PFS .  Tumor r esponse 
will be assessed using modified RANO criteria .  For comparative purposes, response will also be 
assessed by [CONTACT_8225]  (RECIST ) (version 1.1) (Eisenhauer 
2009 ).  MRI scans for assessment of ORR  will be obtained during the Screening period and then every 
[ADDRESS_542172] dose of SL -701.  Clinical assessment for PD will be made at every visit, both 
visits when only scans are performed and when SL -701 is administered (Day 1, every 2 weeks 
thereafter  through Week 26, then approximately every 4 weeks (28 days) after Week 26). 
ORR is defined as the proportion of patients achieving a best response of complete response (CR) or 
partial response (PR) on 2 consecutive MRIs obtained ≥[ADDRESS_542173] .   
OS-12 is defined as the percentage of patients alive 12 months  (52 weeks ) after the initiation of SL -701 
(in an addi tional secondary analysis, OS-12 w ill be evaluated by [CONTACT_5263] -Meier estimate) .  OS is 
defined as the time from the date of initiation of SL -701 to the date of death from any cause .  PFS-6 is 
defined as the percentage of patients alive and progression -free at 6 months (26 weeks ) after the 
initiation of SL -701 (PFS -6 will also be evaluated by [CONTACT_5263] -Meier estimate) .  PFS is defined as the 
time from the date of initiation of SL -[ADDRESS_542174]. 
Safety Assess ments : 
Safety assessments include AEs, serious adverse events (SAEs), physical examinations, vital sign and 
weight measurements, clinical laboratory evaluations, and reasons for treatment discontinuation due to 
toxicity .  Progression of disease and disease -related death will not be considered AEs  or SAEs .  The 
severity of AEs will be assessed using the  NCI CTCAE, Version 4.03 (or higher).  
The AE reporting period for each patient enrolled in the study begins from the time the patient signs the 
ICF and is continuous through [ADDRESS_542175] event that occurs beyond the AE reporting period that the Investigator 
assesses as related to study drug treatment should also be reported as an AE.   
SL-701  Page 18 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Immunologica l Monitoring Studies : 
Blood samples ( 6 × 10 cc green top tubes) will be collected on Day 1,  at Weeks 4, 8, 12, 16, and 24 , 
and then every 8 weeks  thereafter  (approximately)  to evaluate the magnitude of immune response in 
peripheral blood mononuclear cells (PBMC) against the targeted GAA peptides using IFN -γ-enzyme -
linked immuno -spot (ELISPOT) assay  and flow cytometric analyses of lymphocyte activation.  All 
patient samples w ill be collected at the respective treatment sites and promptly  shipped to a single 
central processing laboratory to minimize variability .   
Tumor tissue samples , whenever there is available pretreatment tissue or tumor is biopsied for any 
reason throughou t the duration of the study, will be archived and assessed for GAA expression status 
and infiltration of GAA -specific T -cells.  
Statistical Methods:  
Sample Size : 
The initially planned  sample size of 100 patients was based on the following assumptions for the co -
primary endpoints of OS -12 and ORR  (Wick 2010 , van den Brent 2009 , Batchelor 2013 ): 
OS-12:  
 The null hypothesis is that OS -12 for patients treated with SL -701 is ≤25%;  
 The alternative hypothesis is that OS -12 for patients treated with SL -701 is ≥40%;  
 Testing will be by [CONTACT_428620] -sample binomial superiority test with type I error rate of 
1.25% , 1-sided.  
ORR  (by [CONTACT_428621]) : 
 The null hypothesis is that ORR for patients treated with SL -701 is ≤1 0%;  
 The alternative hypothesis is that ORR for patients treated with SL -701 is ≥ 25%; 
 Testing will be by [CONTACT_428620] -sample binomial superior ity test with type I error rate of 
1.25%, one -sided;  
 At least 80 patients will be evaluable for ORR.  
Based on these assumptions, the power for the  initially planned sample size was approximately 82% for 
OS-12 and 92% for ORR.   Accrual to Stage 1 one of the  study was discontinued following the accrual 
46 patients (all evaluable for ORR) who received SL -701 emulsion, GM-CSF, and imiquimod.  
Consequently the power for Stage 1 given the actual enrollment wa s approximately 48% for OS-12 and  
62% for ORR.  
In Stage 2, the null and alternative hypotheses  for OS -12 will remain the same as those indicated above .  
The null and alternative hypotheses for ORR will be ≤40%  and ≥60%, respectively.  All testi ng in 
Stage 2  will be at a type I error rate of 5%, one -sided.  If 30 patients (assumed all evaluable for ORR) 
are enrolled in  Stage 2 (SL -701 with adjuvant  poly-ICLC and with bevacizumab) the power is 
approximately 71% for OS -12 and 55% for ORR . 
Analysis Conventions : 
Demographic (eg, gender, age, race , ethnicity ) and baseline characteristics (eg, KPS, height, weight, 
and prior therapy) will be summarized with descriptive statistics.  
All enrolled patients who received any amount of study drug will be included in the safety analyses .  
Treatment -emergent AEs through  [ADDRESS_542176] dose of study drug will be summarized by [CONTACT_428622]-701  Page 19 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Dictionary for Regulatory Activities ( MedDRA™ ), Version 13.1 (or higher) , system organ class and 
preferred term .  The incidences and percentages of patients experiencing each AE preferred term will 
be summarized with descriptive statistics .  The severity of AEs will also be summarized by [CONTACT_428623], Version 4.03 (or higher) , grade and by [CONTACT_2235] (relationship to stud y drug).  Grade  3 and 4 
AEs, SAEs, and AEs leading to withdrawal, dose modification, or treatment discontinuation will also 
be summarized by [CONTACT_11702] .   
Laboratory results will be classified according to NCI  CTCAE, Version 4.03 (or higher) .  Laborato ry 
results not corresponding to an NCI  CTCAE term will not be graded .  Incidences of laboratory 
abnormalities will be summarized with descriptive statistics.  
Vital signs and physical examination results will be summarized with descriptive statistics.  
Testi ng for the co -primary endpoints will be by [CONTACT_428624] -sample binomial tests with type I error rate of 
1.25%, 1-sided  for Stage 1 of the study and 5%, 1-sided for Stage [ADDRESS_542177] 2-sided 97.5% 
(Stage 1) or 90% (Stage 2) confidence intervals will  be calculated for OS -12, ORR, and PFS -6.  
Distributions for  DR, OS, and PFS will  be estimated by [CONTACT_5263] -Meier methodology.  
The treatment schedule for Stage 2 is depi[INVESTIGATOR_48393]:  
 
D1 Wk 2 Wk 4 Wk 6 Wk 87 days 7 days
Rx
 Rx
 Rx
 Rx
 Rx
MRI
D8 D4 D11
Rx
 Rx
 Rx
 RxWk 3
SL-701
(poly-ICLC)SL-701 (poly-ICLC) 
+ Bevacizumab 10mg/kg
SL-701
+ Bev:-II--
SL-[ADDRESS_542178] duration of response  
dsRNA  double -stranded RNA  
EAE  Experimental autoimmune encephalomyelitis  
eCRF  electronic case report form  
EGFRvIII  epi[INVESTIGATOR_428565]-701  Page 21 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Abbreviation  Term  
EGW  external genital warts  
ELISPOT  enzyme -linked immunosorbent spot  
EMA  European Medicines Agency  
EphA2  ephrin type -A receptor 2  
FAS full analysis set  
FDA  Food and Drug Administration  
FLAIR  fluid -attenuated inversion recovery  
GAA  glioma -associated antigen  
GBM  glioblastoma multiforme  
GM-CSF granulocyte macrophage -colony stimulating factor  
h hour(s)  
HBsAb  hepatitis B surface antibody  
HGG  high-grade glioma  
HLA  human leukocyte antigen  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
IFN-γ interferon -gamma  
IL Interleukin  
IL-13Rα2  interleukin -[ADDRESS_542179]  
IRT Interactive Response Technology  
IV Intravenous  
KPS Karnofsky performance status  
LGG  low-grade glioma  
MedDRA  Medical Dictionary for Regulatory Activities  
SL-701  Page 22 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Abbreviation  Term  
MHC  major histocompatibility complex  
mmHg  millimeter(s) of mercury  
MRI  magnetic resonance imaging  
N number of patients with an observation  
N number of patients in the dataset or population  
NBSG  non-brain stem glioma  
NCI CTCAE  National Cancer Institute Common Terminology for Adverse Events  
ORE  objective response evaluable  
ORR  objective response rate  
OS overall survival  
OS-[ADDRESS_542180]  upper limit of normal  
US [LOCATION_002]  
VEGF  vascular endothelial growth factor  
VEGFR  vascular endothelial growth factor receptor  
WHO  World Health Organization  
 
SL-701  Page 24 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 1.  INTRODUCTION AND STUDY RATIONALE 
1.1 Glioma Background 
 Description and Characterization  
Glioma, which arises from glial cells, comprises approximately 30% of all primary brain and central 
nervous system (CNS) tumors and 80% of all malignant brain tumors.  Glioma is classified by [CONTACT_428625], as determined by [CONTACT_428626].  The main type of 
glioma, by [CONTACT_306551], is astrocytoma, of which glioblastoma multiforme (GBM) is the most common.  Of 
numerous grading systems currently in use, the most common is the World Health Organization (WHO) 
system for astrocytoma under which tumors are graded from I (least advanced disease and best 
prognosis) to IV (most advanced disease and worst prognosis):  
• Low-grade [WHO Grade II] gliomas ( ie, LGG) are well-differentiated, tend to exhibit benign 
characteristics and portend a better prognosis.  However, they have considerable rates of 
recurrence and of transformation to high-grade gliomas ( HGG) over time and should be 
classified as malignant. 
• High-grade [WHO Grade III –IV] gliomas ( ie, HGG) are undifferentiated or anaplastic.  These 
include anaplastic astrocytomas (Grade III) and GBM (Grade IV), which is frequently also 
referred to as glioblastoma. Most malignant gliomas are HGGs, which are very aggressive, 
difficult to treat, and carry a poor prognosis.   
Glioblastoma (ie, GBM), the most common HGG in adults and primary malignant central nervous 
system tumor, is diagnosed in approximately 11,000 individuals in the [LOCATION_002] (US) each year.  
 Treatment  
Despi[INVESTIGATOR_428566], including surgical resection, radiotherapy, chemotherapy, 
and targeted agents, the prognosis for patients with GBM is poor.  A multi-component treatment 
strategy combining surgical resection, radiotherapy ( RT), and temozolomide (TMZ) chemotherapy is 
considered the standard initial (ie, first-line) treatment in adults with newly diagnosed GBM disease.   
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), 
received accelerated approval by [CONTACT_2165] (FDA) for recurrent GBM based on 
an objective response rate ( ORR ) of approximately 20-25% ( Avastin Package Insert 5/2015 ).  
Nonetheless, all patients ultimately progress on bevacizumab therapy and rapi[INVESTIGATOR_428567] ( Norden 2008 ; Quant 2009 ).  Bevacizumab has not been 
shown to confer prolonged overall survival in GBM, either when incorporated into initial multimodality 
regimens, or in recurrent settings ( Chinot 2014).  It has also been postulated, albeit not proven in 
randomi
zed clinical studies, that cessation of anti-VEGF therapy results in rebound edema and clinical 
deterioration known as the so-called flare response ( Chamberlain 2011 ).  Bevacizumab has been 
associated with progression-free survival ( PFS) and likely symptomatic benefits; recent investigation 
suggests that the magnitude of this benefit is comparable, whether bevacizumab is administered as part 
of initial therapy, at time of GBM recurrence, or at a subsequent progression ( Pi[INVESTIGATOR_428568] 2014).  
The overall poor response of GBM to conventional cytotoxic and more recent biologically-based 
therapi[INVESTIGATOR_014], is attributed to several factors, including limited delivery through the blood-brain-barrier, 1.1.1 
1.1.2 
SL-701  Page 25 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 inherent biologic complexity and redundancy, high-rates of intrinsic and acquired resistance to therapy, 
and inter-as well as intra-tumoral heterogeneity ( Reardon 2006 ; Wen 2008 ). 
The lack of effective treatment options for adult GBM patients has been a motivation for the 
development of alternative therapi[INVESTIGATOR_014], including immunotherapi[INVESTIGATOR_014].  This includes specific T-cell epi[INVESTIGATOR_9230]-
based vaccines, which are under development as a potentially safer approach than whole glioma cell-
based vaccines. 
 Survival  
Outcome for adults with GBM is dismal, with a median overall survival ( OS) of 16  months for newly 
di
agnosed patients despi[INVESTIGATOR_428569] -modality therapy including surgical resection, RT, and TMZ 
chemotherapy .  Following progressive disease (PD) , salvage therapi[INVESTIGATOR_428570], 
with recent meta -analyses of Phase  2 studies conducted by [CONTACT_428627] i um 
and the North Central Cancer Treatment Group indicating  rates of 6 -month progression -free survival 
(PFS -6) and overall radiographic response of less than 10%  (Ballman 2007 , Wu 2010 , Lamborn  2008, 
G
orlia 2012 ). 
I
n view of these discouraging results with both traditional nonspecific cytotoxic and targeted 
therapeutics in malignant glioma, there is interest in developi[INVESTIGATOR_428571], such as vaccine strategies targeting glioma -
associated antigens  (GAAs ). 
1.[ADDRESS_542181] been conducted under investigator-
sponsored investigational new drug applications (INDs) assessing different multi-peptide combinations 
and methods of administration.  Each study included peptides derived from interleukin ( IL)-13 receptor 
alpha 2 protein chain (IL -13Rα2)  and ephrin type -A  receptor 2 (EphA2) antigens, which are highly 
immunogenic and expressed on the cell surface of both HGG and LGG .   
Stemline Therapeutics Inc . (Stemline) has licensed the exclusive worldwide rights to a clinically active 
oncology vaccine directed to multiple defined targets on tumor bulk and cancer stem cells ( CSCs ) from 
the University of Pi[INVESTIGATOR_9109] .  The vaccine targets multiple defined epi[INVESTIGATOR_428572], particularly GBM .  The Stemline vaccine, designa ted SL -701, consists of human 
leukocyte antigen (HLA) -A2 restricted peptides that are derived from CD8+ T cell epi[INVESTIGATOR_428573] 
[ADDRESS_542182] antigens overexpressed by [CONTACT_377289]:  MPS -380 (IL -13Rα2 345-353:1A9V ), MPS -381 (EphA2 883-
891), and MPS -486 (Survivin 95-104:3 M).  MPS -380 and MPS -381 are 9  amino acids in length, and MPS -
486 i
s 10 amino acids in length .  SL -701 also includes MPS -199, a peptide that functions as a helper T 
cell epi[INVESTIGATOR_428574]  (TT) , Tet A830, that is 16  amino acids in len g th.   
The SL-701 vaccine is nearly identical to the GAA/ TT peptide vaccine used in  the University of 
Pi[INVESTIGATOR_428575]08030085, described in Section  1.3, and both are emulsified in Montanide® ISA 
51 (
GAA/TT vaccines) .  The only difference, necessitated by [CONTACT_428628] [ADDRESS_542183] been shown to activate HLA-A2 restricted CD8+ T cells.  Moreover, 
ea
ch peptide has shown similar HLA binding and immunogenicity as demonstrated by [CONTACT_428629], 
interferon -gamma (IFN -γ) enzyme -l inked immunosorbent spo t (ELISPOT), and cytotoxic T 
lymphocyte (CTL) assays, respectively .   
The toll-like receptor (TLR) -3 ligand poly -ICLC  (polyinosinic -pol ycytidylic acid stabilized with poly -
lysine and carboxymethyl cellulose)  administered intramuscularly  (IM) w as utilized as an 
immunostimulatory adjuvant in 4 of the 5 initial clinical studies of the GAA peptide vaccines .  During 
Stage 1,  poly -I CLC was not available for purposes of comprehensive clinical development and 
commercialization ; for this reason, imiqui mod, which activates immune cells through the TLR -7, was  
used as  an i mmunostimulatory adju vant, along with  granulocyte macrophage -col ony stimulating factor  
(GM-CSF). In a preclinical study, the combined use of imiquimod  and GM -C SF has been demonstrated 
to induce a significantly greater immune reaction than either immunoadjuvant administered alone ( Hilf 
2010), and clinically the combination has been observed to be safe and well tolerated in the treatment of 
colorectal cancer using another cancer vaccine (Kuttruff 2012 ; Maughan 2012 ; Mayer 2012) . In Stage [ADDRESS_542184] s of the administration of a sequence of 3  agents – 
SL-701 em
ulsion injection, GM-CSF injection and imiquimod topi[INVESTIGATOR_68549]  – within a n approximate  5-
m
inute time frame.  Topi[INVESTIGATOR_428576] 24 hours 
(h) after each SL -701 emulsion injection.  In Stage 2 of the protocol, a complete dose of study drug 
consists of the administration of a sequence of 2 age nt s – SL -701 em ulsion injection  and poly -ICLC 
injection within an approximate 20 -minute time frame, with concomitant intravenous ( IV) bevacizumab .  
(The 
rationale for this modification to the vaccine adjuvants is provided in Section 1.2.5 .) 
 Rationale for Immunotherapy  in Glioma  
Although the CNS has historically been considered an immune privileged site, several clinical examples 
highlight the ability of the immune system to effectively attack targets within the CNS, including 
multiple sclerosis, encephalitis, and paraneoplastic cerebellar degeneration ( Albert 1998 ).  Experimental 
autoimmune encephalomyelitis (EAE) represents a further example of a potent immune response, in this 
case mediated by T cells, targeting specific CNS structures.  EAE is extensively utilized to model the 
pat
hology of acute disseminated encephalomyelitis and multiple sclerosis in humans ( Handel 2011 ). 
Several early phase clinical studies demonstrated the safety and preliminary therapeutic benefit of 
peripheral vaccinations using autologous, tissue-derived glioma antigens among adult malignant glioma 
patients ( Fadul 2011 ; Wheeler 2008 ; Yu 2004 ; Yu 2001 ; Liau 2005; Rutkowski 2004 ; 
De Vleeschouwer 2008; Y amanaka 2003 ; Yamanaka 2005 ).  One of the first such approaches 
(Rindopepi[INVESTIGATOR_94965]; Celldex Pharmaceuticals) evaluated the immune response against a 13 -amino acid 
peptide derived from epi[INVESTIGATOR_34519] (EGFRvIII), a tumor -specific antige n 
expressed in 25 -30% of GBM tumors ( Wong 1992 ; Heimberger 2005 ).  In a Phase [ADDRESS_542185] GBM therapy with surgery, RT, and TMZ chemotherapy ( Sampson 2010).  Of note, among 
patients who subsequently underwent resection at the time of tumor progression, EGFRvIII-expressing 1.2.2 
SL-701  Page 27 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 tumor cells were no longer detected from 9 of 11 (82%) patients treated with Rindopepi[INVESTIGATOR_94965].  These 
results suggest that a tumor antigen-specific immune response can effectively eliminate its targeted 
tumor cell population within malignant glioma tumors.  Nonetheless, the detection of EGFRvIII-
negative tumor cells at progression suggests that resistance can be mediated by [CONTACT_428630] a tumor 
cell subpopulation not targeted by [CONTACT_428631].  This mechanism of adaptability, referred to as 
immune escape, highlights the need for future vaccine strategies to target multiple tumor-associated 
antigens (TAA) in order to minimize the ability of tumors to expand antigen-negative tumor cell 
populations as a means of evading the immune system.   
One approach to target multiple TAA is the use of whole glioma lysates to stimulate the immune 
system.  Although the use of such an approach raises a theoretical concern for auto-immune responses 
ag
ainst normal CNS tissues, serious auto-immune encephalitis has not been reported with this approach 
thus far ( Yamanaka 2003 ; Yamanaka 2005 ; Yu 2004 ; Yu 2001 ; Liau 2005 ; Wheeler 2008 ; Rutkowski 
2004; De Vleeschouwer 2008 ; Fadul 2011 ).  Nevertheless, GAA vaccines in the form of synthetic 
peptides would be expected to greatly reduce the risk of treated patients developi[INVESTIGATOR_428577].  In addition, a more practical limitation to the use of whole glioma cell vaccines is the 
considerable and time-consuming ex vivo  manipulation of fresh glioma explants required to generate 
cl
inical grade vaccines.  In a previous study incorporating whole glioma lysates, the generation of a 
sufficient number of vaccine cells took [ADDRESS_542186] limited the suitability of this 
protocol for patients presenting with large tumor burdens or those who are at a higher risk of tumor 
progression with a limited life expectancy ( Okada 2000).  
 Rationale for the Selected  GAA Targets  
N
umerous preclinical and proof-of-concept clinical studies with the components of the SL-[ADDRESS_542187] peptides present in the SL-701 vaccine.  A summary of the efficacy and 
sa
fety of targeting these antigens in investigator-sponsored clinical studies of GAA peptide vaccines as 
a treatment for glioma is provided in Section 1.3.  In addition, the safety of Survivin-based vaccines as 
an immunotherapy approach in cancer patients has been established in several clinical studies ( Otto 
2005; Fuessel 2006 ; Wobser 2006 ; Tsuruma 2004 ). 
 Rationale for the Selected Emulsifying Agent  
In the 3 investigator-sponsored GAA vaccine studies summarized in Section 1.3 that involved 
subcutaneous ( SC) injections of emulsified vaccine, Montanide ISA -51was used as the emulsifying 
agent .  Given the favorable safety profile of the emulsified vaccine in these stu dies, Montanide ISA -[ADDRESS_542188] the 
immunizing peptides in a majority of patients without major toxicities ( Mavroudis 2006 ; Bolonaki 
2007; Valmori 2007;  Hamid 2007 ; C elis 2007 ).  Toxicities most commonly observed include local 
discomfort, induration, and erythema at the injection site.  1.2.[ADDRESS_542189], and GM-CSF and with the 
intent of demonstrating efficacy with an improved safety profile relative to poly-ICLC ( Disis 2002 ; 
Staehler 2007 ; Pi[INVESTIGATOR_9387] 2006 ; Peoples 2008 ; Tjoa 1998 ; Adams 2008 ; Fenoglio 2013 ; Smith 2010 ).  The 
justification for co-administration of imiquimod and GM-CSF was based on preclinical data indicating 
that the combination induces significantly greater immune reactivity than either immunoadjuvant 
administered alone ( Hilf 2010 ), which has been confirmed in the clinical setting in the treatment of 
colorectal cancer ( Kuttruff 2012 ). 
During Stage 2 of the study, poly-ICLC is the designated vaccine adjuvant, without the administration 
of topi[INVESTIGATOR_428578]-CSF.  The rationale for poly-ICLC includes its extensive prior use as an 
anticancer vaccine adjuvant, including its use in prior investigator-sponsored GAA vaccine studies, and 
the relatively high rates of early treatment discontinuation due to PD observed during Stage 1 of the 
current study (not observed in prior investigator-sponsored GAA vaccine studies incorporating poly-
ICLC) ( Okada 2011;  Pollack 2014 ).  
P
oly-ICLC is a double-stranded RNA (dsRNA) and was initially evaluated as an anticancer interferon 
inducer in clinical studies during the 1980s ( Levy 1985). These initial high-dose studies were notable 
for considerable toxicity and limited efficacy.  In more recent decades, investigations incorporating 
more modest doses (10-50 μg/kg ) have evaluated this agent in pediatric and adult gliomas, in both 
treatment -naïve and recurrent settings, both as monotherapy and i n combination with other therapeutic 
modalities , i ncluding radiation therapy  (Salazar 1996;  Butowski 2009a ; Butowski 2009b; Hartman 
2014).  Results of these clinical studies indicate a  favorable safety profile, although likely limited 
ant
icancer activity as a monotherapy in adult brain cancers.  Poly-ICLC is believed to activate  T-
lymphocytes and other immune cell populations by [CONTACT_282551]3 stimulation , and has been shown to 
enha
nce the efficacy of GAA -targeting vaccine therapi[INVESTIGATOR_428579]  (Zhu 
2007; Zhu 2010 ).  
1.3 S
tudies of GAA Vaccines Using IL-13R α2, EphA2, and/or Survivin 
Table 1 summarizes the characteristics of 5 investigator-sponsored clinical studies of GAA peptide 
vaccines using IL-13R α2, EphA2, and/or Survivin in adult glioma (4 studies) and pediatric glioma 
(1 study) .  Forty -eight adult patients and [ADDRESS_542190] been evaluated through June 2013 .   1.2.5 
SL-701  Page 29 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Table 1: Characteristics of Clinical Studies of Similar GAA Peptide Vaccines (June 2013)  
Study 
Number  Study Title  Vaccine Administration 
and Regimen  Peptide 
Antigens  Emulsifying 
Agent  Vaccine 
Adjuvant  # Pts 
Treated  
04-136 A Pi[INVESTIGATOR_428580] -1 Dendritic Cells 
Pulsed with Multiple Peptides in 
the Adjuvant Treatment of HLA -
A2 Positive Patients with 
Recurrent Malignant Gliomas  Four IN injections of 
loaded DCs every 2 wks 
for up to 4 vaccinations  IL-13Rα2 
EphA2 
YKL -40 
PADRE  n/a none  3 
05-115 A Phase I/II Evaluation of 
Vaccination with Type -1 Dendritic 
Cells Pulsed with Multiple 
Peptides in the Treatment of HLA -
A2 Positive Patients with 
Recurrent Malignant Gliomas  Four IN injections of 
loaded DCs every 2 wks 
for up to 4 vaccinations 
admi nistered with IM 
injection of poly -ICLC 
twice per week for 8 wks  IL-13Rα2 
EphA2 
YKL -40 
GP100 
PADRE  n/a poly-ICLC  22 
07-057 A Bi -Institutional Pi[INVESTIGATOR_428581] -A2-
Restricted Glioma Antigen -
Peptides in Combination with 
Poly-ICLC for Adults with WHO 
Grade II Low -Grade Gliomas  SC injection of emulsified 
vaccine every 3 wks 
administered with IM 
injection of poly -ICLC on 
the day of and on day 4 
after each vaccine for up 
to 8 vaccinations  IL-13Rα2 
EphA2 
Survi vin1 
WT1  
TETA830  Monta nide2 poly-ICLC  13 
08-135 A Pi[INVESTIGATOR_428582] -
A2-Restricted Glioma Antigen -
Peptides in Combination with 
Poly-ICLC for Adults with 
Recurrent WHO Grade II Gliomas  SC injection of emulsified 
vaccine every 3 wks 
administered with IM 
injection of poly -ICLC on 
the day of and on day 4 
after each vaccine for up 
to 8 vaccinations  IL-13Rα2 
EphA2 
Survivin1 
WT1  
TETA830  Monta nide2 poly-ICLC  10 
PRO -
08030085  A Pi[INVESTIGATOR_428582] -
A2-Restricted Glioma Antigen -
Peptides in Combination with 
Poly-ICLC for Children with 
Newly Diagnosed Malignant or 
Intrinsic Brain Stem  SC injection of emulsified 
vaccine every 3 wks 
administe red with IM 
injection of poly -ICLC for 
up to 8 vaccinations  IL-13Rα2 
EphA2 
Survivin1 
TETA830  Montanide2 poly-ICLC  33 
DC = dendritic cell; GM-CSF = granulocyte macrophage colony-stimulating factor; IM = intramuscular; IN = intranodal; 
n/a = not applicable; poly-ICLC = Hiltonol; SC = subcutaneous; pts = patients; TBD = to be determined; wks = weeks; 
yrs = years 
1 Survivin peptide used is 9 amino acids; SL-701 Survivin is a 10 amino acid peptide 
2 Montanide ISA-51 (GAA/TT vaccines) 
Studies 04-[ADDRESS_542191] similar to the target GBM patient population (05 -115) or utilized a 
peptide vaccine regimen that is most similar to the regimen in the present study (PRO08030085).  
SL-701  Page 30 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 
 Pediatric Study – PRO08030085  
The GAA peptide vaccine utilized in PRO08030085 contains the same peptides ( ie, contains peptides 
targeting the same antigens) and was emulsified in the same agent as SL-701; the GAA Peptide Vaccine 
differs from SL-[ADDRESS_542192] a diagnosis and treatment 
history of one of the following: 
 Newly diagnosed diffuse intrinsic pontine glioma (DIPG) or any biopsy proven HGG involving 
the brainstem, collectively referred to as brain stem glioma (BSG); 
 N
ewly diagnosed, incompletely resected ( ie, definite residual tumor visible on imaging) 
non-brainstem HGG;   
 Unresectable, progressive LGG of any subtype that has recurred despi[INVESTIGATOR_040] 2 prior chemotherapy 
or biological therapy regimens and/or radiation therapy. 
Eligible HGG histologies included GBM, anaplastic astrocytoma (AA), or gliosarcoma.  Other 
eligibility criteria included baseline Karnofsky/Lansky performance status (PS) ≥50; HLA -A2 positivity 
based on flow- cytometry; aged ≥3 years to <21  years; normal organ function (absolute neutrophil count 
[
ANC] ≥1.0×  109/ L, platelet count ≥100×  109/ L, hemoglobin ≥8 g/dL, normal serum creatinine or 
glomerular filtration rate ≥70 mL/min/1.73  m2, bi lirubin ≤1.5  × upper limit of normal [ULN], alanine 
aminotransferase [ALT] < 3× ULN); no overt cardiac, gastrointestinal, pulmonary, or psychiatric 
disease; and no or low-dose corticosteroids for at least 1 week prior to enrollment. 
Patients received GAA Peptide Vaccine emulsified in Montanide® ISA-51 (Seppic, Inc., Fairfield, NJ) 
as
 an SC injection every 3 weeks administered with a 30 g/kg IM injection of poly-ICLC (Oncovir, 
Inc., Washington, DC).  The treatment plan was to continue administration for up to 8 vaccinations, 
although some patients received >8 vaccinations. 
Table 2 summarizes the demographics, baseline disease characteristics, and vaccine administration for 
t
he enrolled patients.  All but 2 patients received RT, which was routinely initiated within a few weeks 
of diagnosis. 1.3.I 
SL-701  Page 31 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Table 2: Patient Demographics, Baseline Disease Characteristics, and Vaccine Administration:  
Study PRO08030085 
Parameter  All Patients  
(N=28)  
Median Age at Diagnosis, years (range)  7.2 (1.8, 17.9)  
Gender, n (%)   
     Male  14 (50.0)  
     Female  14 (50.0)  
Disease, n (%)   
     BSG  17 (60.7)  
     Newly Diagnosed HGG  5 (17.9)  
     Recurrent LGG  3 (10.7)  
     Recurrent HGG  3 (10.7)  
Karnofsky /Lansky  PS, n (%)   
     50 1 (3.6)  
     60 0 
     70 0 
     80 3 (10.7)  
     90 10 (35.7)  
     100 13 (46.4)  
     Missing  1 (3.6)  
Received Radiation, n (%)   
     Yes 26 (92.9)  
     No 2 (7.1)  
Received Chemotherapy, n (%)   
     Yes 16 (57.1)  
     No 12 (42.9)  
Median Time from Diagnosis to Start of Radiation, 
months (range)  0.6 (0.1, 47.1)  
Median Time from Diagnosis to First Vaccine 
Administration, months (range)  3.9 (2.7, 189.2)  
Median Number of Vaccine Doses, n (range)  5 (1, 12)  
BSG = brain stem glioma; HGG = high-grade glioma; LGG = low-grade glioma. 
A summary of treatment-emergent adverse events (TEAEs) ( ie, event onset date was any time after the 
administration of the first dose of study vaccine, or the event was reported prior to first dose date and 
worsened after the initiation of study drug) occurring in ≥20% of all treated patients, regardless of 
SL-701  Page 32 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 relationship to study drug, is presented in Table 3, by [CONTACT_10607] 
(MedDRA), version 15.0, preferred term  (PT) .  All but 2 TEAEs were Grade 1 -2; one patient 
experienced Grade 3 peripheral motor neuropathy that  was judged to be unrelated to study drug , and 
another
 patient experienced Grade 3 vomiting that was judged to be unlikely related to study drug.  
There were no serious adverse events (SAEs) or manifestations of autoimmunity (eg, vitiligo) reported .  
These  safety summaries in Table 3 exclude cases of possible immunologically -mediated 
pseudoprogression .   
Table 3: Summary of Treatment Emergent Adverse Events Occurring in ≥ 20% of All 
Patients:  Study PRO08030085 
MedDRA Preferred Term  All Patients  
(N=28)  
n (%)  
Injection Site Reaction  26 (92.9)  
Induration  25 (89.3)  
Pyrexia  20 (71.4)  
Fatigue  18 (64.3)  
Vomiting  10 (35.7)  
Decreased Appetite  9 (32.1)  
Nausea  9 (32.1)  
Headache  8 (28.6)  
Constipation  7 (25.0)  
Chills  6 (21.4)  
Contusion  6 (21.4)  
Seven (25.0%) patients had radiographic evidence of possible immunologically-mediated 
pseudoprogression.  The median (range) number of vaccinations prior to the detection of 
pseudoprogression was 5 (2, 11), and [ADDRESS_542193] significant in the patients with BSG and in 2 patients was sudden and severe in 
onset, and temporally related to vaccine administration. 
In an update of this 33-patient study, which included 20 patients with BSG ( Pollack 2013 ), [ADDRESS_542194] 18 months after 
di
agnosis compared to 3 of 15 patients with BSG without manifestations resembling pseudoprogression 
(Fisher’s exact test p=0.03) .  This suggests that pseudoprogression does not necessarily lead to a worse 
outcome and in fact may be a surrogate for vaccine-mediated biological activity resulting in an 
improved outcome. (It should be noted that pseudoprogression has been observed in the context of both 
standard and investigational therapi[INVESTIGATOR_428583] ( Van Mieghem 2013) and that pseudoprogression has 
been documented in other tumor types, most notably metastatic melanoma, specifically with agents 
SL-701  Page 33 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 designed to augment an immune response, including those associated with prolongation of survival 
(Wolchok 2009 ; Wolchok 2010).  
B
ased on radiographic evidence, 1 patient with HGG experienced a prolonged disease-free status on 
magnetic resonance imaging (MRI) during vaccination after a prior tumor resection and 3 patients 
expe
rienced a partial response (PR ; BSG, newly diagnosed non-brainstem HGG, and multiply recurrent 
LGG).  Five patients recently initiated treatment and therefore were not fully evaluated for tumor 
r
esponse. 
Median survival from date of diagnosis was 19.5 months for all patients (14 deaths among 28 patients) 
and 13.0 months among the subset of patients with recently diagnosed BSG (9 deaths among 
16 patients).  This median survival is longer than that reported in a large (n=130), Phase 3 study of RT 
versus RT plus chemotherapy in pediatric patients with diffuse BSG (8.0 and 8.5 months, respectively) 
(Broniscer 2004 ). 
In an update of the study that includes 24 patients with newly diagnosed HGG involving the brainstem 
(BSG; n=20) or patients with newly diagnosed HGG involving the non-brainstem region (NBSG; n=4) 
(Pollack 2013 ), median survival was 13.[ADDRESS_542195] radiographic 
response was stable disease (SD) in 18, PR in 2, minor response in one, and sustained disease-free status 
i
n 1 HGG patient who had undergone prior gross total resection following vaccine treatment.  Among 
the 5 patients with pseudoprogression, one exhibited a subsequent PR and survived for 19.5 months, and 
the other 4 patients survived for intervals of 18.4, 19.5, 11.3, and >29.7 months, retrospectively.  It is 
notable that the patient with pseudoprogression who subsequently stopped vaccine therapy and survived 
>29.7 months experienced a PR to subsequent chemotherapy (persisting 29.[ADDRESS_542196]-diagnosis).  
Median OS among BSG patients with pseudoprogression was 19.[ADDRESS_542197] been enrolled and treated with dendritic cell (DC) vaccine in 
Study 05-115.  Safety and efficacy data presented below are from publications and presentations of the 
study data ( Okada 2011 ). 
Eligible patients had histological diagnosis of GBM or anaplastic glioma (AG), including AA, 
anaplastic oligodendroglioma (AO), anaplastic oligoastrocytoma (AOA), or other anaplastic glioma.  
Other eligibility criteria included up to 2 previous recurrences; baseline Karnofsky PS (KPS) ≥ 60; 
HLA- A2 positivity based on flow cytometry; ≥18 years of age; adequate orga n function, as evidenced 
by [CONTACT_428632] ≥2.5 × 109/L, lymphocytes ≥0.4 ×  109/L, platelet count ≥100  × 109/ L, hemoglobin 
≥10 g/dL, left ventricular ejection fraction ≥50%, serum creatinine <  1.5 × ULN, bilirubin ≤2.0  × ULN, 
and AL
T, aspartate transaminase (AST), gamma-glutamyl transferase, lactic dehydrogenase, and 
alkaline phosphatase <2.5 × ULN; no serious concurrent medical illness; and no or low-dose 
cor
ticosteroids.   
Patients received vaccinations at 1 of 2 αDC1 dose levels (1 × 107/dose or 3 × 107/dose) at 2-week 
intervals intranodally for up to 4 vaccinations.  Participants also received twice weekly IM injections of 
20 μg/kg poly -ICLC. 1.3.2 
SL-701  Page 34 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 The median age (range) of treated patients was 48 (28, 71) years and 47% of the patients were female.  
Thirteen patients had GBM, 5 patients had AA, and 3 had AO, and 1 had AOA.  Eleven patients 
received 1 × 107/dose and 11 patients received 3 × 107/dose.  Nineteen patients received ≥4 vaccines.  
TEAEs (possibly, probably, or definitely related to the vaccine and/or poly-ICLC administration) that 
occurred in ≥20% of patients included injection site reactions (82%), fatigue (73%), myalgia (32%), 
headache (32%), body ache (27%), and fever (23%).  A patient with recurrent AO who had achieved a 
complete response (CR) (>29 months duration [ongoing]) experienced a Grade 4 anaphylactic reaction 
following the 18th dose of vaccine during the second booster phase ( 1 × 1 07 αDC1/dose) .  Within several 
minutes following intranodal αDC1 administration, this patient demonstr ated systemic urticaria and 
hypotension, which was managed with hydration, corticosteroids, and vasopressors .  Although the 
patient recovered with this management, the patient was admitted to the hospi[INVESTIGATOR_11297] .  This was 
considered a dose -limiting tox icity, and the patient was withdrawn from the study .  This was the only 
dose-limiting toxicity observed in this study.  
Among 19 patients evaluable for response based on radiographic evidence using M acdonald criteria 
(Macdonald 1990 ), 2 patients (AA, AO) experienced a CR and 3 patients (all with GBM) experienced a 
PR.  Median OS from study entry was 12 months for the patients with GBM and >23 months for the 
patients with AG.  This GBM survival value is consistent with the median OS of 12 months reported for 
patients receiving optimal therapy with surgical resection, RT, and chemotherapy.   
1.4
 Summary of Benefits and Risks  
Despi[INVESTIGATOR_428566], including surgical resection, RT, chemotherapy, and targeted 
agents, the prognosis for many patients with brain tumors remains poor.  The lack of effective treatment 
options for patients has been a motivation for the development of alternative therapi[INVESTIGATOR_014], including 
immunotherapi[INVESTIGATOR_014].  This includes specific T cell epi[INVESTIGATOR_9230]-based vaccines, which are under development 
as a potentially safer approach with greater feasibility than whole glioma cell-based vaccines.   
Through June 2013, 48 adult patients and 33 pediatric patients with HGG (brainstem and non-
brainstem) or LLGs in various settings have been treated with GAA peptide vaccines using Survivin, 
TetA830, and/or IL-13R α2 and EphA2 in 5  investigator -sponsored studies .  The results of these studies, 
which provided the foundation for SL -701 and justification of the planned  clinical program , i ndicate 
clinical activity in the form of objective responses based on radiographic evidence, with an acceptable 
safety profile  without raising the patient risk profile .   
I
n the present study, the amount of each peptide administered during each dose of SL-701 emulsion is 
similar to that used in studies 07-057, 08-135, and PRO08030085, and the frequency of administration 
is similar to Study 05-115 ( Table 1).  In each of these studies of GAA Peptide Vaccines, the 
vaccinations were well tolerated, providing a rationale for the SL-701 dosing regimen in adults with 
glioma.  The emulsifying agent Montanide ISA-51 was used in studies 07-057, 08-135, and 
PR
O08030085, where in each case the GAA Peptide Vaccine emulsion was well tolerated.  Also, the 
doses of the vaccine adjuvants GM-CSF and imiquimod used in Stage 1 are similar to those used in 
other clinical studies where minimal associated toxicity was observed ( Kurtruff 2012 , Disis 2002 , 
Adams 2008 , Fenoglio 2013 ) .  
While there are similarities to the GAA Peptide Vaccines used in the studies described in Section 1.3, 
the present study will be the first clinical study of the SL-701 regimen.  Although the prior experiences 
of the components of the SL-701 regimen indicate acceptable safety profiles, the present study will 
SL-701  Page 35 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 include an intensive safety monitoring plan, including halting of enrollment for unacceptably high rates 
of regimen-limiting toxicities (RLT s) or sudd en or unexpected deaths related to SL -701.   
Although imiquimod (Stage 1 only), GM-CSF (Stage 1 only) and poly-ICLC (Stage 2 only) are 
associated with known adverse events (detailed in Section 4.5 ), these are predominantly mild-moderate 
in severity and unlikely to result in unacceptable toxicity, especially given that the dosing for these 
agents stipulated in the current protocol entails considerably less frequent administration than in the 
pi[INVESTIGATOR_428584]-benefit profile for these agents was established.  The known risk profile 
of these agents is additionally justified by [CONTACT_428633], for which there 
are no available therapi[INVESTIGATOR_428585].  
1.5
 Rationale for Use of Poly-ICLC in Stage 2  
An interim analysis following enrolment of the initial 42 patients in this study (receiving SL-701, GM-
C
SF and topi[INVESTIGATOR_160772]) indicated relatively high incidences of discontinuation during or 
immediately following the initial 16 weeks of study therapy.  Specifically, a preliminary analysis based 
on data as of April 3, 2015 (and confirmed subsequently) indicated that 23 of 26 initial evaluable 
patients (88.5%) had discontinued therapy at or prior to the 16 week disease assessment, the majority 
because of PD or suspected PD .  Pri or and concomitant evaluations, including those performed by [CONTACT_117123] (IDMC), indicated an acceptable safety profile.  Specifically, 
a May 2015 evaluation indicated that among the initial 41 patients receiving investigational therapy, no 
patient had experienced Grade 3 or higher adverse events (AEs) considered related to SL-701 or 
discontinued therapy because of AEs  considered related to SL-701.  Due to unexpected low efficacy 
observed during Stage 1 of this protocol, accrual was interrupted after an initial 46 patients had been 
enrolled, pending evaluation and development of a protocol amendment to incorporate Stage 2. 
Preliminary correlative assessments also indicated evidence of T-lymphocyte recognition/activation of 
the vaccine epi[INVESTIGATOR_322].  Because the time required for cell mediated immune responses may exceed the 
initial 8 or 16 week assessment periods, and because of the rapid growth of recurrent/relapsed GBM, it 
was determined that additional evaluation of the vaccine would be optimized by [CONTACT_3252]-administration of the 
immune-adjuvant poly-ICLC, which was employed in the majority of prior investigator-sponsored 
clinical studies and with which GAA-vaccine administration was associated with durable GBM disease 
control and response.  It was additionally hypothesized that increased chronologic frequency of 
vaccine/adjuvant therapy during the initial weeks of therapy would optimize vaccine epi[INVESTIGATOR_9230]-mediated 
anti-GBM immune response, as has been demonstrated in several pre-clinical investigations ( Wick 
2011; Cho 2013 ). 
1.6 Rat
ionale for Addition of B evacizumab in Stage 2  
It has been hypothesized that the potential efficacy of SL-701 could be optimized by [CONTACT_428634], such as 
bevacizumab.  Additionally, pre-clinical evaluations indicate that inhibition of VEGF-mediated tumor 
neoangiogenesis may enhance immune recognition of neoplasia and concomitant anticancer immune 
mechanisms ( Huang 2012; Schoenfeld 2011 ; Tartour 2011 ). 
The safety profile associated with SL-701 in combination with poly-ICLC in prior investigator-
sponsored research, the safety profile associated with SL-701 in the early portion of STML-701-0114, 
and the known (non-overlappi[INVESTIGATOR_007]) safety profile of bevacizumab suggest that a combination of these 
agents would also have a high likelihood of an acceptable safety profile.  
SL-701  Page 36 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 2. STUDY OBJECTIVES 
The objectives of th is study are to  characterize the efficacy and safety of SL-701 as a treatment for 
recurrent GBM. 
2.1 Primary Objectives 
The primary objectives are to: 
 Characterize the safety and tolerability of SL-701 and SL-701 in combination with 
bevacizumab. 
 Est
imate the percent of patients alive 12 months after the initiation of SL-701 (OS-12). 
 Estimate the ORR. 
2.2 Secondary Objectives 
The secondary objectives are to:  
 Estimate the duration of response (DR). 
 Estimate the percent of patients alive and PFS-6 after the initiation of SL-701. 
 Estimate the distributions of PFS and OS . 
2.3 Exploratory Objectives 
The exploratory objectives are to:  
 Estimate the relationships between measures of immunogenicity and anti-tumor efficacy. 
 Evaluat
e available post-vaccine tumor tissue for GAA expression status and infiltration of 
GAA -specific T-cells . 
3. INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan 
This is a multicenter, open label Phase 1/[ADDRESS_542198] enhanced MRI or computed tomography ( CT) scans.   
During Stage 1, patients will receive SL-[ADDRESS_542199] to the toxicity 
monitoring rules described under Safety Assessments ( Section 3.2.1).  Progression of disease and 
disease-related death will not be considered AEs.  During Stage 2, patients will receive SL-[ADDRESS_542200] screening procedures completed (Days -13 to 0, with the 
exception of HLA testing which may be conducted 28 days prior to the start of investigational therapy).   
SL-701  Page 37 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 In Stage 1, a complete dose of study drug consists of the administration of a sequence of 3 agents, SL -
701 emulsion SC injection, GM-CSF SC injection, and imiquimod topi[INVESTIGATOR_68549], within a 5-minute 
time fra me.  Topi[INVESTIGATOR_428576] 24 h after each 
SL-701 emulsion injection.  For each patient, SL -701 emulsion (SL-701 in Montanide®) wi ll be 
administered by [CONTACT_428635] 1 with imiquimod topi[INVESTIGATOR_68549] 5% applied 
im
mediately (within 5 minutes after SL-701 emulsion injection) to the SL-701 emulsion injection site.  
In addition to the SL-701 emulsion injection, the patient will receive a SC injection of GM-CSF 150 µg 
close to the injection site of SL-701 emulsion (immediately following the SL -701 emulsion injection, 
prior to the application of topi[INVESTIGATOR_160772]).  An additional dose of imiquimod cream will be applied 
at the same site by [CONTACT_102] 24 h later.   
In Stage 2, a complete dose of investigational treatment consists of the administration of a sequence of 
2 agents, SL - 701 emulsion SC injection and poly-ICLC IM injection, within an approximate 20 minute 
time frame.  In Stage 2, patients also will receive IV bevacizumab (10 mg/kg) administered every 
2 weeks, subsequent to the administration of SL-701/poly-ICLC.  Investigational SL- 701 emulsion (and 
the adjuvant poly-ICLC) will be administered twice weekly for the initial 2 weeks, every 7 days during 
the 
subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) 
throug
h Study Week 22, followed by [INVESTIGATOR_135] 4 weeks (for SL-701/poly-ICLC) until study end 
(bevacizumab will continue to be administered every 2 weeks subsequent to Week 22).  Patients will 
continue to receive study drugs according to this schedule until the occurrence of PD, withdrawal of 
informed consent, unacceptable toxicity, or non-compliance, whichever occurs first.   
On days  of s tudy drug administration, patients  will have concomitant medications recorded ,  vital signs 
and weight measured, blood samples taken for serology and laboratory chemistry evaluation, and urine 
taken for urinalysis .  Clinical status will be assessed for significant changes  at ea ch vi sit to the study site  
and A Es will be documented .  During Stage 1, patients will al so receive a paper diary to remind  them 
how
 to apply imiquimod [ADDRESS_542201] be done at exactly 2 weeks after the Day 
1 SL -701 emulsion administra tion date .  Study visits and assessments after the second SL- 701 emulsion 
administration ( Week 2 ) should be  done within a ±  3 day window adhering to the schedule  in Table 4 
(Stage 1) and Table 5 (Stage 2) . 
Blood samples (60 mL per day) for immunological monitoring studies will be collected on S tudy Day 1, 
at Study Weeks 4, 8, 12, 1 6,and 2 4, and t hen every 8 weeks thereafter (approximately) to evaluate the 
magnitude of immune response in peripheral blood mononuclear cells (PBMC)  against the targeted 
G
AA peptides using IFN -γ- ELISPOT assay , major histocompatibility complex ( MHC ) tetramer assay,  
and flow cytometric analyses of lymphocyte activation .  Tumor tissue samples , whenever there is 
available pretreatment tissue or tumor is biopsied for any reason throughout the duration of the study , 
will be archived and assessed for GAA expression status and infiltration of GAA -specific T -cells.  
Approximately every [ADDRESS_542202] scan (the same 
modality as used to qualify for study entry).  Scans should be performed every 8 weeks (± 7 days ; ± 
5 days for the scan performed at Study Week 8 ).  T he interpretations of these imaging scans will be used 
to assess objective tumor response .  Each tumor response assessment will use  modified R esponse 
Assessment in Neuro -Oncology  (RANO ) criteria  and information will be collected on the patient’s 
SL-701  Page 38 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 clinical status (eg, stable, improved, or declining since the last assessment), functional neurological  
status (KPS sc ore) and concomitant medications, including corticosteroid use .   
Wi
thin 2 weeks of the determination of a p atient’s permanent discontinuation of study drug, the patient 
will return to the clinic for a n “End o f Treatment  Visit” .  At this vis it the patient will receive a physical 
examination (including assessment of vital signs and weight), KPS score , and AEs and concomitant 
m
edications will be recorded .  In accordance with current Good Clinical Practice  and regulations, AEs 
w
ill be recorded and monitored for [ADDRESS_542203] dose of study drug.  Disease progression in the 
medical opi[INVESTIGATOR_428586]/or disease -related morbidity and mortality as a study endpoint will 
not be considered an AE or SAE .  In addition, surviva l status and documentation of subsequent salvage 
therapy will continue to be collected  by [CONTACT_428636] [ADDRESS_542204]
udy drug.   
Table 4 provides the schedule of events for the study during Stage 1.  
Table 5 provides the schedule of events for the study during Stage 2.
SL-701  Page 39 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Table 4: Study Event Schedule: Stage 1 
Study Visits  Screen -
ing: 
Day -13 
to 0 Day 1  Weeks 
2, 4, 
and 6  Week 
8 Weeks 
10, 12, 
and 14  Week 
16 Week s 
18, 20, 
and 22  Week 
24 Week 
26 Week 
30 Week 
34 Beyond Week 34  End of 
Treat -
ment  Safety: 
Through 
[ADDRESS_542205] Dose  Every  
4 wks  Every  8 
wks 
Study Procedure s 
Informed consent form  X                
Inclusion/exclusion 
criteria0 X                
Medical history 
including prior 
therapy1  X   
             
Concomitant 
Medications  X X X X X X X X X X X X  X X  
Physical examination  X  X 
week [ADDRESS_542206] patient diary   X X X X X X  X X X  X   
SL-701  Page 40 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Study Visits  Screen -
ing: 
Day -13 
to 0 Day 1  Weeks 
2, 4, 
and 6  Week 
8 Weeks 
10, 12, 
and 14  Week 
16 Week s 
18, 20, 
and 22  Week 
24 Week 
26 Week 
30 Week 
34 Beyond Week 34  End of 
Treat -
ment  Safety: 
Through 
[ADDRESS_542207] Dose  Every  
4 wks  Every  8 
wks 
Study Procedure s 
and unused 
imiquimod12 
Phlebotomy for 
Immune response 
studies8  X X 
week 4  
only X X 
week 12 
only X  X   X  X8 X8   
MRI or CT9 X   X  X  X   X  X11    
Karnofsky 
Performance Status X   X  X  X X  X  X11 X   
Clinical assessment for 
PD10    X  X  X   X  X11 X   
Objective Tumor 
(response ) assessment  X   X  X  X   X  X11    
Tumor tissue 
submission, as 
available  X  
AE monitoring   X X X X X X X X X X X  X X  
Survival & subsequent  
therapy documentation                X X 
Abbreviations: MRI - magnetic resonance imaging; CT - computed tomography; AE – adverse event .   
NOTE: Study Week [ADDRESS_542208] be done 2 weeks (± 3 days) after the Day 1 SL-701 emulsion and adjuvant 
administration date.  Study visits and assessments after the second SL-701 emulsion and adjuvant administration (Week 2) should be don e within a ± [ADDRESS_542209] be done 8 weeks (± 5 days) after the Day [ADDRESS_542210] scans after Study Week 8 should be done every 8 weeks 
± [ADDRESS_542211] scans after Study Week 50 may be performed every 12 weeks (± 14 days). 
0 
Laboratory evaluation of HLA status may be performed within a 28 day period prior to initiation of investigational therapy. Unless otherwise stated, other inclusion/exclusion 
evaluations should be performed within a 14-day period (Days -13 through 0) prior to initial study therapy. 
[ADDRESS_542212] 28 days. ..... , 
SL-701  Page 41 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 2 Pregnancy testing may be done using a urine or serum sample.   
3 Vi
tal signs include blood pressure, heart rate, respi[INVESTIGATOR_697], and body temperature. 
4 Hematology assessments include hematocrit, hemoglobin, red blood cell count, white blood cell count with differential (neutrophils, eosinophils, basophils, lymphocytes, and 
monocytes), platelet count, and reticulocytes. 
[ADDRESS_542213] bilirubin, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total bilirubin , total protein, and uric acid.  
6 Coagulation parameters assessed are prothrombin time  or international normalized ratio (INR) and activated partial thromboplastin time (aPTT).  
7 Urinalysis assessments include bilirubin, blood, color, glucose, ketones, leukocyte esterase, nitrites, pH, protein, specific gravity, turbidity, urobilinogen, and microscopic 
examination (including bacteria, casts, crystals, epi[INVESTIGATOR_1663], red blood cells, and white blood cells). 
8 Peripheral blood for immune response evaluation should be performed at baseline (Day 1), and prior to treatment at Weeks 4, 8, 12, 16, 24, 34 and thereafter every 8 weeks 
through Week 50.  For patients remaining on-study beyond Week 50, peripheral blood should be evaluated every 12 weeks (± 14 days) and at end- of-treatment. 
[ADDRESS_542214], should be taken to assess tumor response as was used to qualify the patient for entry into the study 
(screening scan) .  MRI is the preferred imaging modality as detailed in the protocol.  
10 As part of each tumor response ass essment using modified RANO criteria, information will be collected on the patient’s clinical status ( eg, stable, improved, or declining since 
the last assessment), functional neurological status (KPS score) and concomitant medications, including corticosteroid use. 
[ADDRESS_542215], KPS score, and tumor assessments may be performed every 12 weeks (± 14 days). 
12 Imiquimod (topi[INVESTIGATOR_2855]) and GM-CSF (subcutaneous) are administered during Stage 1 of the study only.   
SL-701  Page 42 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Table 5: Study Event Schedule: Stage 2 
Study Visits  Screen -
ing: 
Day -13 
to 0 Day 1  Days 4, 
8, 11; 
Weeks  
2, 3, 4, 
& 6 Week 
8 Weeks 
10, 12, 
and 14  Week 
16 Week s 
18, 20, 
and 22  Week 
24 Week 
26 Week 
30 Week 
34 Beyond Week 34  End of 
Treat -
ment  Safety: 
Through 
[ADDRESS_542216] Dose  Every  
4 wks  Every  8 
wks 
Study Procedure s 
Informed consent form  X                
Inclusion/exclusion 
criteria1 X                
Medical history incl . 
prior therapy2  X                
Concomitant 
Medications  X X X X X X X X X X X X  X X  
Physical examination  X  X 
wk 2 & [ADDRESS_542217] 3 X             X   
Vital signs4 and weight  X X X X X X X X X X X X  X   
Hematology5 X X X X X X X  X X X X  X   
Serum chemistry6 X X X X X X X  X X X X  X   
Coagulation paramete rs7 X X X  
w 2, 4, 6 X X X X  X X X X  X   
Urinalysis8 X X X 
w 2, 4, 6 X X X X  X X X X  X   
SL-701 and poly-ICLC  
dosing9  X X X X X X  X X X X     
Bevacizumab dosing10  X X 
weeks  
2, 4, 6  X X X X X X X X X     
SL-701  Page 43 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Study Visits  Screen -
ing: 
Day -13 
to 0 Day 1  Days 4, 
8, 11; 
Weeks  
2, 3, 4, 
& 6 Week 
8 Weeks 
10, 12, 
and 14  Week 
16 Week s 
18, 20, 
and 22  Week 
24 Week 
26 Week 
30 Week 
34 Beyond Week 34  End of 
Treat -
ment  Safety: 
Through 
[ADDRESS_542218] Dose  Every  
4 wks  Every  8 
wks 
Study Procedure s 
Phlebotomy for Immune 
response studies11  X X 
week 4  X X 
week 12 X  X   X  X X   
MRI or CT12 X   X  X  X   X  X13    
Karnofsky Performance 
Status X   X  X  X X  X  X13 X   
Clinical assessment for 
PD14    X  X  X   X  X13 X   
Objective Tumor 
(response ) assessment  X   X  X  X   X  X13    
Tumor tissue 
submission, as available  X  
AE monitoring   X X X X X X X X X X X  X X  
Survival & subsequent  
therapy documentation                X X 
Abbreviations: MRI - magnetic resonance imaging; CT - computed tomography; AE – adverse event 
NOTE: During the initial 2 weeks of study therapy (in Stage 2), SL-701 emulsion and adjvuant will administered twice per week.  The Day 4 and Day 11 visits may be performed 
± 1 day (ie, on either Days 3, 4 or 5 and on either Days 9, 10, or 11). The Day 8 (Week 1) visit should be done as closely as possible to a date 1 week after the Day 1 SL-701 
emulsion administration (± 3 days is permitted).  Study visits and assessments subsequent to these initial twice-weekly administrations (Week 3 and beyond) should be done within 
a ± [ADDRESS_542219] be done 8 weeks (± 5 days) after the Day [ADDRESS_542220] scans after Study Week 
8 should be done every 8 weeks ± [ADDRESS_542221] scans after Study Week 50 may be performed every 
12 weeks (± 14 days). 
1  Laboratory evaluation of HLA status may be performed within a 28 day period prior to initiation of investigational therapy .  Unless otherwise stated, other inclusion/exclusion 
evaluations should be performed within a 14 -day period (Day s -13 through 0) prior to initial study therapy.   
[ADDRESS_542222] 28 days.  
3  Pregnancy testing may be done using a urine or serum sample.   
4  Vital signs include blood pressure, heart rate, respi[INVESTIGATOR_697], and body temperature. .... , 
SL-701  Page 44 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 5  Hematology assessments include hematocrit, hemoglobin, red blood cell count, white blood cell count with differential (neutrophils, eosinophils, basophils, lymphocytes, a nd 
monocytes), platelet count, and reticulocytes. 
[ADDRESS_542223] bilirubin, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total bilirubin, total protein, and uric acid.  
7  Coagulation parameters assessed are prothrombin time  or international normalized ratio (INR) and activated partial thromboplasti n time (aPTT).  
8  Urinalysis assessments include bilirubin, blood, color, glucose, ketones, leukocyte esterase, nitrites, pH, protein, specific gravity, turbidity, urobilinogen, and microscopic 
examination (including bacteria, casts, crystals, epi[INVESTIGATOR_1663], red blood cells, and white blood cells). 
9  Poly-ICLC (IM injection) is administered during Stage 2 of the study only. 
10  During study Stage 2, patients will receive SL-701 (including adjuvant) with bevacizumab .  Bevacizumab will be administered at a dose of 10 mg/kg body weight and will be 
administered starting Day 1 and approximately every 2 weeks thereafter.  On days when both SL-701 and bevacizumab are to be administered, bevacizumab should be 
administered following administration of SL-701 and adjuvant.  For patients remaining on-study beyond Weeks 24-26, bevacizumab administration every 2 weeks should continue, 
including Weeks 28 and 32.  Although other study procedures will occur every 4 or 8 weeks beyond Week 34 (and in some cases every 12 weeks beyond Week 50), bevacizumab 
administration should continue every 2 weeks until there is evidence of PD or unacceptable toxicity. 
11 Peripheral blood for immune response evaluation should be performed at baseline (Day 1), and prior to treatment at Weeks 4, 8, 12, 16, 24, 34 and thereafter every 8 weeks 
through Week 50.  For patients remaining on-study beyond Week 50, peripheral blood should be evaluated every 12 weeks (± 14 days) and at end- of-treatment. 
[ADDRESS_542224], should be taken to assess tumor response as was used to qualify the patient for entry into the study 
(screening scan).  MRI is the preferred imaging modality as detailed in the protocol.  
[ADDRESS_542225], KPS score, and tumor assessments may be performed every 12 weeks (± 14 days). 
14 As part of each tumor response assessment using modified RANO criteria, information will be collected on the patien t’s clinical status (eg, stable, improved, or declining since 
the last assessment), functional neurological status (KPS score) and concomitant medications, including corticosteroid use. 
 
SL-701  Page 45 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Figure 1 : Treatment Flow Schedule for Stage 2 
 
D1 Wk 2 Wk 4 Wk 6 Wk 87 days 7 days
Rx
 Rx
 Rx
 Rx
 Rx
MRI
D8 D4 D11
Rx
 Rx
 Rx
 RxWk 3
SL-701
(poly-ICLC)SL-701 (poly-ICLC) 
+ Bevacizumab 10mg/kg
SL-701
+ Bev:
SL-[ADDRESS_542226] 3 doses of SL-701 (and adjuvant) and bevacizumab, died, or are 
w
ithdrawn from the study.  The IDMC will also monitor for RLTs throughout the study ( ie, beyond the 
first 24 treated patients) to confirm the risk of RLTs is <33%, and the Committee may recommend 
interruption of accrual at any time during the study if excessive toxicity is observed.  Details regarding the 
content and timing of these safety reviews will be provided in the IDMC Charter. 
 Toxicity Monitoring Rules  
The toxicity monitoring rules for the following events will be applied to the first [ADDRESS_542227] 12 doses of study treatment 
(ie, from first treatment through approximately 24 weeks), which are considered possibly, probably or 
def
initely related to investigational therapy: 
 ≥Grade3 bronchospasm or Grade 2 bronchospasm that does not resolve within 24 hours despi[INVESTIGATOR_428587] (ie, inhaled albuterol);  
 ≥Grade 3 generalized urticaria; 
 Other ≥Grade 3  allergic reaction, such as exfoliative erythroderma, anaphylaxis, or vascular 
collapse; 
 ≥Grade 3 non-hematologic toxicity (excluding hepatic laboratory toxicity and excluding Grade 3 
hypertension in which blood pressure resolves to <160 [systolic] and <100 [diastolic] with 
intensified antihypertensive therapy) related to the study treatment regimen including ≥Grade 3 
injection site reaction due to SL-701 or immunoadjuvant administration, with the exception of 
transient ≥Grade 3  events as detailed below; 
 Intolerable ≥Grade 3 skin (injection site) r eaction lasting ≥7 days (at Grade 3) or that recurs 
despi[INVESTIGATOR_428560], if applicable; 
 ≥Grade 3 constitutional symptoms (including fatigue, fever, malaise, myalgia, edema [non-
ce
rebral]) that persist for > [ADDRESS_542228] for > 48 h despi[INVESTIGATOR_428561], if applicable; 
 ≥Grade 3 nausea/vomiting or diarrhea exceeding 24 h despi[INVESTIGATOR_428562]-emetic or anti-
diarrheal therapy, respectively; 
 Grade 3 or 4 neutropenia with fever;  
 Grade 4 hematologic toxicity (cytopenia) lasting >5 days; 3.2.1 
3.2.2 
SL-701  Page 47 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Cerebral edema associated with severe clinical manifestations (Grade 4), which in the 
Investigator’s opi[INVESTIGATOR_428563].  Cerebral edema (Grade 4) due to underlying 
tumor progression (based on imaging), change in concurrent medications (such as rapid decrease 
in corticosteroids), or a comorbid event (such as status epi[INVESTIGATOR_7397], severe electrolyte imbalance) 
as well as Grade <[ADDRESS_542229] following each RLT.  Additionally, if a RLT occurs in ≥[ADDRESS_542230] 3 patients, 
≥[ADDRESS_542231] 6 patients, ≥[ADDRESS_542232] 9 patients, ≥[ADDRESS_542233] 12 patients, ≥[ADDRESS_542234] 15 patients, 
≥[ADDRESS_542235] 18 patients, or ≥[ADDRESS_542236] 12 doses of study treatment (ie , 
more than approximately 24 weeks following the start  of investigational therapy) will be considered RLT -
level events.  Evaluation of safety data for RLT -level events will occur according to similar 
guidelines/parameters as defined above (for RLTs).  
Please consult the appropriate components of Section 5.5 for additional criteria for the discontinuation of 
investigational study therapy.  
[IP_ADDRESS]  Sudden or Unexpected Deaths Related to SL-[ADDRESS_542237] following each sudden or unexpected death that is not considered by [CONTACT_138995] a disease -related mortality and is considered to be related to SL -701.  A dditionally, if 
such an event occurs in ≥[ADDRESS_542238] 3  patients, ≥[ADDRESS_542239] 6 patients, ≥[ADDRESS_542240] 9 patients, ≥[ADDRESS_542241] 12 patients, ≥[ADDRESS_542242] 15 patients, ≥[ADDRESS_542243] 18 patients, or ≥[ADDRESS_542244] 24  patients, 
accrual will be suspended and the Investigator, Medical Monitor , and Spo nsor will make decisions 
regarding th e continuation of study accrual .  (No te: these are general guidelines, and lower rates of 
treatment -related deaths would likely result in study discontinuation .)  Glioblastoma multiforme -related 
mortality and morbidity will not be reported as expedited IND  safety reports, unless there is a serious and 
unexpe
cted event with evidence of a causal relationship between study drug and the event.  
SL-701  Page 48 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 [IP_ADDRESS]  Diagnosis and Management of Suspected SL-701-Induced Pseudoprogression 
I
f pseudoprogression is suspected within 12 months following the initiation of SL-701 and the patient is 
neurologically worse sufficient to warrant the initiation of or an increase in the dosage of cortico steroids , 
subs
equent doses of SL -701along with the applicable adjuvants (GM -CSF and imiquimod in St age 1 and 
poly-ICLC with bevacizumab in Stage 2)  will not be administered pending evaluation as per the 
g
uidelines described below. Pseudoprogression refers to increased enhancement of the primary tumor 
and/or surrounding tissue without unequivocal evidence of tumor progression on imaging that may be due 
to inflammation associated with study therapy, changes in relevant medications (ie,  decreased 
cor
ticosteroid dosing), or the development of a co -morbid event.   T he following is a summary of how 
suspe cted pseudoprogression will be managed within the protocol . 
 If a scan shows a ≤50% increase in tumor size and the patient is asymptomatic or symptoms are 
sufficiently mild as to not warrant initiation of or an increase in the dosage of corticosteroids, SL-[ADDRESS_542245]-enhancing tumor ≤1cm, unless 
there is additional clinical/radiographic evidence of unequivocal GBM progression.  
 If a scan shows increased size of the enhancing tumor and the patient demonstrates worsening 
neurological status sufficient to warrant the initiation of or an increase in the dosage of 
corticosteroids, SL-701 will be held and dexamethasone will be administered or increased as 
clinically warranted for symptom control.  Re -imaging should be performed every 4 weeks  (± 7 days ) 
(
maximum 4 -month duration ) to determine disease status on the lowest possible cortico steroid dose .  
Inability to wean the cortico steroid dose to dexamethasone  ≤4 mg/day during this interval will result 
in permanent discontinuation of SL -701. 
o If the repeat scan on increased cortico steroid  dose  i s unchanged or worse, and/or the patient’s 
clinical status has no t improved, a biopsy (or resection, if clinically indicated) may be considered 
to differentiate between pseudo - and true tumor progression .  When a biopsy or resection is 
performed, the histopathological specimen should be carefully examined for evidence o f 
inflammatory/lymphocytic infiltration (pseudoprogression) .  If inflammatory/ lymphocytic 
infiltration and/or necrosis comprise the majority of the specimen, patients may remain on study 
and restart SL -701 once they are clinically stable  in the opi[INVESTIGATOR_428588]  
≤4 mg/day dexamethasone for at least 7 days .  If the majority of the resected specimen consists of 
persistent/recurrent tumor, the patient will be considered to have true tumor progression and SL -
701 will b e permanently discontinued.  
o In patients who refuse to undergo a biopsy or when a biopsy is prohibitive, re-imaging should be 
performed every 4  weeks (±  7 days) (for a maximum 4 -month duration ) to determine disease 
status and cortico steroids should be weane d if possible to ≤4 mg/ day dexamethasone .  If the 
repeat scan done after SL-[ADDRESS_542246] been  initiated or increased 
is worse, and/or the patient’s clinical status has declined  despi[INVESTIGATOR_428589], 
the pa tient will be permanently discontinued from SL -701 due to presumed tumor progression .  
The patient may restart SL -701 provided the following criteria are met: 1)  the repeat scan shows 
t
he tumor is stable or improved ; 2) t he patient is clinically stable or improved (even if they have 
partial resolution of symptoms and have not returned to pre -pseudoprogression status) ; and 3 ) 
there is no evidence of new tumor spread . 
SL-[ADDRESS_542247], true PD is associated with worsening that fails to improve with 
corticosteroid therapy or continues to progress or recurs on weaning the corticosteroids prior to additional 
vaccine treatment.   
 Routine Safety Assessme nts 
Routine safety assessments include the collection of data on AEs, SAEs, physical examinations, vital sign 
and weight measurements, clinical laboratory evaluations, and reasons for treatment discontinuation.   
The AE reporting period for each patient enrolled in the study begins from the time the patient signs the 
informed consent form  (ICF) and is continuous through [ADDRESS_542248] event that occurs beyond th e AE reporting period that the Investigator assesses as 
related to study drug treatment should also be reported as an AE.  
[IP_ADDRESS]  Clinical Laboratory Testing 
Blood and urine samples will be collected for clinical laboratory tests (hematology, serum chemistry, and 
urinalysis) a ccording to the Study Event Schedule in Table 4 (Stage 1) and Table 5 (Stage 2) .   
The following clinical laboratory parameters will be measured:  
Hematology  Hematocrit, hemoglobin, red blood cell count, white blood cell count with 
differential (neutrophils, eosinophils, basophils, lymphocytes, and monocytes), 
platelet count, and reticulocytes  
Serum Chemistry  ALT , albumin, alkaline phosp hatase, AST , blood urea nitrogen, calcium, carbon 
dioxide, chloride, creatine kinase, creatinine, direct bilirubin, glucose, lactate 
dehydrogenase, phosphorus, potassium, sodium, total bilirubin, total protein, and 
uric acid  
Coagulation Parameters  Prothrom bin time  or international normalized ratio (INR), and activated partial 
thromboplastin time (aPTT)  
Urinalysis  Bilirubin, blood, color, glucose, ketones, leukocyte esterase, nitrites, pH, protein, 
specific gravity, turbidity, urobilinogen, and microscopic examination (including 
bacteria, casts, crystals, epi[INVESTIGATOR_1663], red blood cells, and white blood cells)  
Local laboratories will be used for all clinical laboratory testing .  Blood for laboratory evaluation may be 
obtained either the day of investigatio nal therapy, or within a 72-hour period prior to treatment (with the 3.2.3 
SL-701  Page 50 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 exception of  Day 1).  Please consult Section 5.3 regarding postponement/administration of investigational 
therapy in the setting of laboratory abnormalities.    
Laboratory reports will be reviewed, signed, and dated by [CONTACT_29517] d elegated physician .  
Clinical laboratory results outside of the reference ranges will be flagged in the data listings and evaluated 
for clinical significance by [CONTACT_737].  
[IP_ADDRESS]  Vital Sign  Measurement s and Weight  
Vital sign measurements (systolic blood pressure, diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], and 
body temperature) and weight measurement will be performed periodically throughout the study, 
according to the Study Event Schedule ( Table 4 [Stage 1] and Table 5 [Stage 2]) .  Blood pressure and 
pul
se rate will be measured after the patient  has been resting in the supi[INVESTIGATOR_21683] 5  minutes.  
[IP_ADDRESS]  P
hysical Examination 
A complete physical examination  will be performed during the Screening period , periodically during the 
study,  and at the  End of Treatment  Visit (T able 4  [Stage 1] a nd Table 5 [Stage 2]) .  Height  in cm will be 
measured once during the Screening period .  The examination will include the following body systems: 
general appearance; eyes, ears, nose and throat, head and neck; chest and lungs; cardiovascular; abdomen; 
musculoskeletal; lymphatic; dermatologic; neurologic; psychiatric; and ext remities .  Physical 
examinations will be conducted by a physician or health professional listed on the Form FDA 1572 and 
licensed to perform physical examinations.  
[IP_ADDRESS]  Site Reaction Assessment 
At each study visit after Day 1, study personnel will assess the in jection/application site of study drug 
from previous visits  for evidence of cutaneous AEs .   
[IP_ADDRESS]  Demographics and Medical and Medication History  
Demographic information, medical history, and prior and concurrent medications, including treatments 
received related to any brain tumor, will be reviewed and recorded before the first dose of study drug, 
during the Screening period, as detailed in the Study Event Schedule ( Table 4 [Stage 1] and Table 5 
[Stage 2] ).   
 Total Blood Sample Volume  
The volume of blood collected from each patient  is expected to be approximately  50 mL for clinical 
laboratory testing, and 60 mL for immune response testing  at each collection time point  (immune 
response samples are to be collected in 6  × 10 cc green top tubes  at each time point ).  The total blood 
volume to be collected at a study visit when both clinical lab oratory and immune response testing is done 
will be 110 mL.  These schedules for these tests are shown in Table 4 (Stage 1) and Table 5  (Stage 2) , 
Study Event Schedule.   
3.[ADDRESS_542249], OS, OS-12, PFS, and PFS-6.   
In study
 Stage 1, clinical assessments will nominally be made every 2 weeks, starting on Study Day 1 
through Study Week 22, and then every 4 weeks (28 days) after Study Week 22.  In study Stage 2, 
clinical assessments will nominally be made twice weekly during Weeks 1 and 2, every week between 
Week 2 and Week 4, and then every 2 weeks through Study Week 22, and then every 4 weeks (28 days) 3.2.4 
SL-701  Page 51 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 after Study Week 22.  These study days correspond to days that SL-701 emulsion is administered to the 
patient at the study site.  Tumor response assessments using modified RANO criteria (for ORR, DR, and 
progression) will be based on MRI/CT scans obtained 8 weeks after Study Day 1 (±  5 days) and then 
ev
ery 8 weeks (± 7 days) compared with the patient’s MRI or CT scan obtained during screening for this 
study.  Each tumor response assessment will use modified RANO criteria and information will be 
collected on the patient’s clinical and functional neurological status and concomitant medications, 
including corticosteroid use.  For comparative purposes, response will also be assessed by [CONTACT_44852] (RECIST) criteria (see Appendix 14.3). 
A patient with radiographic evidence of PD after initiating study drug may continue study drug for an 
additional 8 weeks, provided that the patient does not experience significant clinical deterioration and/or 
significant toxicity, as determined by [CONTACT_428637].  If follow-up imaging after [ADDRESS_542250]-enhancing tumor ≤1cm, unless there is additional clinical/ 
radiographic evidence of unequivocal GBM progression.  Follow-up imaging may be performed <8 
weeks after the initial detection of PD ( eg, after 4 weeks) if medically appropriate.  If PD is confirmed on 
follow-up imaging at 2 consecutive time points ≥4  weeks apart, the PD date will be the date that PD 
cr
iteria were initially met.  Please consult Section [IP_ADDRESS] for additional definitions of pseudoprogression 
and protocol conduct in the setting of potential pseudoprogression and/or progression. 
Blood samples (60 mL per day) for immunological monitoring studies will be collected on Day 1, at 
Study Weeks 4, 8, 12, [ADDRESS_542251] the targeted GAA peptides using IFN- γ-enzyme-linked immuno-spot 
(ELISPOT) assay, MHC tetramer assay, and flow cytometric analyses of lymphocyte activation.  All 
pat
ient samples will be collected at the respective treatment sites and promptly shipped to a single central 
processing laboratory to minimize variability.  Tumor tissue samples, whenever there is available 
pretreatment tissue or tumor is biopsied for any reason throughout the duration of the study, will be 
archived and assessed for GAA expression status and infiltration of GAA-specific T-cells. 
Tumor response for ORR, DR, and PFS measurements will be assessed using modified RANO criteria 
(Appendix 14.2) , based on MRI or CT scans obtained 8 weeks after Day 1 (± 5 days) and then every 8 
w
eeks (± 7 days).  As part of each tumor response assessment using modified RANO criteria, information 
will be collected on the patient’s clinical status ( eg, stable, improved, or declining since the last 
assessment), functional neurological status (KPS score) and concomitant medications, including 
corticosteroid use. 
Using the modified RANO criteria ( Appendix 14.2 ), ORR is defined as the proportion of patients 
achieving a best response of CR or PR on 2 consecutive MRIs obtained ≥[ADDRESS_542252] 24 patients treated for each study Stage (1 & 2):  
 RLT. 
 Sudden or unexpected deaths related to SL-701 or, in Stage 2, SL -701 in combination with 
bevacizumab.  
Seconda
ry safety endpoints in all enrolled  patients will be AEs and SAE s, physical examinations, vital 
sign and weight measurements, clinical laboratory evaluations (hematology, serum chemistry, coagulation 
parameters, urinalysis) and reasons for discontinuation .   
 Efficacy Endpoints  
Primary efficacy endpoints include: 
 OS-12, per Kaplan-Meier estimate. 
 ORR : Tumor response on 2 consecutive MRI assessments ≥4 weeks apart judged by [CONTACT_428638]. 
Secondary efficacy endpoints include: 
 Duration of tumor response (modified RANO criteria) ( Wen 2010 ) (see Appendix 14.2).  
 PFS (modified RANO criteria). 
 OS. 
 Ma
gnitude of immune response in PBMCs .   
 Tumor response, duration of tumor response, and PFS, judged by [CONTACT_307418] (version 1.1) criteria 
(Eisenhauer 2009)  (see A ppendix  14.3 ). 
Explor
atory endpoints include: 
 Correlation between measures of immunogenicity and anti-tumor efficacy. 
 Correlation between anti-tumor efficacy and either presence of glioma associated antigen in or 
infiltration of GAA- specific T -cells into available post -vaccine tumor tissue . 
 Comparison of response based measures as assessed by [CONTACT_428639] . 
 Correlation of pseudoprogression (as defined in Section [IP_ADDRESS] ) and prolonged OS . 3.4.1 
3.4.2 
SL-701  Page 53 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 4. STUDY TREATMENTS  
4.1 Study Drug Dosage and Administration 
In Stage 1, a complete dose of study drug consists of the administration of a sequence of 3 agents, SL -701 
emulsion (SL-701 in Montanide®) SC injection, GM-CSF SC injection, and imiquimod topi[INVESTIGATOR_68549], 
administered within a 5 minute time frame.  Topi[INVESTIGATOR_428590] 24 h after each SL-701 emulsion injection.  Each patient will be treated with SC injections 
of SL-701 emulsion every 14 days initially for 12 doses, followed by [CONTACT_428640] 28 days until 
determination of PD , withdrawal of informed consent, unacceptable toxicity, or noncompliance.  
Administration parameters for SL-701 emulsion and the adjuvants, GM -CSF and imiquimod, are 
summarized in Table 6.   Study site personnel and patients should be instructed to wash hands before and 
after imiquimod topi[INVESTIGATOR_44785] .  Before applying, the treatment area should be washed with mild soap and 
water a nd allowed to dry thoroughly (at least 10 minutes) .  The treatment area should not be bandaged or 
otherwise occluded .  Specific instructions for treatment site preparation and designation is provided in the 
study reference manual.  
Table 6: Study Drug Dosage and Administration: Stage 1 
Agent and Dose  Preparation and Route of Administration  Schedule  
SL-701 in 
Montanide®; 
1.0 mL injection 
taken from  0.7 mL 
of SL -701 mixed at 
a 1:1 (v/v) ratio 
with 0. 7 mL of 
Montanide®* Preferred site of SC injection is in the right or left upper arms 
with intact draining axillary nodes, alternating locations between 
individual vaccination dates .  In case participants do not possess 
intact axillary lymph nodes as the draining nodes, ad ministration 
is in the upper thigh on the same side with intact inguinal lymph 
nodes .   
The injection site should be selected and the area cleaned with 
soap and water and then dried thoroughly for at least [ADDRESS_542253] with a radius of 18 mm will be marked out with ink at 
the injection site prior to SC injection to serve as a guide for the  
GM-CSF injection  and imiquimod application.  Day 1 ; Weeks 2, 4, 6, 
8, 10, 12, 14, 16, 18, 
20, and 22, then every 
4 weeks thereafter  
GM-CSF 150  µg GM-CSF should be administered as a SC injection immediately  
after SL -701 emulsion administration and within 1 cm from the 
center of the SL -701 emulsion injection site, prior to application 
of topi[INVESTIGATOR_160772].  Day of each SL -701 
emulsion dose  
SL-701  Page 54 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Agent and Dose  Preparation and Route of Administration  Schedule  
Imiquimod Cream, 
5% supplied in 
250 mg single -use 
packets  Immediately (within 5 minutes) following the administration of 
the SL -701 emulsion, approximately one-half packet (125 mg) of 
imiquimod cream will be applied topi[INVESTIGATOR_428555] .  
Study site personnel and patients will be instructed to wash hands 
before and after imiquimod topi[INVESTIGATOR_44785] .  Patients will be provided 
with instructions for the application process for the imiquimod 
cream at 24  h at the SL -701 emulsion injection site and told not 
wash  the area for 48 h after the SL -701 emulsion injection (24 h 
after the second imiquimod application) .**  The imiquimod 
cream should be rubbed in until the cream is no longer visible.  Day of each SL -701 
emulsion dose and 24 
h after each SL -701 
emulsion dose   
* A 1.0 mL dose of the emulsion contains 0.3 mg each of the MPS-380 , MPS-381, and MPS-486 peptides and 0.2 mg of the 
M
PS-199 peptide. 
** In situations where the 24h topi[INVESTIGATOR_428591] (ie , the patient forgets to apply at 24 h), the patient may apply imiquimod during an additional 24-hour  period 
subsequent to the stipulated administration  time.  Subsequent to this 24 hour window, the imiquimod dose will be 
considered “missed” and should not be applied.  
In study Stage 2, a complete dose of investigational treatment consists of the administration of a sequence 
of 2 agents, SL -701 emulsion injection and poly-ICLC ( IM) injection, within an approximate 20 minute 
time frame.  Each patient will be treated with SC injections of SL-701 emulsion (SL-701 in Montanide®) 
twice weekly for the initial 2 weeks (5 doses), every 7 days during the subsequent 2 weeks (Weeks 3 and 
4 treatment doses), and subsequently every 14 days for the subsequent 9 doses (16 doses total during 
approximately 22 weeks), followed by [CONTACT_428640] 28 days until determination of PD , 
withdrawal of informed consent, unacceptable toxicity, or noncompliance.   
Patients will also receive IV bevacizumab at a dose of 10 mg/kg body weight starting on Day 1 and 
approximately every 2 weeks thereafter. For patients receiving study therapy beyond Week 22, 
bevacizumab will continue to be administered every 2 weeks until determination of PD, withdrawal of 
informed consent, unacceptable toxicity, or noncompliance.  
Administration parameters for SL-701 emulsion and the adjuvant poly-ICLC are summarized in Table 7. 
SL-701  Page 55 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Table 7: Study Drug Dosage and Administration: Stage 2 
Agent and Dose  Preparation and Route of Administration  Schedule  
SL-701 in 
Montanide®; 
1.0 mL injection 
taken from  0.7 mL 
of SL -701 mixed at 
a 1:1  (v/v) ratio 
with 0.7  mL of  
Montanide®* Preferred site of SC injection is in the right or left upper arms 
with intact draining axillary nodes, alternating locations between 
individual vaccination dates.  In case participants do not possess 
intact axillary lymph nodes as the draining  nodes, administration 
is in the upper thigh on the same side with intact inguinal lymph 
nodes.   
The injection site should be selected and the area cleaned with 
soap and water (or alcohol) and then dried thoroughly for at least 
10 minutes.   Day 1,  Days 4, 8 
(Week 1),  11, Weeks  
2, 3, 4, 6, 8, 10, 12, 14, 
16, 18, 20, and 22, 
then every 4 weeks 
thereafter  
Poly-ICLC  1.6 mg 
(1,600 µg)  Within 20 minutes  following the administration of the SL -701 
emulsion, poly-ICLC should be administered as an IM injection 
in the same extremity (within 3 cm whenever possible) as was 
administered the SL -701 (deltoid muscle, unless 
contraindicated).  Day of each SL -701 
emulsion dose  
Bevacizumab  
Solution for 
intravenous 
injection  Following the administration of SL -701 and poly-ICLC , 
bevacizumab will b e administered IV at a dose of 10  mg/kg.  
Bevacizumab infusions may occur over 30, 60 or 90 minutes in 
accordance with institutional practices and guidelines.   Day 1, Weeks 2, 4, 6, 
8, 10, 12, 14, 16, 18, 
20, and 22, then every 
2 weeks thereafter  
* A 1.0 mL dose of the emulsion contains 0.3 mg each of the MPS-380, MPS-381, and MPS-486 peptides and 0.2 mg of the 
MPS-199 peptide.  
4.2 Allowed Concomitant Treatment 
Concomitant systemic corticosteroids are to be avoided if medically feasible.  If used, corticosteroid doses 
should be the minimum necessary for appropriate clinical management.  Any patient requiring initiation 
or significant increase in corticosteroid dosing due to progressive neurologic signs or symptoms should 
undergo a rigorous evaluation for progressing GBM .  Efforts should be made to taper off corticosteroids 
as quickly as possible in the absence of PD .  Topi[INVESTIGATOR_428592] e 
reactions.  Inhaled corticosteroids may be administered as needed.  As appropriate, topi[INVESTIGATOR_428593]-steroidal anti-inflammatory or antihistamines may be used as alternatives.  Patients with a history of 
prior Hepatitis B infection with evidence of immunity (ie, positive hepatitis B surface antibody [HBsAb]) 
should be treated with appropriate anti-viral therapy (ie, lamivudine, adefovir, or similar anti-viral agents) 
for the duration of investigational therapy. 
All concomitant medications will be recorded on the electronic case report form ( eCRF ).  The 
conc
omitant medication documentation for sexually active females of childbearing potential and sexually 
active males  should support contraceptive usage, as applica b le. 
4.3 Prohibited Medications and Restrictions 
Therapi[INVESTIGATOR_428594]-tumor intent, including  chemotherapy, 
bev
acizumab (or other VEGF/VEGF receptor [VEGFR] -directed agent) s, or investigational anticancer 
agent s are prohib i ted during participation in  the study .   
SL-701  Page 56 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 4.4 Assessment of Patient Compliance  
On study drug administration days, patients will receive a paper diary (imiquimod diary) to remind them 
how to apply imiquimod [ADDRESS_542254]
udy visit and at the End of Treatment visit. 
4.5 Study Drug Description 
During Stage 1, a complete dose of study drug cons ists of the administration of a sequence of 3  agents , 
SL-701 emulsion injection, GM -CSF injection  and imiquimod topi[INVESTIGATOR_68549] , within a 5-m inute time 
frame ; topi [INVESTIGATOR_428576] 24 h after each SL -701 
emulsion injection .   
D
uring Stage 2, a complete dose of investigational treatment consists of the administration of a sequence 
of 2 agents , SL-701 em ulsion injection  and poly -I CLC ( IM) injection , within an approximate 20 -m inute 
time frame.  Patients will also receive IV bevacizumab ; the bevacizumab infusion  should occur following 
the administration  of the other agents.   
 SL-701 Emulsion (Stages 1 and 2)  
SL-701 consists of HLA -A2 restricted epi[INVESTIGATOR_304964], MPS -380 ( IL-13Rα2 345-353:1A9V ), MPS -381 
(EphA
2883-891), and MPS -486 ( Survivin 95-104:3M), der ived from 3  antigens that are overexpressed by [CONTACT_428641] 
r
elative to normal tissues .  SL-701 also includes MPS -199, a peptide that functions as a helper T -ce ll 
epi[INVESTIGATOR_428595], Tet A830.  Each vial of SL -701 contains each of the HLA peptides ( MPS -380, 
MPS -381, and MPS -486) at a concentration of 0.6 mg/mL and contains the TT peptide MPS -199 at a 
concentration of 0.4 mg/mL . Please refer to Se ctions 1.2 and  1.3 regarding preliminary clinical experience 
with similar GAA peptide vaccines. 
Montanide® (Montanide I SA 51 VG ) is an oil -based adjuvant (containing a surfactant system ) that is 
mixed 1:[ADDRESS_542255] ug administration .  Each emulsion dose delivered to the 
patient nominally will contain 0.3  mg of each of the HLA  peptides and 0.2 mg of the tetanus toxoid 
peptide .   
 GM-CSF  (Stage 1)  
GM-CSF (LE[LOCATION_006]INE, sargramostim) is a yeast-expressed recombinant human granulocyte-macrophage 
colony stimulating factor (rhu- GM-CSF).  GM-CSF is a hematopo ietic growth factor that stimul ates 
proliferation and differentiation of hematopoetic progenitor cells.  GM -CSF is approved by [CONTACT_428642], for use in mobilization and following 
transplantation of autologous peripheral blood progenitor cells, for use in myeloid reconstitution after 
autologous or allogeneic bone marrow transplantation, and for use in bone marrow transplantation failure 
or engraftment delay. GM -CSF has been used experimentally in the development of cancer vaccin es. 
Approved routes of GM -CSF administration are daily IV infusion or SC injection, with daily regimens of 
up to 14 days (or longer in some instances) administered in the pi[INVESTIGATOR_36491].  
In the pi[INVESTIGATOR_428596]-CSF, the majority of AEs observ ed did not occur at higher 
frequency in patients receiving GM -CSF versus those receiving placebo.  AEs occurring at higher 
frequency in patients receiving GM -CSF infusion included fluid retention (peripheral edema, pleural 
effusion and pericardial infusion , without evidence of capi[INVESTIGATOR_12737]), occasional dyspnea or 4.5.1 
4.5.2 
SL-701  Page 57 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 other respi[INVESTIGATOR_1856] (predominantly in patients with underlying lung disease), cardiac arrhythmia 
(predominantly in patients with a previous history of cardiac arrhythmia, reversible on discontinuation of 
GM-CSF), and increases in serum creatinine, or bilirubin and hepatic enzymes (transient and reversible, 
not observed at higher frequency in placebo-controlled clinical studies)  (GM-CSF [LOCATION_002] Package 
Insert ).  
 Imiquimod Cream, 5%  (Stage 1)   
Imiquimod cream, 5% (ALDARA) is a topi[INVESTIGATOR_428597] (AK), primary superficial basal cell carcinoma (sBCC), and external 
genital and perianal warts/condyloma acuminata (EGW).  Approved regimens include topi[INVESTIGATOR_59407] 
2X/week (AK), 3X/week (EGW) and 5X/week (sBCC). Imiquimod is approved only for topi[INVESTIGATOR_50034]. 
In controlled clinical studies, local skin and application site reactions were the most frequently reported 
adverse reactions, characterized as: itching, burning, erythema, flaking/scaling/dryness, scabbing/crusting, 
edema, induration, excoriation, erosion and ulceration.  Severe local inflammatory reactions have been 
reported including skin weepi[INVESTIGATOR_428598] (which in some instances required dose interruptions in the 
pi[INVESTIGATOR_428599] 2 /week, 3/week and 5 /week administration regimens).  Flu-like systemic 
signs and symptoms have also been reported, including malaise, fever, nausea, myalgias, and rigors.  
Fatigue, fever and headache were reported in >1% of patients in pi[INVESTIGATOR_36491], and at a higher frequency 
in patients receiving imiquimod (versus vehicle alone) ( Imiquimod. [LOCATION_002] Package Insert ). 
 Poly -ICLC (Stage 2)  
Poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose) is a 
dsRNA that has been evaluated in multiple clinical cancer studies including pediatric and adult gliomas, 
in both treatment -naïve and recurrent settings, both as a monotherapy and in conjunction with other 
therapeutic modalities including radiation therapy.  It is no t licensed for commercial use in the US.  Poly -
I
CLC was co -administered with GAA vaccine in 4 of 5  prior investigator -spons ored studies  (schedules 
i
ncluded both twice -weekly administration and every -3-week administration) , and prior combination 
therapy was  generally safe and well tolerated.  T he most common AEs observed in prior studies 
evaluating poly -ICLC were injection site reactions (discomfort, soreness, pain) which were 
predominantly mild and transient.   Flu-l ike symptoms, including fever, fatigue, ma laise, myalgias, 
arthralgia, chills/rigors and headache, have also been identified frequently, and were also predominantly 
mild and transient , although infrequent incidences of Grade [ADDRESS_542256] also been observed infrequently, including infrequent 
G
rade 3 leukopenia.  Increased transaminases (including infrequent Grade 3 elevations) have also been 
des
cribed.  The majority of AEs identified in studies evaluating poly -I CLC have be en mild and largely 
transient, with infrequent Grade 3 level events.  In studies in which multiple doses (within the 10 -50 
µg/kg range) have been evaluated, dose -limiting toxicities have not been identified  (Sal azar 1996 ; Okada 
2011; Butowski 2009a ; B utowski 2009b ; Hartman 2014 ). 
 Bevacizumab  (Stage 2)  
Bevacizumab (Avastin) is an anti-angiogenic monoclonal antibody directed against vascular endothelial 
growth factor (VEGF-A) and was initially approved in the US in 2004 for the treatment of colorectal 
cancer.  Bevacizumab is currently indicated in metastatic colorectal cancer, non-squamous non-small cell 4.5.3 
4.5.4 
4.5.5 
SL-701  Page 58 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 lung cancer, renal cancer, cervical cancer, ovarian cancer, and glioblastoma.  In the neoplasia other than 
glioblastoma, bevacizumab is approved for use in conjunction with other anticancer agents (interferon-
alpha in renal cancer, chemotherapy agents/combinations in the other diseases).  Bevacizumab is 
approved in glioblastoma as a single agent for adult patients with PD following prior therapy, based on 
i
mprovement in ORR in randomized studies.  Side effects associated with bevacizumab include 
gastrointestinal perforations and fistulae, non-gastrointestinal fistulae, surgery and wound-healing 
complications, hemorrhage (ranging from frequent low-grade epi[INVESTIGATOR_428600]/fatal bleeding events), 
arterial thromboembolic events (mostly identified in patients receiving bevacizumab in combination with 
chemotherapy regimens, in patients with a history of prior arterial thromboembolism, diabetes, or age 65 
or older), venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome 
(reported in fewer than 0.5% of patients enrolled in clinical studies), proteinuria (including nephrotic 
syndrome, reported in fewer than 1% of patients enrolled in clinical studies), infusion related reactions, 
and ovarian failure (in premenopausal women in combination with chemotherapy regimens).  Although 
adequate studies evaluating bevacizumab in pregnancy have not been performed, this agent and other 
angiogenesis inhibitors have been shown to be teratogenic in animal studies; bevacizumab is classified as 
Pregnancy category C ( Avastin Package Insert 5/2015 ). 
4.6 Study Drug Packaging and Storage 
SL-701 vials , packaged into labeled single  vial cartons, will be shipped to sites frozen ( -20 C).  SL -701 
cartons should be unpacked, counted, inspected for damage and registered in the I nteractive Response 
Technology ( IRT) system  prior to pl acing in frozen storage (-20°C) at the clinical site .  If a temperature 
excursion has  occurred,  register this event in the IRT System and do not use the product until directed to 
do so by [CONTACT_1034] .  For additional handling and drug preparation instructions, please see the study 
pharmacy manual.  
Montanide ISA 51 VG, pack ed in 10 vial cartons bearing a clinical label, will be shipped to sites 
cont
rolled ambient temperature (15 - 25° C).  Montanide® cartons should be unpacked , counted, inspected 
for damage and registered in the IRT system prior to storage at the clinical site .  For additional handling 
and drug preparation instructions, please see the study pharmacy manual.  
Leukine, 250µg (GM-CSF; Stage 1), pack ed in commercial 5 vial cartons bearing a clinical label, will be 
shi
pped to sites refrigerated (2 - 8° C).  Leukine cartons should be unpacked, counted, inspected for 
damage and registered in the IRT system prior to placing in refrigerated storage at the clinical site.  If a 
temperature excursion has occurred, register this event in the IRT System and do not use the product until 
di
rected to do so by [CONTACT_1034].  For additional handling and drug preparation instructions, please see the 
study pharmacy manual.   
Imiquimod 5% cream packets (Stage 1), pack ed int o 3 packet cartons, will be shipped to sites controlled 
ambient temperature (15 - 25° C).  Imiquimod cartons should be unpacked, counted, inspected for damage 
and registered in the IRT system prior to storage at the clinical site.  For additional handling and drug 
preparation instructions, please see the study pharmacy manual. 
Poly-ICLC (Hiltonol; Stage 2), packaged into labeled single vial cartons , will be shipped to 
sites refrigerated (2 - 8°C).  Poly -I CLC  cartons should be unpacked, counted,  inspected for damage and 
registered in the IRT system  prior to pl acing in refrigerated storage at the clinical site .  If a temperature 
excursion has  occurred,  r egister this event in the IRT System and do not use the pr oduct until di rected to 
SL-[ADDRESS_542257]. Please 
consult Section 6.1 and  Section 6.2  concerning the timing and sequence of events beginning with consent 
for protocol evaluation and leading up to initial treatment with investigational therapy.  The pre-treatment 
(ie, bas eline)  MRI or CT  sh ould be performed within [ADDRESS_542258] scan demonstrating recurrent or PD was obtained >[ADDRESS_542259] be performed .  Subsequent tumor response assessments will be 
performed every 8 weeks (± 7 days ) t hereafter until the Investigator determines there is evidence of PD 
using modified RANO response criteria ( Wen 2010 ) (see Appendix  14.2).  Patients who are evaluable for 
ob
jective response will  also be followed for  DR, and all treated patients will be followed for OS and PFS 
until assessment of the primary objectives is completed.  
5.[ADDRESS_542260] meet the following criteria during the Screening period (see 
Tabl
e 4 (Stage 1) and Table 5 (Stage 2) , Study Event Schedule) :  
1.
 18 years of age or older.   
2. Histologically confirmed GBM  or WHO Grade IV variants (gliosarcoma, glioblastoma with 
ol
igodendroglial features, or giant cell glioblastoma). 
3. Unequivocal evidence of a first tumor recurrence or progression on the initial treatment 
regimen (prior to enrollment on this study), consisting of surgical intervention (biopsy and/or 
resection), radiation, and TMZ chemotherapy, as assessed by [CONTACT_428643] [ADDRESS_542261] apply: 
 Recovery from the effects of surgery. 
 Residual disease following resection of recurrent tumor is not mandated for eligibility 
into the study.  To best assess the extent of residual disease post-operatively, an MRI 
should be performed: 
o No later than [ADDRESS_542262]-operative period; or  
o At least [ADDRESS_542263]-craniotomy (7 days for stereotactic biopsy), within [ADDRESS_542264] 1 cm in 2 planes (axial, coronal, or 
sagittal). 
7. No evidence of hemorrhage on the baseline MRI or CT scan other than those that are 
≤Grade1 and either post-operative or stable on at least 2 consecutive scans. 
8. Recovery from prior therapy toxicity, defined as resolution of all treatment-related AEs to 
≤Grade 1 or pre-treatment baseline (except alopecia and lymphopenia).   
9.
 At least [ADDRESS_542265] 3 weeks prior to the start of SL-701. 
11. HLA-A2 positive. 
12. A tumor tissue sample is provided for immunohistochemical analysis of relevant antigens, 
immune markers and potential prognostic factors.  Preferably a paraffin block or 10-
12 unstained slides will be submitted prior to study entry.  Patients for whom tumor samples 
are unavailable or inadequate are permitted to participate in the study; however, the absence 
of available/adequate tumor specimen must be documented.  
13. KPS score ≥70%.  
14. Adequate organ function, including the following: 
 ANC ≥1,000/μL, platelets ≥100,000/μL . 
SL-701  Page 61 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Serum creatinine ≤1.5 × the ULN. 
 Bi
lirubin ≤1.5 × ULN. 
 ALT and AST ≤2.5 × ULN. 
15. Women of childbearing potential must have a negative serum or urine pregnancy test within 
[ADDRESS_542266] agree to use 
an acceptable form of contraception for heterosexual a ctivity ( ie, oral contraceptives, 
doubl
e-barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal 
ligation, or vasectomy of their sexual partner(s)  for >[ADDRESS_542267] dose of study drug.  
17. Female patients without childbearing potential (spontaneous amenorrhea for >12 months or 
surgically sterilized by [CONTACT_306620], hysterectomy, or bilateral oophorectomy >6 months 
before Screening) are eligible for inclusion without contraceptive use restriction. 
18. Able and willing to comply with protocol requirements, in the opi[INVESTIGATOR_689] . 
19. A written and voluntarily signed informed consent must be obtained from the patient or 
legally authorized representative, in accordance with local regulations, before the initiation of 
any study-related procedures.  The patient or legally authorized representative must be able to 
read and understand the ICF. 
5.2
 Exclusion Criteria 
Potential patients who meet any of the following criteria at Screening will be excluded from the study: 
1. Prior cancer chemotherapy, bevacizumab (or other VEGF/VEGFR-directed agent), or an 
investigational agent for recurrent/progressive GBM or prior bevacizumab as part of initial 
therapy (prior chemotherapy or investigational agents are permitted as part of initial therapy; 
VEGF/VEGFR-directed agents are not permitted). 
2. A contrast-enhancing brain tumor that is any of the following: 
 Multi-focal (defined as [ADDRESS_542268] 1 cm in 
2 planes that are not contiguous on either fluid-attenuated inversion recovery [ FLA IR] or T2 
sequences); 
 Associated with either diffuse subependymal or leptomeningeal dissemination; or 
 ≥4 cm  in any dimension. 
3.
 Requirement of systemic corticosteroid therapy >4 mg/day of dexamethasone or equivalent or 
requirement of increasing dose of systemic corticosteroids during the 7 days prior to the start of 
SL-701 treatment. 
4. Surgical resection or major surgical procedure within 4 weeks prior to the start of SL-701, or 
stereotactic biopsy within 7 days prior to the start of SL-701. 
SL-701  Page 62 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 5. Radiation therapy, local therapy (except for surgical re-resection), or systemic therapy following 
first recurrence or PD.  Excluded local therapi[INVESTIGATOR_428601]/ PD i nclude 
stereotactic radiation boost, implantation of carmustine, biodegradable wafers (Gliadel), 
intratumoral or convection-enhanced delivery administered agents, etc. 
6. Active infection requiring IV antibiotics. 
7.
 History of cancer (other than GBM) within the past [ADDRESS_542269] survival and/or potentially confound tumor 
response assessments within this study. 
8. Clinically significant cardiovascular disease (eg, uncontrolled or any [LOCATION_001] Heart 
Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial 
infarction or stroke within 6 months of study entry, uncontrolled hypertension or clinically 
significant arrhythmias not controlled by [CONTACT_12617]). 
9. Known immunosuppressive disease or active systemic autoimmune disease such as systemic 
lupus erythematosus, human immunodeficiency virus infection, active or chronic Hepatitis B or 
Hepatitis C, or has taken an immunosuppressive agent within 4 weeks prior to the start of SL-701 
treatment.  Patients with vitiligo, type 1 diabetes mellitus, hypothyroidism due to autoimmune 
condit
ion only requiring hormone replacement therapy, psoriasis not requiring systemic therapy, 
or conditions not expected to recur in the absence of an external trigger are permitted to enroll.   
10. Any condition that in the  Investigator's opi[INVESTIGATOR_428602] . 
11.
 Requires therapeutic anticoagulation with warfarin at baseline; patients must be off warfarin or 
warfarin-derivative anti-coagulants for at least 7 days prior to starting study drug; however, 
therapeutic or prophylactic therapy with low-molecular weight heparin is allowed. 
12. Has history of known coagulopathy that increases risk of bleeding or a history of clinically 
significant hemorrhage within 12 months of start of study drug. 
13. Has evidence of intratumoral or peritumoral hemorrhage on baseline MRI scan other than those 
that are ≤Grade [ADDRESS_542270] 2 consecutive MRI scans  
14. Has gastrointestinal bleeding or any other hemorrhage/bleeding event Nation al Cancer Institute 
(NCI) Common Terminology Criteria for Adverse Events ( CTCAE ) >G rade [ADDRESS_542271] circumstances, the investigational regimen may be modified in the setting of specific adverse 
ev
ents. No dose reduction for any of the treatment components is permitted. If SL-701 is discontinued for 
any reason, the imiquimod (Stage 1), GM-CSF (Stage 1) , and  poly -ICLC (Stage 2) adjuvants will be 
discontinued.  SL -701 may be continued with discontinuation of either  imiquimod , GM -C SF  or poly -
ICLC  under th e f ollowing circumstances:  
 Adverse Events Not Meeting the Definition of RLT  
In the setting of a ≥Grade 3 skin (injection site) reaction lasting <7 days (at ≥Grade 3) or <Grade  3 skin 
(
injection site) reaction that recurs and either results in treatment delay or substantial patient discomfort in 
the opi[INVESTIGATOR_689], imiquimod  (during Stage 1) or poly -I CLC (during Stage 2)  may be 
w
ithheld (“skipped”) or discontinued and SL -701 (and GM -CSF [Stage 1] ) continued.   Any such 
modification should be discussed with the Medical Monitor and/or Investigator , and may  be evaluated as 
a pot
ential  RLT during safety reviews/IDMC assessments.  
I
n the setting of constitutional symptoms (including fatigue, fever, malaise, myalgia, edema [non-
cerebral]) that do not meet the criteria for RLT but represent substantial patient discomfort and are at least 
possibly related to investigational therapy in the opi[INVESTIGATOR_689] (ie , ≥G rade 3 lasting 
≤48 hours, or  persistent <Grade 3, imiquimod  (during Stage 1) or poly -ICLC (during Stage 2) may be 
withheld (“skipped”) or discontinued and SL -701 (and GM -CSF [Stage 1] )  continued.  Any such 
modification should be discussed with the Medical Monitor and/or Investigator, and may be evaluated a s 
a potential  RLT during safety reviews/IDMC assessments.    
I
n the setting of fluid retention (ie , as cites, pleural effusion) or dyspnea not meeting the criteria for RLT 
but representing substantial patient discomfort in the opi[INVESTIGATOR_428603], G M-CSF (during 
Stage  1) m ay be withheld (“skipped”) or discontinued and SL- 701 (and imiquimod) continued. Any such 
modification should be discussed with the Medical Monitor and/or Investigator, and may be evaluated as 
a potential  RLT during safety reviews/IDMC assessments.  
In Stage 2, in the setting of Grade 3 or higher transaminase elevations or leukopenia not meeting the 
criteria for RLT, poly- ICLC may be withheld (“skipped”) or discontinued and SL -701 ( and bevacizumab) 
continue d.  Any such modification should be discussed with the Medical Monitor and/or Investigator, and 
may be evaluated as a potential  RLT during safety reviews/IDMC assessments.    
 RLT and RLT -level Adverse Events  
In the setting of a Grade ≥ 3 skin (injection site) reaction lasting ≥ 7 days (at Grade ≥ 3); imiquimod 
(during Stage 1) or poly-ICLC (during Stage 2) may be discontinued and SL-701 (with GM-CSF 
[Stage  1])  continued pending adequate resolution (Grade 1 or less) or the reaction.  If the Grade ≥ 3 
r
eaction recurs then SL -701 (and GM -CSF) will be discontinued.  
In the setting of Grade ≥ 3 constitutional symptoms (including fatigue, fever, malaise, myalgia, edema 
[
non-cerebral]) that persist for > 48 hours, imiquimod (during Stage 1) or poly-ICLC (during Stage 2) 
may be discontinued and SL-701 (with GM-CSF [Stage 1]) continued pending adequate resolution (Grade 
1 or less). If a Grade ≥ 3 event recurs then SL-701 (and GM-CSF) will be discontinued. 5.4.1 
5.4.2 
SL-701  Page 64 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 During Study Stage 2, any event resulting in the permane nt withdrawal of SL- 701 will also warrant 
withdrawal of poly -ICLC.  Bevacizumab may be continued following permanent cessation of SL -701 
(and poly -ICLC).   
 Modification of Bevacizumab  
Bevacizumab should not be dose-reduced (or increased) during the course of study therapy.  In specific 
settings, bevacizumab should be withheld pending either further evaluation of adverse events or 
resolution.  Such settings include severe hypertension not adequately controlled by [CONTACT_91633], 
proteinuria greater than or equal to 2g/24 hours, hemoptysis of ≥½ teaspoon (2.5 cc) of blood, or other 
Grade 1-2 adverse events attributed to bevacizumab that are burdensome to the patient and for which a 
temporary interruption of bevacizumab may enable improvement, in the opi[INVESTIGATOR_689].  For 
full dosing recommendations, warnings and precautions, please consult the bevacizumab package insert 
(Avastin Package Insert 5/2015 ). 
Patients for whom bevacizumab has withheld (“skipped”) may continue to receive SL-701 (and poly-
ICLC) during Stage 2 of the study. 
5.5 Patient  Withdrawal  
 Reasons for Withdrawal 
Patients will be informed that they are free to withdraw from the study at any time and for any reason.  
Patients will be discontinued from the study if any of the following occur: 
 In the opi[INVESTIGATOR_689], it is not in the best interest of the patient  to continue the study . 
 T
here is a change in compliance with an inclusion/exclusion criterion that is clinically relevant 
and affects patient  safety . 
 T
he patient  takes a concomitant medication that might affect patient  safety or study 
as
sessments/objectives . 
 T
he patient develops RLT as defined in Section 3.2.2 , or an RLT-level toxicity (for patients 
receiving ongoing therapy beyond the initial 12 doses of investigational therapy), other than the 
specific situations defined in Section 5.4 (Modification of Investigational Regimen ). 
 The patient develops a persistent toxicity that does not meet the criteria for RLT, but that  is 
nonetheless intolerable in the opi[INVESTIGATOR_428604]/or the Investigator.  
 Unequivocal evidence of PD as detailed in Section [IP_ADDRESS] and  Section 3.3  (in situations where 
potential pseudoprogression is under clinical/radiographic evaluation, investigational therapy may 
be administered or postponed as detailed in these sections). 
Patient  participation in the study  may be stopped at any time at the discretion of the In vestigator or at the 
request of the Sponsor .  Discontinuation procedures are described in Section 5.5.3 . 
 Withdrawal of Bevacizu mab  
Bevacizumab therapy should be permanently discontinued in the setting of gastrointestinal perforations, 
fistulae (gastrointestinal or non-gastrointestinal), necrotizing fasciitis, severe hemorrhage, severe 
arteriothromboembolic events, life threatening venous thromboembolic events (including pulmonary 5.4.3 
5.5.1 
5.5.2 
SL-701  Page 65 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 embolism), hypertensive crisis or hypertensive encephalopathy, posterior reversible encephalopathy 
syndrome, nephrotic syndrome , or severe infusion related reaction.  For comprehensive warnings and 
pr
ecautions, please consult the bevacizumab package insert (Avastin Package Insert 5/2015 ). 
Patients for whom bevacizumab has been discontinued may continue to receive SL-701 (and poly-ICLC) 
during Stage 2 of the study. 
 Handling of Withdrawals  
Patients who discontinue SL-701 should return for a final visit, consisting of all tests and procedures 
listed for the End of Treatment visit in Table 4 (Stage 1) and Table 5 (Stage 2).  If the patient is in CR/PR 
at the time of discontinuation, tumor assessments should continue to be performed as described in 
Section 7.[ADDRESS_542272] udy site  regarding his or her status in 
t
he study .  If a patient  does not return for the final visit, and th e a ppropriate permission has been obtained, 
the Investigator may obtain a verbal report on the patient ’s health status from the patient ’s local health 
care provider.  
 Replacements  
At the discretion of the Sponsor, additional patients may be enrolled to supplement patient data 
compromised due to premature study dropout or other reasons.  Only patients who have enrolled in the 
study and have withdrawn or been designated as a screen failure prior to receiving the first dose of study 
drug will be replaced.  If dosed, patients who withdraw will not be replaced.   
 Termination of Study  by [CONTACT_48676], it reserves the right to discontinue the 
study at any time for clinical or administrative reasons or if r equired by [CONTACT_1622] .  Both the Sponsor and 
the contract research organization ( CRO ) Me dical Monitors will review the safety of the study  drug 
r
egimen throughout the study .  The study may be halted at any time for safety concerns.  
6. STUDY VISITS 
All study visits, assessments, and procedures involving study patients will be performed at a 
Sponsor - approved investigat i ve site, and assessments and procedures will be performed by [CONTACT_428644] .  Study drug will be administered only at an approved 
investigat ive site.   5.5.3 
5.5.4 
5.5.5 
SL-701  Page 66 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Study drug administration (including adjuvant administration) will be the last procedure performed during 
each study visit at which study drug is scheduled to be administered.  The dosing date and times for all [ADDRESS_542273] be recorded. 
6.1 Screening 
The following will be done after the patient  or legally authorized representative provides informed 
cons
ent, with measurements and results recorded in the eCRF : 
 Record medications taken in the 28 days before Screening.   
 Verify and document satisfaction of entry criteria. 
o Local laboratory results obtained within a [ADDRESS_542274] dose of study drug.   
o If patient has evaluable but not measurable disease, confirm enrollment with Sponsor (at 
least [ADDRESS_542275] measurable disease) . 
 R
ecord medical and surgical history. 
 Record all current medications . 
 Conduct complete physical examination and measure height. 
 Perform  serum or  urine pregnancy test for w omen of childbearing potential.  
 Record vital sign  measurement s a nd weight.  
 Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples (the results of 
any
 test obtained within the 14-day screening period may be used for screening purposes). 
 Perform MRI or CT scan.  Retain as source document for the study.  
 Perform objective tumor measurements/assessment  by [CONTACT_393] (version 1.1) (see Appendix  14.3 ) 
and m
odified RANO criteria (see Appendix 14.2) .  Document tumor evaluation .   
 Evaluate K PS score  (see Appendix 14.1 ) .   
 Tumor tissue submission, as available.   If tumor tissue is collected and available  f ollowing 
initiation of study therapy , or at any time point throughout the duration of the study, then a  
sa
mple must be submitted for immunohistochemical analysi s. 
6.[ADDRESS_542276] begin within 24 h of the end of the Screening  period.  Day 1 procedures include:  
 Record all concomitant  medications . 
 Record vital signs and weight. 
SL-701  Page 67 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples  
 Perform phlebotomy for immune response studies and send blood to central laboratory 
 Wash and dry dosing site with mild soap and water and allow to dry at least 10 minutes .  Prepare 
and mark skin ([ADDRESS_542277]) to designate treatment area .  Spec ific treatment site 
preparation instructions are provided in the study reference manual .   
 Administer first dose of SL-701 emulsion by [CONTACT_10530] . 
Stage 1:  
 Immediately following the injection of SL -[ADDRESS_542278] 150 µg GM -C SF within 1  cm 
of
 the center of the SL -701 emulsion injection site  (Stage 1 only ). 
 Within 5 minutes after injecti on of  SL-701 emulsion , study personnel will apply one -half 
packet of imiquimod cream to an area within 18 mm of the SL -701 emulsion injection site  
(Stage 1 only ).   
 Instruct patient not to wash the area within 18 mm of the SL -701 emulsion injection site for 
48 h after the time of the SL -701 emulsion injection  (Stage 1 only ).   
 Instruct patient to apply one -half packet of imiquimod cream to the area within 18 mm of the 
SL-701 emulsion injection site,  24 h after the SL -701 emulsion injection .  Patients will be 
given a packet of imiquimod Cream 5% to take home.  Instruct patient that in the setting of a 
severe skin or injection site reaction occurring within 24 hours after the SL -701 emulsion 
injection, to remove the imiquimod by [CONTACT_428645] d soap and water, and to not 
administer the additional half -packet of imiquimod 24 hours subsequent to the SL- 701 
emulsion injection (non -occlusive dressings such as cotton gauze may be used for imiquimod 
related skin [injection site] reactions) (Stage 1 o nly).  
 Dispense patient imiquimod diary, and instruct patient in the use thereof.  Remind patients to 
bring back unused packet of imiquimod on next study visit (Stage 1 only ).   
  
Stage 2 :  
 Within [ADDRESS_542279] 1,600 µg  (1.6 mg) 
poly-ICLC IM in the same extremity (within 3 cm) as was administered the SL -701 injection 
(Stage 2 only ).   
 Administer IV bevacizumab at a dose of 10 mg/kg of body weight (infusion to be given over 
30, 60 o
r 90 minutes in accordance with institutional practices and guidelines).  
 Record  any AEs since last visit .   
6.3 Day 4, Day 8 (Week  1), Day 11, and Week 3 (Stage 2 only)  
D
uring the initial 2 weeks of study therapy (in Stage 2), SL -701 e mulsion and adj uvant will administered 
twice per wee k.  The Day 4 and Day 11 visits may be performed ± 1 day (ie , on either Days 3, 4 , or  5 and 
on either Days 9, 10, or 11). The Day 8 ( Week 1) visit shoul d  be done as closely as possible to  a date 1 
SL-701  Page 68 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 week after the Day 1 SL -701 emulsion administration (± 3 days is permitted) . T he following procedures 
will be performed at Study  Days 4, 8  (Week  1), 11 and Week  3 with the results recorded in the eCRF: 
 R
ecord all concomitant  medications . 
 R
ecord vital signs and weight. 
 Obtain hematology and serum chemistry samples . 
 Wash and dry dosing site with mild soap and water and allow to dry at least 10 minutes.  Prepare 
and mark skin ([ADDRESS_542280]) to designate treatment area.  Specific treatment site 
preparation instructions are provided in the study reference manual.   
 Administer dose of SL-701 emulsion by [CONTACT_10530]. 
Stage 2: 
 Within [ADDRESS_542281] 1,600 µg  (1.6 mg) 
poly-ICLC IM in the same extremity (within 3 cm)  as was administered the SL - 701 injection 
(Stage 2 only). 
 Record  any AEs since last visit  and status of unresolved AEs . 
6.4 Weeks 2, 4, 6, 10, 12, 14, 18, 20, and  22 
T
he Week 2 visit should be done as closely as possible to a date 2 weeks after the Day 1 SL -701 emulsion 
administration date  (± 3 days is  permitted) .  Study visits and assessments after the SL -701 emulsion 
administration at Week 2 should be done within a ± 3 day  window adhering to the schedule in Table 4 
(Stage 1) and Table 5 (Stage 2).  The following procedures will be performed at Study Weeks 2, 4, 6, 1 0, 
12, 14, 18, 20 and 22, with the results recorded in the eCRF : 
 Record all concomitant  medications . 
 Phy
sical examination (Weeks 4, 12 and 20). 
 Record vital signs and weight. 
 Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples  
 Perform phlebotomy for immune response studies and send blood to central laboratory (Weeks 4, 
and 12). 
 Wash and dry dosing site with mild soap and water and allow to dry at least 10 minutes.  Prepare 
and mark skin ([ADDRESS_542282]) to designate treatment area.  Specific treatment site 
preparation instructions are provided in the study reference manual.   
 Administer dose of SL-701 emulsion by [CONTACT_10530]. 
Stage 1: 
 Immediately after injecting SL-[ADDRESS_542283] 150 µg GM-CSF within 1 cm of the 
ce
nter of the SL-701 emulsion injection site (Stage 1 only). 
SL-701  Page 69 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Within 5 minutes after injecting SL-701 emulsion, study personnel will apply one-half packet 
of imiquimod cream to an area within 18 mm of the SL-701 emulsion injection site (Stage 1 
only).   
 Instruct patient not to wash the area within 18 mm of the SL-701 emulsion injection site for 
48 h after the time of the SL-701 emulsion injection (Stage 1 only).   
 Instruct patient to apply one-half packet of imiquimod cream to the area within 18 mm of the 
SL-701 emulsion injection site, 24 h after the SL-701 emulsion injection.  Patients will be 
given a packet of imiquimod Cream 5% to take home.  Instruct patient that in the setting of a 
severe skin or injection site reaction occurring within 24 hours after the SL-701 emulsion 
injection, to remove the imiquimod by [CONTACT_428646], and to not  
administer the additional half-packet of imiquimod 24 hours subsequent to the SL-701 
emulsion injection (non-occlusive dressings such as cotton gauze may be used for imiquimod 
related skin [injection site] reactions) (Stage 1 only ). 
 Collect patient im iquimod diary and remainder of unused imiquimod ( Stage 1 only ).   
 Dispense patient imiquimod diary, and instruct patient in the use thereof.  Remind patients to 
bring back unused packet of imiquimod on next study visit (Stage 1 only ). 
Stage 2: 
 Within [ADDRESS_542284] 1,600 µg  (1.6 mg) 
poly-ICLC IM in the same extremity (within 3 cm)  as was administered the SL -701 i njection 
(Stage 2 only ). 
 Administer IV bevacizumab at a dose of 10 mg/kg of body weight (infusion to be given over 
30, 60 or 90 minutes in accordance with institutional practices and guidelines). 
 Record  any AEs since last visit  and status of unresolved AEs . 
6.5
 Weeks 8 and 16  
The following procedures will be performed at Weeks 8 and 16 , with the results recorded in the eCRF : 
 Record all concomitant medications . 
 Physical examination. 
 Record vital signs and weight. 
 Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples. 
 Perform phlebotomy for immune response studies and send blood to central laboratory.  
 Perform clinical assessment for  PD.   
 Per
form brain MRI or CT scan, depending on what type of scan was used to qualify the patient 
during Screening.   
 Perform objective tumor response assessment  using R ECIST criteria, version 1.1 (see 
Appendix  14.3) and modified RANO criteria (see Appendix 14.2).  
SL-701  Page 70 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Evaluate K PS score  (see Appendix 14.1 ) .   
 Wash and dry dosing site with mild soap and water and allow to dry at least 10 minutes.  Prepare 
and mark skin ([ADDRESS_542285]) to designate treatment area.  Specific treatment site 
preparation instructions are provided in the study reference manual. 
 Administer dose of SL -701 emulsion by [CONTACT_10530] . 
Stage 1: 
 Immediately after injecting SL -[ADDRESS_542286] 150 µg GM -CSF within 1  cm of the 
ce
nter of the SL -701 emulsion injection site (Stage 1 only ). 
 Within 5 minutes after injecting SL -701 emulsion, study personnel will apply one- half packet 
of imiquimod cream to an area within 18 mm of the SL -701 emulsion injection site  (Stage 1 
only).   
 Instruct patient not to wash the area within 18 mm of the SL -701 emulsion injection site for 
48 h after the time of the SL -701 emulsion injection  (Stage 1 only ).   
 Instruct patient to apply one-half packet of imiquimod cream to the area within 18 mm of the 
SL-701 emulsion in jection site, 24 h after  the SL- 701 em ulsion injection .  Pati ents will be 
given a packet of imiquimod Cream 5% to take home .  Instruct patient that in the setting of a 
severe skin or injection  site reaction occurring within 24 hours after the SL -701 emulsion 
injection, to remove the imiquimod by [CONTACT_428646], and to not 
administer the additional half -packet of imiquimod 24 hours subsequent to the SL- 701 
emulsion injection (non -occlusive dressings such as cotton gauze may be used for imiquimod 
related skin [ injection site ] reactions)  (S tage 1 only ). 
 Collect patient imiquimod diary and remainder of unused imiquimod (Stage 1 only ). 
 Dispense patient imiquimod diary, and instruct patient in the use thereof.  Remind patients to 
bring back unused packet of imiquimod on next study visit (Stage 1 only) . 
Stage 2: 
 Within [ADDRESS_542287] 1,600 µg  (1.6 mg) 
poly-ICLC IM in the same extremity (within 3 cm)  as was administered the SL -701 i njection 
(Stage 2 only ). 
 Administer IV bevacizumab at a dose of 10 mg/kg of body weight (infusion to be given over 
30, 60 o
r 90 minutes in accordance with institutional practices and guidelines).  
 Record  any AEs since last visit  and status of unresolved AEs . 
6.6
 Week 24  
The following procedures will be performed at Week 24, with the results recorded in the eCRF: 
 Record all concomitant  medications . 
 R
ecord vital signs and weight. 
SL-701  Page 71 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Collect patient imiquimod diary and remainder of unused imiquimod (Stage 1 only ). 
 Perform phlebotomy for immune response studies and send blood to central laboratory. 
 Perform clinical assessment for  PD. 
 Per
form brain MRI or CT scan, depending on what type of scan was used to qualify the patient 
during Screening. 
 Perform objective tumor response assessment  using RECIST criteria, version 1.1 (see 
A
ppendix  14.3 )  and modified RANO criteria (see Appendix 14.2).  
 Evaluate K PS score  (see Appendix 14.1 ) .   
 Record  any AEs since last visit and status of unresolved AEs . 
6.7 Weeks  26 and 30  
The following procedures will be performed at Week s 26 and 30, (some evaluations are to be performed 
at
 only Week 26 or Week 30 as indicated below), with the results recorded in the eCRF : 
 Record all concomitant  medications  
 Phy
sical examination.   
 Record vital signs and weight. 
 Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples. 
 Evaluate K PS score  (see Appendix 14.1 ; W eek 26 only ). 
 A
dminister dose of SL-701 emulsion by [CONTACT_10530]. 
Stage 1: 
 Collect patient imiquimod diary and remainder of unused imiquimod (Week 30,  Stage 1 
only). 
 Immediately after injecting SL -[ADDRESS_542288] 150 µg GM -CSF within 1  cm of the 
ce
nter of the SL -701 emulsion injection site  (Stage 1 only ). 
 Within 5 minutes after injecting SL -701 emulsion, study personnel will apply one- half packet 
of imiquimod cream to an area within 18 mm of the SL -701 emulsion injection site  (Stage 1 
only). 
 Instruct patient not to wash the area within 18 mm of the SL -701 emulsion i njection site for 
48 h after the time of the SL -701 emulsion injection  (Stage 1 only ). 
 Instruct patient to apply one-half packet of imiquimod cream to the area within 18 mm of the 
SL-701 emulsion in jection site, 24 h after the SL -701 emulsion injection .  Patients will be 
given a packet of imiquimod Cream 5% to take home .  Instruct patient that in the setting of a 
severe skin or injection  site reaction occurring within 24 hours after the SL -701 emulsion 
injection, to remove the imiquimod by [CONTACT_428647], and to not 
administer the additional half -packet of imiquimod 24 hours subsequent to the SL- 701 
SL-701  Page 72 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 emulsion injection (non-occlusive dressings such as cotton gauze may be used for imiquimod 
related skin [ injection site ] reactions)  (S tage 1 on ly). 
 Dispense patient imiquimod diary, and instruct patient in the use thereof.  Remind patients to 
bring back unused packet of imiquimod on next study visit (Stage 1 only) . 
Stage 2: 
 Within [ADDRESS_542289] 1,600 µg  (1.6 mg) 
poly-ICLC IM in the same extremity (within 3 cm)  as was administered the SL -701 i njection 
(Stage 2 only ). 
 Administer IV bevacizumab at a dose of 10 mg/kg of body weight (infusion to be given over 
30, 60 o
r 90 minutes in accordance with institutional practices and guidelines) . 
 Record any AEs since last visit and status of unresolved AEs.   
6.8 Weeks 28  and 32 (Stage 2 only) 
In Stage 2, the following procedures will be performed at Weeks 28  and 32, with the results recorded in 
t
he eCRF:  
 Record all concomitant  medications  
 R
ecord vital signs and weight. 
 Administer IV bevacizumab at a dose of 10 mg/kg of body weight (infusion to be given over 30, 
60
, or 90 minutes in accordance with institutional practices and guidelines.    
 Record any AEs since last visit and status of unresolved AEs. 
6.9 Week 34 
The following procedures will be performed at Week 34, with the results recorded in the eCRF: 
 Record all concomitant medications. 
 Physical examination. 
 Record vital signs and weight. 
 Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples.   
 Perform phlebotomy for immune response studies and send blood to central laboratory. 
 Perform clinical assessment for  PD. 
 Per
form brain MRI or CT scan, depending on what type of scan was used to qualify the patient 
during Screening . 
 Per
form objective tumor response assessment  using RECIST criteria, version 1.1 (see 
A
ppendix  14.3 )  and modified RANO criteria (see Appendix 14.2).  
 Evaluate K PS score  (see Appendix 14.1 ) . 
SL-701  Page 73 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Wash and dry dosing site with mild soap and water and allow to dry at least 10 minutes.  Prepare 
and mark skin ([ADDRESS_542290]) to designate treatment area.  Specific treatment site 
preparation instructions are provided in the study reference manual.   
 Administer dose of SL-701 emulsion by [CONTACT_10530]. 
Stage 1: 
 Collect patient imiquimod diary and remainder of unused imiquimod ( Stage 1 only ).   
 Immediately after injecting SL-[ADDRESS_542291] 150 µg GM-CSF within 1 cm of the 
ce
nter of the SL-701 emulsion injection site (Stage 1 only ). 
 Within 5 minutes after injecting SL-701 emulsion, study personnel will apply one-half packet 
of imiquimod cream to an area within 18 mm of the SL-701 emulsion injection site (Stage 1 
only).   
 Instruct patient not to wash the area within 18 mm of the SL-701 emulsion injection site for 
48 h after the time of the SL-701 emulsion injection (Stage 1 only).   
 Instruct patient to apply one-half packet of imiquimod cream to the area within 18 mm of the 
SL-701 emulsion injection site, 24 h after the SL-701 emulsion injection.  Patients will be 
given a packet of imiquimod Cream 5% to take home.  Instruct patient that in the setting of a 
severe skin or injecti on site reaction occurring within 24 hours after the SL -701 emulsion 
injection, to remove the imiquimod by [CONTACT_428646], and to not 
administer the additional half -packet of imiquimod 24 hours subsequent to the SL- 701 
emulsion injection (non-occlusive dressings such as cotton gauze may be used for imiquimod 
related skin [ injection site ] reactions)  (S tage 1 only ). 
 Dispense patient imiquimod diary, and instruct patient in the use thereof.  Remind patients to 
bring back unused packet of imiquimod on next study visit (Stage 1 only ). 
Stage 2: 
 Within [ADDRESS_542292] 1, 600 µg (1. 6 mg) 
poly-ICLC IM in the same extremity (within 3 cm)  as was administered the SL -701 i njection 
(Stage 2 only).  
 Administer IV bevacizumab at a dose of 10 mg/kg of body weight (infusion to be given over 
30, 60
, or 90 minutes in accordance with institutional practices and guidelines) . 
 Record any AEs since last visit and status of unresolved AEs. 
6.10 Subsequent to Week 34 
The following assessments will be performed every 4 weeks unless otherwise stipulated, until the end of 
treatment visit, with the results recorded in the eCRF. 
 Collect patient imiquimod diary and remainder of unused imiquimod ( Stage 1 only ).   
 Record all concomitant medications. 
SL-701  Page 74 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Physical examination. 
 Record vital signs and weight. 
 Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples.   
 Perform phlebotomy for immune response studies and send blood to central laboratory (every 
8 weeks through Week 50; every 12 weeks thereafter and at end-of-treatment visit). 
 Per
form clinical assessment for PD (every 8 weeks though Week 50; every 12  weeks thereafter) . 
 Perform brain MRI or CT scan, depending on what type of scan was used to qualify the patient 
during Screening ( every 8 weeks though Week 50; every 12 weeks thereafter) . 
 Perform objective tumor response assessment  using RECIST criteria, version 1.1 (see 
A
ppendix  14.3 )  and modified RANO criteria (see Appendix 14.2; every 8 weeks though Week 
50; every 12 weeks thereafter ). 
 Evaluate K PS score  (see Appendix 14.1 ;  every 8 weeks though Week 50; every 12 weeks 
thereafter ). 
 Wash and dry dosing site with mild soap and water and allow to dry at least 10 minutes.  Prepare 
and mark skin ([ADDRESS_542293]) to designate treatment area.  Specific treatment site 
preparation instructions are provided in the study reference manual.   
 Administer dose of SL-701 emulsion by [CONTACT_10530]. 
Stage 1: 
 Immediately after injecting SL-[ADDRESS_542294] 150 µg GM-CSF within 1 cm of the 
ce
nter of the SL-701 emulsion injection site (Stage 1 only).   
 Within 5 minutes after injecting SL-701 emulsion, study personnel will apply one-half packet 
of imiquimod cream to an area within 18 mm of the SL-701 emulsion injection site (Stage 1 
only).   
 Instruct patient not to wash the area within 18 mm of the SL-701 emulsion injection site for 
48 h after the time of the SL-701 emulsion injection (Stage 1 only).   
 Instruct patient to apply one-half packet of imiquimod cream to the area within 18 mm of the 
SL-701 emulsion injection site, 24 h after the SL-701 emulsion injection.  Patients will be 
given a packet of imiquimod Cream 5% to take home.  Instruct patient that in the setting of a 
severe skin or injection  site reaction occurring wi thin 24 hours after the SL -701 emulsion 
injection, to remove the imiquimod by [CONTACT_428646], and to not 
administer the additional half -packet of imiquimod 24 hours subsequent to the SL- 701 
emulsion injection (non -occlusive dressings such as cotton gauze may be used for imiquimod 
related skin [injection] reactions)  (Stage 1 only ). 
 Dispense patient imiquimod diary, and instruct patient in the use thereof.  Remind patients to 
bring back unused packet of imiquimod on next study visit  (Stage 1 only ). 
SL-701  Page 75 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Stage 2: 
 Within [ADDRESS_542295] 1,600  µg (1. 6 mg) 
poly-ICLC IM in the same extremity (within 3 cm)  as was administered the SL -701 i njection 
(Stage 2 only ). 
 Administer IV bevacizumab at a dose of 10 mg/kg of body weight (infusion to be given over 
30, 60
, or 90 minutes in accordance with institutional practices and guidelines); bevacizumab 
should be administered every 2 weeks  until PD or  unacceptable toxicity.  
 Record any AEs since last visit and status of unresolved AEs. 
6.11 End of Treatment Visit  
The End of Treatment  Visit for each patient will occur approximately  14 days a fter  determination t hat 
withdrawal from the study  is necessary, either because  of PD, RLT , or  other reason initiated by [CONTACT_428648] .  The visit at which the determination for study discontinuation is made is not 
the End of Treatment Visit, and should be recorded in the eCRF based on the study week ( eg, W eek 18) , 
r
egardless of whether treatment is administered at that visit.  The followin g procedures will be performed 
at the End of Treatment  Visit:   
 R
ecord all concomitant  medications . 
 Per
form physical examination  
 Perform  serum or urine pregnancy test in women of childbearing potential . 
 Record vital signs and weight. 
 Obtain hematology, serum chemistry, blood coagulation, and urinalysis samples .  
 C
ollect patient imiquimod diary and remainder of unused imiquimod (Stage 1 only).   
 Perform phlebotomy for immune response studies and send blood to central laboratory . 
 Evaluate K PS score  (see Appendix 14.1 ) .   
 Perform clinical assessment for  PD.   
 Record any AEs since last visit and status of unresolved AEs.   
6.[ADDRESS_542296] d ose of SL -701 emulsion .  Site staff will remind women of childbearing potential 
and sexually active male patients to continue to use an acceptable form of contraception for heterosexual 
activity ( ie, oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted 
cont
raceptives, tubal ligation, or vasectomy of their sexual partner(s) for [ADDRESS_542297] of care  
for GBM patients , and perform these assessments on  the scheduled study visit days .  The results of all 
study assessments are to be recorded promptly in the eCRF .   
7.1 Tumor Response Assessment 
The primary criteria for assessing tumor response will be the modified RANO criteria (Wen 2010 ) (see 
Appendix  14.2 ).  RECIST  (version 1.1)  ( see Appendix  14.3) will be secondary criteria ( Eisenhauer 2009 ).  
The categories of response are : CR, PR , SD, and PD.  A  board certified radiologist will be responsible for 
the objective measurements and evaluations of each patient’s MRI  or CT  scans .   While each investigat ive 
site may use its own radiologist, it is desirable that a single  radiologist b e assigned to review all the scans 
for a single patient, and, ideally all the patients at a particular site .  Ther e will not be a central radiologist 
reviewing all scans, nor a team of radiologists reviewing all MRI or CT scans .  Each I nvesti gator will be 
responsible for integrating the radiology reports of the MRI  or CT  scans with the clinically assessed 
pr
ogress of each patient .  Tumor response assessments will follow each MRI or CT scan within [ADDRESS_542298] scans will be performed according to 
the Study Event Schedule ( Table 4  [Stage 1] and T able 5 [Stage 2] ).  As part of the RANO criteria  
assessment,  information will be collected on the patient’s clinical status ( eg, st able, improved, or 
decli ning since the last assessment), functional neurological status using the KPS sc ore and concomitant 
medications, including corticosteroid use.  
The modified RANO criteria include an overall assessment of clinical deterioration that is based on the 
clinical and functional neurological status of the patient.  The KPS score, a commonly used scale for 
rating a patient’s capacity to function under the burden of his disease , will be used to provide consistency 
in this assessment across sites.  The Investigator will record each patient’s KPS score at each study visit.  
The KPS scale is found in Appendix 14.1. 
7.2 Demographic Data/Medical History 
Demographic data and a complete medical and surgical history will be collected at Screening.  The 
medical history should include the past 2 years whenever possible.  Data related to the current tumor 
under study should not be recorded in the medical history , but r ather under signs and symptoms.  
7.3 Prior Medications 
All medications taken in the 28 days before Screening, including nonprescription medications, dietary 
supplements and the specific dose/schedule of any systemic corticosteroid agents, will be recorded.   
SL-[ADDRESS_542299] will be 
collected at Screening, on Day 1, at Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 26, 30, and 34, and then 
ev
ery 4 weeks after that date or at the End of Treatment visit.  Tests to be performed include hematology, 
serum chemistry, coagulation parameters, and urinalysi s as found in  T able 4 (Stage 1) and Table 5 (Stage 
2).  A serum or urine pregnancy test will be performed in women of childbearing potential at Screening 
and at the End of Treatment visit.  Laboratory tests may be performed either on the day of a treatment 
visit, or during the 3 days prior to a treatment visit (it should be noted that if a test is performed during the 
days prior to a treatment visit, the results should nonetheless be considered as part of the visit for the 
week at which the treatment is subsequently administered; for example a laboratory test performed 2 days 
prior to the Week 6 visit is technically conducted during the 5th week of study participation, but should be 
r
ecorded as the “Week 6” laboratory assessment ). 
7.5 Vital Sign Measurements and Body Weight 
Blood pressure, heart rate, respi[INVESTIGATOR_697], body temperature, and body weight measurements will be 
obtained at every study visit.  Body weight will be measured in kg.  
7.6
 Physical Examination 
A complete physical examination will be performed during Screening and at the End of Treatment  visit.  
The examination will include the following body systems: general appearance; eyes, ears, nose and throat, 
head and neck; chest and lungs; cardiovascular; abdomen; musculoskeletal; lymphatic; dermatologic; 
neurologic; psychiatric; and extremities .  Physical examinations will be  conducted by a physician or 
health professional listed on the Form FDA 1572 and licensed to perform physical examinations .  The 
physical examination at Screening will include a height measurement (cm) . A directed physical 
examination involving any body sy stems for which abnormal findings were present during screening (or 
prior) examinations, and any systems determined relevant by [CONTACT_737], will be conducted every 4 
weeks, as indicated in Table 4 (Stage 1) and Table 5 (Stage 2) . 
7.7 Concomitant Medications 
All concomitant medications will be recorded from the time the patient  signs t he ICF through the End of 
Treatment  Visit  and t elephone call follow -up.  Nonprescription medications, medications given as part of 
any surgical procedure, and dietary supplements  will be included , a s will the specific dose/schedule of 
any systemic corticosteroid agents .  The concomitant medication documentation for sexually active 
females of childbearing potential and sexually active males should support contraceptive usage, as 
applicable.   Concomitant medications that are allowed or prohibited during the study are described in 
Sections  4.2 and 4.3. 
If a severe allergic reaction occurs and is believed to be related to investigational therapy, the Investigator 
should discontinue treatment (if ongoing) and follow the medically acceptable  standard of care .  T he 
reaction will be recorded as an AE, and all medications given will be recorded as concomitant 
medications.  
7.[ADDRESS_542300] be used for the 
remainder of the study .  Imaging assessments are to be performed approximately every 8 weeks during 
SL-701  Page 78 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 participation in the study.  Imaging evaluat ion (MRI or CT) may be performed either on the day of a 
treatment visit, or during the 7 days prior to a treatment visit ( during the 5 days prior for the Week 8 
evaluation ); it should be noted that if an assessment is performed during the days prior to a t reatment 
visit, the results should nonetheless be considered as part of the visit for the week at which the treatment 
is subsequently administered; for example an MRI performed 3 days prior to the Wee k 8 visit is 
technically conducted during the 7th week o f  study participation, but should be recorded as the “Week 8” 
imaging assessment.  For patients with evidence of disease control ongoing beyond [ADDRESS_542301] 
sc
ans after Week 50 may be performed every 12 weeks (± 14 days).  
7.9 Immun ological  Monitoring Response Assessment  
Immune response assessment testing will be performed by a central laboratory.  Specific instructions on 
t
he collection, processing, and shipment of blood samples are provided in the laboratory manual.  The 
blood samples will be analyzed us ing a qualified  method by  [CONTACT_428649] o ratory:  
ABL, Inc. 
[ADDRESS_542302] be submitted for immunohistochemical analysis.   
This tumor tissue may be used to evaluate relevant antigen expression (including GAA expression status 
and infiltration of GAA-specific T-cells), other immune markers and potential additional prognostic 
factors.  Tumor tissue paraffin blocks or unstained slides are preferred .   
8. REPORTING ADVERSE EV ENTS  
8.[ADDRESS_542303] the Investigator or subinvestigator at any time after signing the informed consent if any symptoms 
develop .  PD and disease -related death will not be considered AEs  or SAEs . 
A TEA
E is defined as any event not present before exposure to study drug or any event already present 
t
hat worsens in either intensity or frequency aft er exposure to study drug . 
SL-701  Page 79 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 An SAE is defined as any event that 
 Results in death, 
 Is immediately life -threatening,  
 Requires inpatient hospi[INVESTIGATOR_1081], 
 Results in persistent or significant disability/incapacity, 
 Is a congenital anomaly/birth defect. 
Important medical events that may not result in death, be life threatening, or require hospi[INVESTIGATOR_71154], based upon appropriate medical judgment, they may jeopardize the patient  
and may require medical or surgical inter vention to prevent one of the outcomes listed in this definition .  
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient ho spi[INVESTIGATOR_059], 
or the development of drug dependency or drug abuse.   Please consult Section 8.[ADDRESS_542304]’s last dose, or until resolution, whichever comes first.  Pre-existing AEs that worsen 
should be followed until [ADDRESS_542305]’s last dose or resolution to the AE level present at study 
entry.  The description of t he AE will include the onset date, duration, date of resolution, severity, 
seriousness (see Section  8.6) , etiology, and the likelihood of relationship of the AE to study  drug . 
A
t every study visit, patients will be asked nondirective questions to elicit any medically related changes 
i
n their well-being.  They will also be asked if they have been hospi[INVESTIGATOR_057], had any accidents, used any 
new medications, or changed concomitant medication regimens (both prescription and over-the-counter 
medications). 
In addition to patient  observations, AEs will be documented from any data collected on the eCRF or other 
docum
ents that are relevant to patient  safety.  An y allergic reaction to t he agents administered as study 
drug treatment m ust be reported as an AE.  
8.3 Adverse Event Reporting 
All AEs reported or observed during the study will be recorded on the AE eCRF.  Disease progression in 
the medical opi[INVESTIGATOR_428586]/or disease-related morbidity and mortality as a study endpoint 
will not be considered an AE or SAE.  Information to be collected includes drug treatment, dosage, type 
of event, time of onset, Investigator -specified assessment of severity  and relationship to study drug, time 
of
 resolution of the event, seriousness, any required treatment or evaluations, and outcome .  Adverse 
events resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent 
medications, or progression of disease states must also be reported .  All AEs will be followed  for [ADDRESS_542306]’s last dose, or until resolution, whichever comes first .  The MedDRA  will be used to 
code
 all AEs.  
SL-701  Page 80 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Preexisting conditions (present before the start of the AE collection period) are considered concurrent 
medical conditions and should not be recorded as AEs.  However, if the patient  experiences a worsening 
or
 complication of such a concurrent condition, the worsening or complication should be record ed as an 
AE.  Pre -existing AEs that worsen should be followed until [ADDRESS_542307]’s last dose or 
resolution to the AE level present at study entr y. Investigators should ensure that the AE term recorded 
captures the change in the condition ( eg, “worsening of [condition]”).  
I
nsufficient clinical response, efficacy, or pharmacological action should NOT be recorded as an AE.  The 
Investigator must make the distinction between exacerbation of preexisting illness and lack of therapeutic 
efficacy.   Pro g ressive disease is NOT an AE; however some seque lae of PD (ie , pain, neurologic 
impairment) may be reported as AEs (generally not related to investigational therapy).  
Abnormal laboratory values or test results constitute AEs only if they induce clinical signs or symptoms, 
are considered clinically significant, require therapy or further diagnosis beyond repeat testing for 
confirmation, or (if not associated with clinical signs or symptoms) they remain at levels consistent with 
severe abnormalities despi[INVESTIGATOR_346970]. 
It is requested that when reporting AEs for which potentially redundant CTCAE terms exist, the 
Investigator utilize s the more clinically -oriented terminology (for example, “anemia” is preferable to 
“hemoglobin decreased ”). 
It is also requested that in the setting of an allergic reaction or suspected allergic reaction considered by 
[CONTACT_428650], that the Investigator report s both the specific 
sym
ptoms associated with the reaction (ie, “urticaria” , “dy spnea”) and also report the appropriate term 
indicating the allergic reaction (“allergic reaction” or “anaphylaxis” if appropriate [Immune System 
Disorders; CTCAE v4. 03, page 26]).  
8.4 Assessment of Causality 
The I nvestigator’s assessment  of an AE's relationship to study drug is part of the documentation process, 
but
 it is not a factor in determining what is or is not reported in the study .  If there is any doubt as to 
whether a clinical observation is an AE, the event should be reported.  
In this study, the investigational medicinal product is SL-701.  The relationship of an AE to the 
investigational product should be classified using the following guidelines: 
Related:  A temporal relationship exists between the event onset and administration of SL-701.  It cannot 
be readily explained by [CONTACT_102]’s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014] .  In case 
of cessation or reduction of the dose, the event abates or resolves and reappears upon rechallenge.  This 
includes events that are considered possibly, probably, or definitely related to SL-701.  
Not Related:  Evidence exists that the AE has an etiology other than the study drug ( eg, pre-existing 
condition, underlying disease, intercurrent illness, or concomitant medication).  This includes events that 
are considered probably not or not related to SL-701.   It should be emphasized that ineffective study drug 
t
reatment should not be considered as causally related in the context of adverse event reporting (in other 
words, PD is not considered an AE ;  however some sequelae of PD may be reported as AEs and should 
generally be reported as AEs not related to investigational therapy). 
SL-701  Page 81 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 The additional medications evaluated in this study are GM-CSF and topi[INVESTIGATOR_160772] (Stage 1) or poly-
ICLC (Stage 2) as vaccine adjuvants and bevacizumab as an anti-tumor agent (Stage 2).  The relationship 
of
 an AE to each of these agents should be classified according to the same guidelines as detailed above. 
8.5 Assessment of Severity 
The severity of AEs will be assessed using the NCI CTCAE, Version 4.03 (or higher).  The intensity of 
the AE will be rated as mild, moderate, or severe using the following criteria:  
Mild: These events require minimal or no treatment and do not interfere with the patient ’s daily activities.  
These are generally considered Grade 1 events in the NCI  CTCAE.  
Moderate: These events result in a low level of inconvenience or concern with the therapeutic measures.  
Moderate events may cause some interference with functioning. These are generally considered Grade 2 
events in the NCI CTCAE. 
Severe: These events interrupt a patient ’s usual daily activity and may require systemic drug therapy or 
other treatment .  Severe events are usually incapacitating.   These are generally considered Grade 3 -4 
ev
ents in the NCI CTCAE (Grade 4 is generally for AEs that are considered life -threatening).  
Changes in the severity of an AE should be documented to allow an assessment of the duration of the 
event at each level of intensity to be performed.  Adverse events characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865]. 
8.6 Serious Adverse Event Reporting 
Any AE considered serious by [CONTACT_428651] 
(Section 8.1) that  occurs from signing t he ICF through [ADDRESS_542308]
ug (expedited report) as soon as possible but no later than [ADDRESS_542309] 
(IRB) /Independent Ethics Committee (IEC) .  Copi[INVESTIGATOR_428605] s or 
subi
nvestigators, governing authorities, ethics committees, and the Sponsor must be submitted to INC 
Research for filing.  
SL-[ADDRESS_542310] be followed to resolution or, if resolution is unlikely, to  stabilization . 
Study
 endpoints in GBM patients include disease-related mortality and morbidity which will not be 
reported as expedited IND safety reports, unless there is a serious and unexpected event with evidence of 
a causal relationship between study drug and the event.  As appropriate and based on the frequency of 
occurrence, SAEs in the study will be reported to FDA at an appropriate interval, such as inclusion in the 
periodic update IND annual report.   
The following SAEs will not be reported individually in an expedited manner because they are anticipated 
to occur in the GBM  study population receiving stand of care treatment at some frequency independent of 
study drug exposure: 
o Progression of disease, glioma. 
o Death as a consequence of the underlying disease, glioma. 
Please consult Section 8.[ADDRESS_542311] be reported to the INC Research Ph arm acovigilance 
Department staff .  The pregnancy is not considered an AE; however pregnancy complications, including 
miscarriage or spontaneous abortion, are considered AEs .  Any untoward outcome for the mother or 
infant is considered an SAE.  
8.[ADDRESS_542312] deviation, median, minimum, and maximum.  Categorical variables will be 
sum
marized using the number of and percentage of patients.  Missing data will not be imputed.  All data 
obtai
ned in this study will be analyzed using SAS® software (version 9.3 or higher). 
SL-701  Page 83 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 9.1 Stage 1  Sample Size  
T
he initially planned sample size of 100 patients was based on the following assumptions for the 
2 alternative primary endpoints of OS-12 and ORR  (Wick 2010 , van den Brent 2009 , and B atchelor 
2013):  
OS-12: 
 The null hypothesis is that OS-12 for patients treated with SL- 701 is ≤25%;  
 The alternative hypothesis is that OS-12 for patients treated with SL-701 is ≥40%;  
 Testing will be by [CONTACT_428620]-sample binomial superiority test with a type I error rate of 1.25%, 
one-sided ( ie, a Bonferroni correction will be applied to the usual type I error rate of 2.5% to 
adjust for the analysis of 2 primary endpoints). 
ORR  (by [CONTACT_428621]): 
 T
he null hypothesis is that ORR for patients treated with SL- 701 is ≤10%;  
 The alternative hypothesis is that ORR for patients treated with SL- 701 is ≥ 25%; 
 Testing will be by [CONTACT_428620]-sample binomial superiority test with type I error rate of 1.25%, 
one-sided; 
 At least 80 patients will be evaluable for ORR. 
Based on these assumptions, the power for the initially planned sample size was approximately 82% for 
OS-12 and 92% for ORR.  Accrual to Stage 1 one of the study was discontinued following the accrual of 
46 patients (all evaluable for ORR) who received SL-701 emulsion, GM-CSF, and imiquimod.  
Consequently the power for Stage 1 given the actual enrollment was approximately 48% for OS-12 and 
62% for ORR. 
9.2 Stage 2  Sample Size  
A
 total of 30 patients are planned to be enrolled in Stage 2.  In this stage, the null and alternative 
hypotheses for OS-12 will remain the same as those utilized in Stage 1, described in Section 9.1.  The null 
and alternative hypotheses for ORR will be ≤40%  and ≥ 60%, respectively.  Testing in Stage 2 will be at a 
t
ype I error rate of 5%, one-sided.  If 30 patients (assumed all evaluable for ORR) are enrolled in Stage 2, 
the power is approximately 71% for OS-12 and 55% for ORR.  
9.3 Analysis Populations 
Full Analysis Set  
The full analysis set (FAS) will include all enrolled patients  who received at least 1 dose of study drug .  
T
he FAS will be used to analyze all safety data and any efficacy assessments based solely on survival 
(ie, OS-12 and OS ). 
Objective Response Evaluable Set 
The objective response evaluable ( ORE ) set will consist of all pa tients  in the f ull analysis set who had 
measurable t umors on MRI scans at Screening .  The ORE set will be used to analyze any efficacy 
SL-701  Page 84 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 assessments that involve objective response ( ie, ORR, PFS-6, PFS, and DR ). 
9.4 Patient  Disposition  
T
he number of patients who were screened, ent ered and complete d the study , as  well as the reason for 
discontinuing study drug or withdrawing from the study  will be tabulated .  The reason for discontinuing 
study drug or withdrawing from the study will be listed by [CONTACT_4676] .   
9.5 Demographics and Baseline Data 
Demographic ( eg, gender, age, race, ethnicity) and baseline characteristics ( eg, KPS, height, weight, and 
pr
ior therapy) will be summarized using descriptive statistics.  Supportive data will be listed by [CONTACT_4676]. 
Medical history will be summarized for the FAS using the number of ob servations and percentage of 
patients  reporting each category .   
9.6
 Study Drug Administration  
The number of doses of study drug administered to each patient will be summarized using descriptive 
statistics.  In Stage 1, information collected in the paper diary (imiquimod diary) will be used to document 
patient compliance with the imiquimod cream self-application [ADDRESS_542313] one-sample binomial tests with a type I error rate of 1.25%, one-sided for Stage 1 of the study and 
5%, one-sided for Stage 2 of the study will assess whether the percentage of patients surviving 12 months 
after initiation of SL-701 ( ie, OS-12) is >25%.  Exact 2-sided 97.5% (Stage 1) or 90% (Stage 2) 
confidence intervals ( CIs) will also be reported for OS-12.  The analysis of this primary endpoint will be 
conducted using the FAS.  (An additional, secondary evaluation of OS-[ADDRESS_542314] CIs).   
Exact one-sample binomial tests with a type I error rate of 1.25%, one-sided for Stage 1 and 5%, 
one-sided for Stage [ADDRESS_542315] response of either 
CR or PR documented on 2 co nsecutive MRIs obtained ≥4  weeks apart ( ie,  ORR) is > 10%.  Exact 2-sided 
97.5% (Stage 1) or 90% (Stage 2) CI s will also be reported for ORR.  The analysis of this primary 
endpoint will be conducted using the ORE set and the modified RANO criteria. 
The clinical study will be considered to have met its efficacy objectives if either one of the primary 
endpoints achieves statistical significance. 
 Secondary Endpoints  
The following analyses will be performed for the Stage 1 and Stage 2 cohorts.  
Descriptive statistics will be used to summarize all secondary efficacy endpoints; no inferential testing 
will be performed.  Two-sided 95% CIs will be reported for key descriptive statistics as noted below. 
Median values for the DR, PFS, and OS (in months) and the ir 2-sided 95% (Stage 1) or 90% (Stage 2) 
C
Is will be estimated using the method of Kaplan-Meier.  The analysis of OR and PFS will use the 
modified RANO criteria and the ORE set.  The analysis of OS will use the FAS. 9.7.[ADDRESS_542316] (version 
1.1).  An exact 2-sided 97.5% (Stage 1) or 90% (Stage 2) CI will be reported for ORR.  Median values for 
D
R and PFS (in months) and their 2-sided 95% CIs will be estimated using the method of Kaplan-Meier.  
Analyses of ORR, DR, and PFS using RECIST (version 1.1) will use the ORE set. 
T
he distributions of DR and PFS will be displayed by [CONTACT_428652]-Meier methodology as a function of time.  These distributions will be shown using both 
the modified RANO criteria and RECIST (version 1.1) using the ORE set.  PFS-[ADDRESS_542317] proportion and via Kaplan-Meier estimate. 
The magnitude of immune response in PBMCs will be summarized by [CONTACT_15449].  Spot counts for 
glioma-associated antigen (ELISPOT) will be summarized descriptively by [CONTACT_428653].  Similarly, the number of GAA-specific T-cells infiltrating 
post-v
accine tumor tissue will be summarized descriptively by [CONTACT_428654].   
The percentage of surviving patients who have been considered to have mounted an immune response to 
each of the antigens will be reported by [CONTACT_428655] 2-sided 95% (Stage 1) or 90% 
(Stag
e 2) CI.   
 Exploratory Endpoints  
Cox regression will be used to determine whether there is a correlation between various measures of 
tumor efficacy ( ie, PFS and OS) and measures of immunogenicity.  Cox regression will also be used to 
determine whether there is an association between PFS or OS and the presence of GAA  in or infiltration 
of
 GAA-specific T-cells into post-vaccine tumor tissue.  These analyses will be conducted using the ORE 
set for PFS and the FAS for OS. 
9.8 Safety Analysis  
The FAS will be used to report all safety analyses.   
 Adverse Events  
An AE will be considered treatment-emergent (ie, a TEAE) if it starts on or after the time of the first dose 
of
 study drug and up to [ADDRESS_542318] dose of study drug.  AEs wi ll be summarized by 
[CONTACT_428656]™ , Version 13.1 (or higher), system organ class (SOC) and PT.  The severity of AEs will also 
be summarized by [CONTACT_4652], Version 4.03 (or higher).  Non- TEA Es will be included in the patient 
listings and flagged as such but will not be included in the summary tables.  Where an AE date is partial 
or missing, and it is unclear whether the AE is treatment-emergent, the AE will be assumed to be 
treatment-emergent. 
The number and percentage of patients who experience TEAEs will be summarized overall by [CONTACT_428657].   
D
escriptive analysis of AEs will include incidence of TEAEs and SAEs grouped by: 
 SOC and PT. 
 SOC, PT and severity. 9.7.3 
9.8.1 
SL-701  Page 86 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  SOC, PT and causality. 
 SOC and PT leading to discontinuation from the study. 
 SOC and PT for events with CTCAE ≥Grade 3. 
 SOC and PT leading to death. 
Individual listings of all AEs will also be provided. 
 Laboratory Parameters  
Laboratory results (hematology, serum chemistry, coagulation parameters, and urinalysis) will be 
cl
assified according to NCI CTCAE, Version 4.03 (or higher).  Laboratory results not corresponding to an 
NCI CTCAE term will not be graded.  Incidences of laboratory abnormalities will be summarized with 
descriptive statistics by [CONTACT_15449]. 
Shift tables will display intra-individual changes from baseline to each study visit using categorizations 
provided by [CONTACT_12082].  Categorization will be done by [CONTACT_428658], low, normal, and high.  Shift tables will also be shown for intra-individual 
cha
nges from baseline in CTCAE grade for each study visit.  CTCAE <Grade [ADDRESS_542319]-baseline or 
whose evaluations worsen after baseline.  Frequency tables will display the number and frequency of 
patients with any abnormalities by [CONTACT_15449].  The results of abnormal physical examinations will also be 
listed. 
9.9 Interim Analysis 
There is no interim efficacy analysis planned for this study. 
9.10 Study Completion, Extension Phase, End- of-Study  
The study is considered complete when sufficient information is available to enable assessment of the 
primary endpoint(s) and other critical secondary endpoints. In the weeks subsequent to a determination 
that sufficient information is available for these assessments, a date for database lock will be assigned, 
and any outstanding inquiries concerning data elements will be resolved.  The Study Completion date 
will be the date beyond which study data is no longer entered into the primary database (this study 
completion date generally precedes the date on which the database lock occurs by [CONTACT_428659]/months).  
In the event that patients continue to receive investigational therapy without evidence of PD or intolerable 
toxicity at the time of study completion, and the Investigator(s) believe that ongoing administration of 
investigational therapy is likel y to confer additional benefit, a Study Extension Phase may be 
implemented, in which investigational therapy is made available to patients who continue to meet criteria 9.8.2 
9.8.3 
9.8.4 
SL-701  Page 87 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 for therapy (and who provide an additional informed consent in order to receive ongoing therapy).  
During the Study Extension Phase , Inv estigators are encouraged to continue evaluation of patients 
(including laboratory and imaging assessments) at a schedule similar to that which was stipulated during 
the conduct of the study.  Data collectio n by [CONTACT_428660] (dose, chronology), AEs, SAEs, and reasons for 
discontinuation of study therapy  (supplemental efficacy data including information on patient s ’ overall 
survival status may be considered if applicable) .  The End-of-Study  occurs a pproximately [ADDRESS_542320] to current International Conference on  Harmonization  
(
ICH) E6(R1) guideline , Good Clinical Practice: Consolidated Guideline , and current standard operating 
procedures.  
10.3 Inspection of Records 
The I nvestigator or subinvestigator and institution involved in the study will permit study -related 
moni toring, audits, IRB / IEC  review, and regulatory inspection(s) by [CONTACT_428661] 
r
ecords .  In the event of an audit, the Investigator or subinvestigator agrees to allow the Sponsor, 
representatives of the Sponsor, the FDA, or other reg ulatory agency access to all study records.  
SL-[ADDRESS_542321] operating 
pr
ocedures or working practice documents or guidelines .  Administrative change will be reported to the 
IRB/IEC  but w i ll not result in protocol amendments.  
11.1 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner 
designed to maintain patient  confidentiality .  All records will be kept in a secure storage area with limited 
access .  Clinical information will not be released without the written permission of the patient  (or the 
pat
ient’s legal representative), except as necessary for monitoring and auditing by [CONTACT_1034], its 
designee, the FDA, the European Medic ines Agency ( EMA ), or the IRB / IEC . 
The I nvestigator or subinvestigator and all employees and coworkers involved with this study may not 
disclose or use for any purpose other than performance of the study, any data, record, or other 
unpublished, confidentia l information disclosed to those individuals for the purpose of the study .  Prior 
written agreement from the Sponsor or its designee must be obtained for the disclosure of any said 
confidential information to other parties.  
11.[ADDRESS_542322]/Research Ethics Board 
Federal regulations and the ICH guidelines require that approval be obtained from an IRB/IEC before 
participation of human patients in research studies.  Before the study onset, the protocol, informed 
consent, advertisements to be used for patient  r ecruitment, and any other written information regarding 
this study to be provided to the patient  or the pa tient ’s legal representative must be approved by [CONTACT_5040]/IEC .  Documentation of all IRB /IEC  approvals and of the IRB / IEC compliance with ICH E6 (R 1) 
guidelines will be maintained by [CONTACT_428662].  
All IRB/IEC approvals should be signed by [CONTACT_1201]/IEC chairman or designee and must identify the 
IRB/IEC name [CONTACT_3816], the clinical protocol by [CONTACT_29985]/or protocol number, and the date approval 
and/or favorable opi[INVESTIGATOR_11744]. 
SL-701  Page 89 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 The I nvestigator or subinvestigator is responsible for obtaining continued review of the clinical research 
at intervals not exceedin g 1 year or otherwise specified by [CONTACT_1201]/IEC .  The Investigator or 
subinvestigator must supply the Sponsor or its designee with written documentation of continued review 
of the clinical research.  
11.[ADDRESS_542323] be submitted in writing to the Investigator’s or subinvestigator’s IRB/I EC and, if applicable, to the 
appr
opriate regulatory authorities for approval before patients  can be enrolled into an amended protocol.  
11.4 In
formed Consent 
Written informed consent , i n compliance with US Title 21 Code of Federal Regulations (CFR) , Part 50 , 
current ICH E6 (E1) guidelines, and other applicable regulatory requirements , sha ll be obtained from each 
patient  or legally authorized representative before entering the study or performing any unusual or 
nonr
outine procedure that involves risk to the patie nt.  An ICF template may be provided by [CONTACT_428663] s.  If any institution -specific modifications to study -related procedures are proposed or made 
by [CONTACT_3452] , the consent should be reviewed by [CONTACT_1052]/or its designee, if appropriate, before 
IRB/IEC  submission .  Once reviewed, the ICF will be submitted by [CONTACT_428664]/IEC  for review and approval before the start of the study .  If the ICF is revised duri ng the 
course of the study, all active participating patients  or their legally authorized representatives must sign 
the revised ICF. 
B
efore recruitment and enrollment, each prospective patient  or his/her legally authorized representative 
will be given a fu ll explanation of the study and allowed to read the approved ICF.  Once the Investigator 
or subinvestigator is assured that the patient /legal representative understands the implications of 
participating in the study, the patient /legal representative will b e asked to give consent to participate in 
the study by [CONTACT_12568]. 
T
he Investigator or subinvestigator shall provide a copy of the signed informed consent to the patient  
and/or legal representative .  The original form shall be maintained in the patien t’s medical records at the 
study site . 
11.[ADDRESS_542324] document and explain in the patient ’s source 
documentation any deviation from the approved protocol .  The Investigator or subinve stigator may 
implement a deviation from, or a change of, the protocol to eliminate an immediate hazard to study  
patients  without prior I RB/IEC  approval .  As soon as possible after such an occurrence, the implemented 
deviation or change, the reasons for it, and any proposed protocol amendment(s) should be submitted to 
the IRB/IEC  for review and approval, to the Sponso r for agreement, and to the regulatory au thorities, if 
required.  
A deviation from the protocol is an unintended and/or unanticipated departure from the procedures and/or 
processes approved by [CONTACT_1035]/IEC  and agreed to by [CONTACT_428665] .  
Deviations usually hav e an impact on individual patients  or a small group of pat ients  and do not involve 
inclusion/exclusion or primary endpoint criteria .  A protocol violation occurs when there is nonadherence 
SL-701  Page 90 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 to the protocol that results in a significant, additional risk to the patient , when the patient  or Inv estigator 
or subinvestigator has failed to adhere to significant protocol requirements ( eg, inclusion/exclusion 
criteria) and the patient  was enrolled without prior Spo nsor approval, or when there is nonadherence to 
FDA or other applicable regulations and/or ICH E6 (R1) guidelines.  
The clinical monitor will document protocol violations and deviations throughout the course of 
monitoring visits.  The monitor will notify the Investigator or subinvestigator during a visit and/ or in 
writing of all violations and deviations .  The IRB/IEC  should be notified of all protocol violations and 
dev
iations in a timely manner.  
11.6 Study Reporting Requirements 
By [CONTACT_4907], the Investigator or subinvestigator agrees to submit reports of SAEs 
according to the timeline and method outlined in the protocol .  In addition, the Investigator or 
subinvestigator agrees to submit annual reports to his/her IRB/IEC  as appropriate .  The Investigator or 
subinvestigator also agrees to provide the Sponsor with an adequate report shortly after completion of the 
Investigator’s or subinvestigator’s participation in the study.  
11.[ADDRESS_542325] pr ovide to the Sponsor a commitment to 
update promptly this information if any relevant changes occur during the course of the investigation and 
for 1 year after the completion of the study.  
Neither the Sponsor nor the CRO is financially responsible for furt her testing/treatment of any medical 
condition, which may be detected during the screening process .  In addition, in the absence of specific 
arrangements, neither the Sponsor nor the CRO is financially responsible for further treatment of the 
patient ’s dis ease.  
11.8 Investigator Documentation 
Before beginning the study, the Investigator will be asked to comply with ICH E6 (R1) 8.2, 21  CFR, and 
ot
her applicable regulations by [CONTACT_44074], including but not limited to:  
 An original Investigator -signed Investigator Agreement page of the protocol . 
 An IRB/IEC-approved ICF, samples of study site  advertisements for recruitment for this study, 
and a
ny other written information regarding this study that is to be provided to the patient  or le g al 
representative . 
 IRB/IEC approval. 
 Form FDA 1572, fully executed, and all updates on a new fully executed Form FDA 1572. 
 Curriculum vitae for the Investigator and each subinvestigator listed on Form FDA [ADDRESS_542326] be noted on the curriculum vitae .  They will be signed and dated by [CONTACT_428666] -up, indicating that they are accurate and current.  
SL-701  Page 91 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
  Financial disclosure information to allow the Sponsor to submit complete and accurate 
certification or disclosure statements required under [ADDRESS_542327] provide to the Sponsor a commitment to promptly update this information if any relevant 
changes occur during the course of the investigation and for 1 year after the com pletion of the 
study.  
 Laboratory certifications and reference ranges for any local laboratories used by [CONTACT_3452], in 
accordance with [ADDRESS_542328] 
The I nvestigator agrees that the study will be conducted according to the principles of the  ICH  E6 ( R 1) 
and the principles of the World Medical Association Declaration of Helsinki .  The I nvestigator will 
conduct all aspects of this study in accordance with all national, state, and local laws or regulations.  
11.10  Publications 
After completion of the study, the data may be considered for reporting at a scientific meeting or for 
publication in a scientific journal.  In these cases, the Sponsor will be responsible for these activities and 
will work with the Investigators to determine how the manuscript is  written and edited, the number and 
or
der of authors, the publication to which it will be submitted, and other related issues .  The Sponsor has 
final approval authority over all such  issues.  
Data are the property of the Sponsor and cannot be published with out prior authorization from the 
Sponsor, but data and publication thereof will not be unduly withheld.  
SL-701  Page 92 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 12. INVESTIGATOR’S STATE MENT 
I agree to conduct the study as described in the protocol entitled “ A Phase 1/2 Study of SL -701, a 
Subcutaneously Injected Mult ivalent Glioma -Associated Antigen Vaccine, in Adult Patients with 
Recurrent Glioblastoma  Multiforme ” i n accordance with Good Clinical Practice guidelines , the 
Declaration of Helsinki, and all applicable law and regulations .  I have read and understan d all sections of 
the protocol, including Section  11, Administrative Considerations .  
 
 
 
 
 
Principal Investigator’s Signature  
  [CONTACT_294160]’s Name (printed)  
   
 
 
SL-701  Page 93 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 13. REFERENCES 
Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al.  Immunization of malignant 
melanoma patients with full-length NY- ESO -[ADDRESS_542329] imiquimod as vaccine 
adjuvant.  J Immunol 2008;181(1):776-84. 
Albert ML , Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB.  Tumor-specific killer cells in 
paraneoplastic cerebellar degeneration.  Nat Med 1998;4(11):1321-4.  
Avastin® (bevacizumab) prescribing information.  Genentech, Inc.,  May 2015 . 
B
allman KV , Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR,  et al.  The relationship between 
six-month progression -free survival and 12 -month overall survival end points for phase II trials in 
patients with glioblastoma multiforme .  Neuro Oncol 2007 ;9:29-38. 
Batchelor TT , Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al .  Phase III randomized 
trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus 
lomustine alone in patients with recurrent glioblastoma .  J Clin Oncol 2013 ;31(26):3212 -8. 
Bolonaki I , Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, et al.  Vaccination of 
patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse 
transcriptase peptide.  J Clin Oncol 2007;25(19):2727-34. 
Broniscer A , Gajjar A.  Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two 
challenges for the pediatric oncologist.  Oncologist 2004;9:197 –206. 
B
utowski N , Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM , et al. A North American 
br
ain tumor consortium phase II study of poly -ICLC for adul t patients with recurrent anaplastic gliomas. J 
Neurooncol 2009 a;91:183 -9. 
Butowski N , Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K , et al. A phase II trial of poly -ICLC 
with radiation for adult patients with newly diagnosed supratentorial glioblastom a: a North American 
Brain Tumor Consortium (NABTC01 -05).  J Neurooncol 2009 b;91:175- 82.  
Celis E , Melanoma Study Group of the Mayo Clinic Cancer Center.  Overlappi[INVESTIGATOR_428606] I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence 
of systemic immune dysfunction.  Cancer 2007;110(1):203-14.  
Chamberlain MC .  Bevacizumab for the treatment of recurrent glioblastoma.  C lin Med Insights Oncol 
2011;5:117 -29. 
Chinot OL , Wick W, Mason W , Henriksson R, Saran F, N ishikawa R,  et al. Bevacizumab plus 
r
adiotherapy -temazolamide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709 -22. 
Cho HI , Barrios K, Lee YR, Linowski AK, Celis E.  BiVax: a peptide/poly -I C subunit vaccine that 
mimics an acute infection elic its vast and effective anti -tumor CD8 T -cell responses. Cancer Immunol 
Immunother 2013;62(4):787 -99. 
De Vleeschouwer S , Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, et al.  
Postoperative adjuvant dendritic cell-based  immunotherapy in patients with relapsed glioblastoma 
multiforme .  Clin Cancer Res 2008;14(10):3098 -104. 
SL-701  Page 94 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Disis ML , Gooley TA, Rinn K, Davis D, Pi[INVESTIGATOR_428607] M, Cheever MA, et al.  Generation of T-cell immunity 
to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.  J Clin 
Oncol 2002;20(11):2624-32. 
Eisenhauer EA , Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J,  et al.  New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) .  Eur J Cancer 2009;4 5:228 -
247. 
Fadul CE , Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, et al.  Immune response in patients with 
newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell 
vaccination after radiation chemotherapy.  J Immunother 2011;34(4):382-9. 
Fenoglio D , Traverso P, Parodi A, Tomasello L, Negrini S, Kalli F, et al.  A multi-peptide, dual-adjuvant 
telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.  Cancer 
Immunol Immunother 2013;62(6):1041-52. 
Fuessel S , Meye A, Schmitz M, Zastrow S, Linné C, Richter K, et al.  Vaccination of hormone-refractory 
prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.  
Prostate 2006;66(8):811-21. 
Gorlia T , Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, et al .  New prognostic factors and 
calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC 
Brain Tumour Group phase  I and II clinical trials .  Eur J Cancer 2012;48(8):1176 -84. 
Hamid O , Solomon JC, Scotland R, Garcia M, Sian S, Ye W, et al.  Alum with  interleukin -12 augments 
immunity to a melanoma peptide vaccine:  correlation with time to relapse in patients with resect ed h igh-
risk disease .  Clin Cancer Res 2007;13(1):[ADDRESS_542330] MR, Ramagopalan SV.  Of mice and men: experimental autoimmune encephalitis 
and multiple sclerosis.  Eur J Clin Invest 2011;41(11):1254-8. 
Hartman LLR , Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM et al. Pediatric phase II trials 
of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol 
Oncol 2014;36(6):451-7. 
Heimberger AB , Hlatky R, Suki D, Yang D, Weinberg J,Gilbert M, et al.  Prognostic effect of epi[INVESTIGATOR_428608] .  Clin Cancer Res 
2005;11(4):1462 -6. 
Hilf N , Pawlowski N, Flohr S, Schoor O, Weinschenk T, Singh H.  Synergy of the immunomodulators 
GM-
CSF and imiquimod for peptide-based therapeutic vaccines [abstract].  In:  Proceedings of the 101st 
Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC.  
Philadelphia (PA): AACR; Cancer Res 2010;70([ADDRESS_542331]):Abstract nr 5623. 
Huang Y , Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J , et al. Vascular normalizing doses of 
antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance 
immunotherapy. Proc Natl Acad Sci [LOCATION_003] 2012;109(43):[ZIP_CODE] -6.  
Kuttruff S , Weinschenk T, Schoor O, Lindner J, Kutscher S, Maurer D, et al.  Immune responses and 
association with clinical outcome of advanced colorectal cancer patients treated with the multi-peptide 
vaccine IMA910.  J Clin Oncol 2012;30(Suppl):   Abstract nr 2522.  
SL-701  Page 95 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Lamborn KR , Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al .  Progression -free 
survival: an important end point in evaluating therapy for recurrent high -grade gliomas .  Neuro Oncol 
2008;10:162 -170. 
Levy HB . Historical overview of the use of polynucleotides in cancer. J Biol Response Mod 1985;4:475-
80. 
Liau LM , Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al.  Dendritic cell 
vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by [CONTACT_428667].  Clin Cancer Res 2005;11(15):5515-25. 
Macdonald DR , Cascino TL, Schold Jr SC, Cairncross JG.  Response criteria for phase II studies of 
supratentorial malignant glioma.  J Clin Oncol 1990;8(7):1277 –80. 
Ma
ughan TS , Adams RA, Mayer-Mokler A, Nowara E, Torday L, Cseh J, et al.  Overall survival of 
advanced colorectal cancer patients treated with the multi-peptide vaccine IMA910: Results of a matched-
pair analysis with Arm C patients from the MRC COIN trial.  Poster presented at:  2012 ASCO Annual 
Meeting; June 1-5, 2012; Chicago, IL. 
Mavroudis D , Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, et al.  A phase I study of the 
optimized cryptic peptide TERT(572y) in patients with advanced malignancies.  Oncology 
2006;70(4):306-14. 
Mayer F, Mayer-Mokler A, Nowara E, Torday L, Ludwig J, Kuttruff S, et al.  A phase 1/2 trial of the 
multi-peptide cancer vaccine IMA910 shows improved clinical outcome in advanced colorectal cancer 
(CRC) patients mounting specific T-cell responses.  Poster presented at:  2012 Gastrointestinal Cancers 
Symposium; January 19-21, 2012; San Francisco, CA. 
Norden AD , Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al.  Bevacizumab for 
recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.  Neurology 2008;70(10):779-
87. 
Okada H , Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, et al.  Characterization and 
transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine 
kinase for glioma tumor vaccine therapy.  Cancer Gene Ther 2000;7(3):486-94. 
Okada H , Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al.  Induction of CD8+ T -cell 
responses against novel glioma -associated antigen peptides and  clinical activity by [CONTACT_384026] 
{al
pha}- type 1 polarized dendritic cells and polyinosinic -polycytidylic acid stabilized by [CONTACT_396842].  J Clin Oncol 2011;29(3):[ADDRESS_542332] the universal tumour antigen survivin.  Vaccine 2005;23: 884-889. 
Peoples GE , Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, et al.  Combined clinical trial 
r
esults of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: 
U.S.  Military Cancer Institute Clinical Trials Group Study I-01 and I-02.  Clin Cancer Res 
2008;
14(3):797-803. 
Pi[INVESTIGATOR_428609] , Selfridge J, Mody RR et al. Deferred use of bevacizumab for recurrent glioblastoma is not 
as
sociated with diminished efficacy. Neuro-Oncology 2014;16(6):815-22. 
SL-701  Page 96 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Pi[INVESTIGATOR_9387] L , Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, et al.  A phase II trial of vaccination 
with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-
CSF and interferon-alpha in metastatic melanoma patients.  Cancer Immunol Immunother  
2006;55(8):958 -68. 
Pollack IF , Jakacki RI, Butterfield LH, Okada H.  Peptide vaccine therapy for childhood gliomas.  
Neurosurgery 2013;[ADDRESS_542333] 1:113-9. 
Pollack IF , Jakacki RI, Butterfield LH, Hamilton RI, Panigrahy A, Porter DM et al. Antigen-specific 
immune responses and clinical outcome with glioma-associated antigen peptides and polyinosinic-
polycytidylic acid stabilized by [CONTACT_428668]. J Clin Oncol 2014;32:2050-58. 
Quant EC , Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, et al.  Role of a second 
chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.  Neuro Oncol 
2009;11(5):550-5. 
Reardon DA , Wen PY.  Therapeutic advances in the treatment of glioblastoma:  rationale and poten t ial 
role of targeted agents .  Oncologist 2006;11(2):152 -64. 
Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kühl J, Demaerel P, et al.  Surgery and 
adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility 
study.  Br J Cancer 2004;91(9):1656-62. 
Salazar AM , Levy HB, Ondra S, Kende M, Scherokman B, Brown D et al. Long-term treatment of 
malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with 
polylysine and carboxymethylcellulose: an open pi[INVESTIGATOR_799]. Neurosurgery 1996;38(6):1096-1103. 
Sampson JH , Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al.  Immunologic 
escape after prolonged progression-free  survival with epi[INVESTIGATOR_428610] .  J Clin Oncol 2010;28(31):4722 -9. 
Schoenfeld JD , Dranoff G. Antiangiogenic immunotherapy.  Human Vaccines 2011; 7(9): 976-81. 
Smith BD , Kasamon YL, Kowalski J, Gocke C, Murphy K,Miller CB, et al.  K562/GM-CSF 
immunotherapy reduces tumor burden in chronic  myeloid leukemia patients with residual disease on 
i
matinib mesylate .  Clin Cancer Res 2010;16(1):338 -47. 
Staehler M , Stenzl A, Dietrich PY, Eisen T, Haferkamp A, Beck J, et al.  A phase I study to evaluate 
safety, immunogenicity and anti-tumor activity of the multi-peptide vaccine IMA901 in renal cell 
carcinoma patients (RCC).  J Clin Oncol (Meeting Abstracts) 2007;25([ADDRESS_542334]): Abstract nr 5098. 
Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J , et al. Angiogenesis and immunity: a 
bi
directional link potentially relevant for the monitoring of antiangiogenic therapy and the development 
of novel therapeutic combination with immunotherapy. Cancer Metasasis Rev 2011 ; 30: 83 -95. 
Tjoa BA , Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, et al.  Evaluation of phase I/II 
clinical trials in prostate cancer with dendritic cells and PSMA peptides.  Prostate 1998;36(1):39-44. 
SL-701  Page 97 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Tsuruma T , Hata F, Torigoe T, Furuhata T, Idenoue S,Kurotaki T, et al.  Phase I clinical study of anti-
apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent 
colorectal cancer.  J Transl Med 2004;2(1):19. 
Valmori D , Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, et al.  Vaccination with NY-
ESO -1 protein and CpG in Montanide  induces integrated antibody/Th1 responses and CD8 T cells 
t
hrough cross -priming .  Proc Natl Acad Sci U S A  2007;104(21):8947 -52.  
van den Brent MJ , Brandes AA, Rampling R,  Kouwenhoven MCM, Kros JM, Carpentier AF, et al .  
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: 
EORTC brain tumor group study [ZIP_CODE] .  J Clin Oncol 2009;27(8):1268 -74. 
Van Mieghem E , Wozniak A, Geussens Y, Menten J, De Vleeschouwer S, Van Calenbergh F, et al. 
Defining pseudoprogression in glioblastoma multiforme. Eur J Neurol 2013; 20: 1335-41. 
Wen PY , Kesari S.  Malignant gliomas in adults.  N Engl J Med 2008;359(5):492-507. 
Wen PY , Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E,  et al.  Updated response 
assessment criteria for high -grade gliomas: response assessment in neuro -oncology working group .  J 
Clin Oncol 2010; 28:1963 -1972 .   
Wheeler CJ , Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, et al.  Vaccination elicits correlated 
immune and clinical responses in glioblastoma multiforme patients.  Cancer Res 2008;68(14):5955-64. 
Wick
 W, Puduvalli VK, Chamberlain MC, van den Brent MJ, Carpentier AF, Cher LM, et al .  Phase III 
study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioma .  J Clin 
Oncol 2010;28(7):1168 -74. 
Wick DA , Martin SD, Nelson BH, Webb JR. Profound CD8+ T cell immunity elicited by [CONTACT_428669]3 agonist poly(I:C).  Vaccine 2011; 29:984-993. 
Wobser M , Keikavoussi P, Kunzmann V, Weininger M, Andersen M, Becker J.  Complete remission of 
liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the 
universal tumor antigen survivin.  Cancer Immunol Immunother 2006;55(10):1294-8. 
Wol
chok J , Hoos A, O’Day S , Weber JS, Hamid O, Lebbé C,  et al. Guidelines for the evaluation of 
i
mmune therapy activity in solid tumors: immune -related response criteria. Clin Cancer Res 2009; 15: 
7412- 20. 
Wolchok J , Neyns B, Linette G , Negrier S, Lutzky J, Thomas L,  et al. Ipi[INVESTIGATOR_428611] w ith pretreated advanced melanoma: a randomised, double -blind, multicentre, phase 2, dose -
ranging study. Lancet Oncol 2010;11:155 -64. 
Wong AJ , Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al.  Structural alterations 
of the epi[INVESTIGATOR_428612].  Proc Natl Acad Sci U S A 
1992;89(7):2965-9. 
Wu W , Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O'Fallon JR, et al.  Joint NCCTG and 
NABTC prognostic factors analysis for high-grade recurrent glioma.  Neuro Oncol 2010;12(2):164-72. 
SL-701  Page 98 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 Yamanaka R , Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al.  Vaccination of recurrent 
glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical 
phase I/II trial.  Br J Cancer 2003;89(7):1172-9. 
Yamanaka R , Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al.  Clinical evaluation of 
dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.  Clin 
Cancer Res 2005;11(11):4160-7.  
Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.  Vaccination with tumor lysate-pulsed 
dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.  Cancer Res 
2004;64(14):4973-9. 
Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al.  Vaccination of malignant glioma 
patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.  
Cancer Res 2001;61(3):842-7. 
Zhu X , Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J , et al. Toll like receptor -3 l igand poly -ICLC 
promotes the efficacy of peripheral vaccinations with tumor antigen -derived peptide epi[INVESTIGATOR_428613]. J Transl Med 2007; 5:10. 
Zhu X , Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER , et al. Poly -I CLC 
promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN -α 
and IFN -γ dependent manners. Cancer Immunol Immunother 2010;59:1401 -9. 
Package Insert References for GM-CSF and Imiquimod: 
GM-CSF [LOCATION_002] Package Insert . 
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=723782d7-a2ab-4cc6-a767-387975ccec80  
Imiquimod. [LOCATION_002] Package Insert . 
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7fccca4e-fb8f-42b8-9555-8f78a5804ed3 
SL-701  Page 99 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 14. APPENDI CES  
14.1 Karnofsky Performance Scale 
From:  Oxford Textbook of Palliative Medicine, Oxford University Press.  1993; 109 
100 Normal, no complaints; no evidence of disease 
90 Able to carry on normal activity; minor signs or symptoms of disease 
80 Normal activity with effort; some signs or symptoms of disease 
70 Cares for self; unable to carry on normal activity or do active work 
[ADDRESS_542335] personal needs 
50 Requires considerable assistance and frequent medical care 
40 Disabled; requires special care and assistance 
30 Severely disabled; hospi[INVESTIGATOR_89648], although death is not imminent 
20 Very sick; hospi[INVESTIGATOR_20545]; active support treatment is necessary 
10 Moribund; fatal processes progressing rapi[INVESTIGATOR_375] 
0 Dead 
SL-701  Page 100 
Protocol STML -701-0114 Amendment 2   10 July  2015  
Stemline Therapeutics, Inc.   FINAL, Confidential  
 
 14.2 RANO  Criteria for Response Assessment 
From
:  Wen 2010 . 
Response  Criteria  
Complete Response  Requires all of the following: complete disappearance of all enhancing 
measurable and nonmeasurable disease sustained for at least 4 weeks; no 
new lesions; stable or improved nonenhancing (T2FLAIR) lesions; 
patients must be off corticosteroids (or on physiologic replacement doses 
only); and stable or improved clinically .  Note: Patients with 
nonmeasurable disease only cannot have a complete response; the best 
response possible is stable disease.  
Partial Response  Requires all of  the following:≥ 50% decrease compared with baseline in 
the sum of products of perpendicular diameters of all measurable 
enhancing lesions sustained for at least 4 weeks; no progression of 
nonmeasurable disease; no new lesions; stable or improved nonenhanc ing 
(T2/FLAIR) lesions on same or lower dose of corticosteroids compared 
with baseline scan; the corticosteroid dose at the time of the scan 
evaluation should be no greater that the dose at the time of baseline scan; 
and stable or improved clinically .  Note: Patients with nonmeasurable 
disease only cannot have a partial response; the best response possible is 
stable disease.  
Stable Disease  Requires all of the following: does not qualify for complete response, 
partial response, or progression; stable nonen hancing (T2/FLAIR) lesions 
on same or lower dose of corticosteroids compared with baseline scan .  In 
the event that the corticosteroid dose was increased for new symptoms 
and signs without confirmation of disease progression on neuroimaging, 
and subsequent  follow -up imaging show that this increase in 
corticosteroids was required because of disease progression, the last scan 
considered to show stable disease will be the scan obtained when the 
corticosteroid dose was equivalent to the baseline dose.  
Progress ive Disease  Defined by [CONTACT_39132]: ≥ 25% increase in the sum of the 
products of maximal perpendicular diameters of enhancing tumor(s) 
compared to the smaller of pre -SL-[ADDRESS_542336] response 
following initiation of SL -701; New measureable  contrast -enhancing 
lesion(s) defined as lesion(s) that measure at least [ADDRESS_542337] 2 
planes; Significant clinical decline not attributable to co -morbid event or 
change in concurrently administered medication.  
NOTE: All measurable and nonmeasurable lesions must be assessed using the same techniques as at 
baseline .  Abbreviation: FLAIR, fluid -attenuated inversion recovery . 
 
SL-[ADDRESS_542338]  Criteria (v er sion 1.1) for Response Evaluation  
From:  Eisenhauer 2009 . 
Evaluation of target lesions   
Complete Response (CR)  Disappearance of all target lesions.  
Any pathological lymph nodes (whether target or non -target)  
must have reduction in short axis to <10 mm.  
Partial Response (PR)  At least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters.  
Stable Disease (SD)  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum 
diameters while on study.  
Progressive Disease (PD)  
 At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum on study (this includes the 
baseline sum if that is the smallest on study) .  In addition to  the 
relative increase of 20%, the sum must als o demonstrate an 
absolute increase of at least 5 mm.  
 
(Note: the appearance of one or more new lesions is also 
considered progression).  
 
Evaluation of non -target lesions   
Complete Response (CR)  Disappearance of all non -target lesions and normalisation of  
tumour marker level .  All lymph nodes must be non -pathological in 
size (<10mm short axis).  
Non-CR/Non -PD Persistence of one or more non -target lesion(s) and/or maintenance 
of tumour marker level above the normal limits.  
Progressive Disease (PD)  Unequivocal progression (see comments below) of existing 
non-target lesions.  
(Note: the appearance of one or more new lesions is also 
considered progression).  
 